1H-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

专利摘要:
The inventions relates to compounds of (I) and therapeutic uses thereof : (I) The terms Z, Y, and R
公开号:AU2013213954A1
申请号:U2013213954
申请日:2013-01-30
公开日:2014-08-07
发明作者:Christoper John GRAHAM；Stuart Christopher RAY；Emma Jayne STEFANIAK；Stephen Stokes
申请人:Vernalis R&D Ltd；
IPC主号:C07D471-04

专利说明:
WO 2013/114113 PCT/GB2013/050212 1 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors Field of Invention This invention relates to novel 1H-pyrrolo[2,3-b]pyridine derivatives having 5 checkpoint kinase 1 (CHK1) inhibitory activity, to the use of such compounds in medicine, in relation to the treatment of cancer, via the inhibition of aberrant cell proliferation, and to pharmaceutical compositions containing such compounds. Background of the invention DNA damaging cytotoxic chemotherapeutic agents and ionizing radiation are the 10 mainstay of current cancer treatment regimens. These therapies are effective, especially when administered in combinations, against a wide variety of neoplasms and are likely to remain the standard of care for cancer treatment for the foreseeable future. These agents, due to their mechanism of action, have limitations which restrict their overall effectiveness. As these agents target DNA, 15 they are effective against any cell especially those actively replicating and therefore lack tumor cell specificity. Administration is usually at the maximum tolerated dose (MTD) resulting in a narrow therapeutic index and toxicity to normal tissue especially those with an actively dividing cell component such as the gastrointestinal tract, hematological system and other organs. Acquired or 20 intrinsic resistance can further limit the usefulness of these agents making many patients' tumors refractory to the drug. Multiple mechanisms can contribute to acquired resistance including reduced cellular levels of active drug (through increased metabolism, detoxification or active efflux), increased DNA repair, loss of p53 or attenuation of apoptotic signaling. 25 Despite inducing DNA damaging through multiple mechanisms (e.g. topoisomerase inhibition, direct DNA alkylation or reduction of deoxyribonucleotides), DNA damaging cytotoxic chemotherapeutic agents such as cisplatin, irinotecan or gemcitabine activate cell cycle checkpoints. Cell cycle checkpoints exist to protect the fidelity of DNA replication and division, and 30 ensure the correct timing of cell cycle events. As DNA cannot be replaced, these pathways are critical in protecting genomic integrity and preventing the onset of cancer. Checkpoints exist at multiple phases of the cell cycle and can be activated during the GI-, S- or G2-phase of the cell cycle in response to DNA damage. Alternatively, the mitotic checkpoint is activated by improper WO 2013/114113 PCT/GB2013/050212 2 chromosome attachment to a bipolar spindle and exists to ensure accurate chromosome segregation and protect against aneuploidy. In mammalian cells, the key effector proteins are p53 and the checkpoint kinases Chk1 and Chk2. A large proportion of human cancers are defective for the p53-pathway in some 5 form thereby lacking a functional G1 checkpoint. Therefore, these human tumors are highly reliant on the Chk kinases to protect them in response to DNA damaging insults. DNA damaging agents, along with ionizing radiation, activate DNA damage checkpoints and induce cell cycle arrest in G1, S, or at the G2-M transition. 10 Damage sensors, such as the Mrell complex (Mrell, Rad50 and Nbs1) that recognize double strand breaks, or the Rad17 and the Rad9-Husl-Radl complex that recognize replication stress, activate the central transducing kinases ATM and ATR. In turn, these kinases directly activate the effector kinases Chk1 and Chk2. Chk1 and Chk2 negatively regulate the Cdc25 family of 15 phosphatases thereby preventing cell cycle progression as well as directly modulating repair proteins resulting in increased lesion repair. This allows the cell to pause replication, repair the damaged DNA, then resume replication. Biochemical and genetic studies have demonstrated Chk1 to be essential and indispensible for the S- and G2-M checkpoints. 20 Chk1 inhibition, therefore, represents a novel therapeutic strategy to increase the lethality of DNA-damaging chemotherapeutic drugs in p53 pathway defective cancers. Abrogation of the remaining intact checkpoint should result in increased tumor cell death. Chk1 inhibitors have demonstrated potentatiation of a range of cytotoxic chemotherapy drugs both in vitro and in a range of pre-clinical models 25 of human cancer including gemcitabine, irinotecan and paclitaxel. This "synthetic lethality" approach should increase the therapeutic activity of the chemotherapeutic drug without increasing the systemic toxicity as normal cells should remain protected by their functional p53 pathway. Chk1 inhibitors have, therefore, the potential to be combined with a wide range of cytotoxic 30 chemotherapeutic agents for the treatment of a diverse selection of human cancers. This approach has started to be tested clinically with several small molecule inhibitors of Chk1 (GDC0425, GDC0575, LY2603618 and LY2606368) currently undergoing Phase I/Il clinical evaluation in combination with gemcitabine, irinotecan and cytarabine. Additional agents including AZD7762, WO 2013/114113 PCT/GB2013/050212 3 PF00477736, SCH900776 and XL844 have undergone Phase I trials but the development of these agents has subsequently been stopped. W02009140320 and W02009089352 disclose pyrrolopyridines as CHK1 and/or CHK2 inhibitors. 5 It has now been found that certain 1 H-pyrrolo[2,3-b]pyridine derivatives show efficacy as CHK1 inhibitors. Summary of the Invention The present invention relates to a class of substituted 1 H-pyrrolo[2,3-b]pyridine 10 compounds useful as CHK1 inhibitors, for example, for the treatment of cancer. A core 1 H-pyrrolo[2,3-b]pyridine template, with optional substitution in the 4 and 5 position and in the three position by a substituted-pyrazolyl amido-linked group are principle characterising features of the compounds with which the invention is concerned. 15 The present invention is a compound of formula I: N H N /0 Z Z HN / IN N Y R1 (I) 20 or a pharmaceutically acceptable salt thereof, wherein: each Z is independently (Alk)n-Rn-(Alk)n-X, wherein each Alk is independently (C1 to C12) alkylene or (C2 to C12) alkenylene, each of which may be optionally substituted, WO 2013/114113 PCT/GB2013/050212 4 each n is independently 0 or 1; each R is independently optionally substituted arylene or heteroarylene, or optionally substituted cycloalkylene or heterocyclic, -0-, -S-, -(C=0)-, -(C=S)-, SO 2 -, -C(=O)O-, -C(=O)NRA-, -C(=S)NRA-, -SO 2 NRA-, -NRAC(=O)-, -NRAS02 5 or -NRA- wherein RA is hydrogen, C1-C alkyl, -C1-C alkyl(cycloalkyl), C1-C alkyl(C 1 -C alkoxy) or C1-C alkoxy; each X is independently halogen, -H, -ORA, NRARA, optionally substituted aryl or heteroaryl, or optionally substituted cycloalkyl or heterocyclic, CN or C(halogen)aHb, where a is 1, 2, or 3, and b is (3-a); 10 Y is optionally substituted aryl or heteroaryl, or optionally substituted cycloalkyl or heterocyclic; and
R
1 is H or C 1 -C alkyl. Description of Preferred Embodiments Terminology 15 As used herein, the term "(C-Cb)alkyl" wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms. Thus when a is 1 and b is 6, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl. As used herein the term "(C-Cb)alkylene" wherein a and b are integers refers to 20 a saturated hydrocarbon chain having from a to b carbon atoms and two unsatisfied valences, such as -CH 2 -, -CH 2
CH
2 -, -CH 2
CH
2
CH
2 -, CH 2
CH(CH
3
)CH
2 - and -CH 2
C(CH
3
)
2
CH
2 -. For the avoidance of doubt, it is to be understood that a divalent branched chain (CO-Cb)alkylene radical includes those wherein one of the carbons of the hydrocarbon chain is a ring carbon of a 25 cycloalkyl ring (ie is a spiro centre). As used herein the term "cycloalkyl" refers to a saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. As used herein the term "carbocyclic" refers to a mono- or bi-cyclic radical 30 whose ring atoms are all carbon, and includes monocyclic aryl, cycloalkyl, and cycloalkenyl radicals, provided that no single ring present has more than 8 ring members. A "carbocyclic" group includes a mono-bridged or multiply-bridged cyclic alkyl group.
WO 2013/114113 PCT/GB2013/050212 5 As used herein the term "aryl" refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical. Illustrative of such radicals are phenyl, biphenyl and napthyl. As used herein the term "heteroaryl" refers to a mono-, bi- or tri-cyclic aromatic 5 radical containing one or more heteroatoms selected from S, N and 0. Illustrative of such radicals are thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, 10 pyrazinyl, triazinyl, indolyl and indazolyl. As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in particular refers to a mono-, bi- or tri-cyclic non- aromatic radical containing one or more heteroatoms selected from S, N and 0, to groups consisting of a monocyclic non-aromatic radical containing one 15 or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical, and to a mono-, bi- or tri-cyclic non-aromatic radical containing one or more heteroatoms selected from S, N and 0 which is mono-bridged or multiply-bridged. Illustrative of such radicals are pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, 20 pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl, benzimidazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups. Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with at least one 25 substituent, for example selected from (C1-C)alkyl, (C 1 -C)alkoxy, hydroxy, hydroxy(C 1 -C)alkyl, mercapto, mercapto(C 1 -C)alkyl, (C 1 -C)alkylthio, halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, -COOH, -COORA, -CORA, -SO 2 RA, -CONH 2 , -SO 2
NH
2 , -CONHRA
-SO
2 NHRA, -CONRARB, -SO 2 NRARB, -NH 2 , -NHRA, -NRA RB, -OCONH 2 , 30 -OCONHRA, -OCONRARB, -NHCORA, -NHBCOOR A, -NRB COORA,
-NHSO
2 ORA, -NRBSO 2 ORA, -NHCONH 2 , -NRACONH 2 , -NHCONHRB, -NRACONHRB, -NHCONRARB or -NRACONRARB wherein RA and RB are independently a (C 1
C
6 )alkyl group, or RA and RB when attached to the same nitrogen may form a cyclic amino ring such as a morpholinyl, piperidinyl or WO 2013/114113 PCT/GB2013/050212 6 piperazinyl ring. An "optional substituent" or "substituent" may be one of the foregoing substituent groups. As used herein the term "salt" includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, 5 including pharmaceutically or veterinarily acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides, alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides, with organic bases e.g. N-ethyl piperidine, dibenzylamine and the like. Those compounds (I) which are basic can form salts, including pharmaceutically or veterinarily 10 acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic and p-toluene sulphonic acids and the like. 15 For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002). Compounds of the invention are expected to be isolatable as hydrates and solvates. The term 'solvate' is used herein to describe a molecular complex 20 comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is H 2 0. Any reference herein to a compound of formula(l) is to be understood as including such hydrates and solvates. 25 Compounds with which the invention is concerned which may exist in one or more stereoisomeric form, because of the presence of asymmetric atoms or rotational restrictions, can exist as a number of stereoisomers with R or S stereochemistry at each chiral centre or as atropisomeres with R or S stereochemistry at each chiral axis. The invention includes all such enantiomers 30 and diastereoisomers and mixtures thereof. So-called 'pro-drugs' of the compounds of formula (I) are also within the scope of the invention. Thus certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired WO 2013/114113 PCT/GB2013/050212 7 activity, for example, by hydrolytic cleavage. Such derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (ed. E. 5 B. Roche, American Pharmaceutical Association). Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985). 10 Also included within the scope of the invention are metabolites of compounds of formula (I), that is, compounds formed in vivo upon administration of the drug. Some examples of metabolites include (i) where the compound of formula (I) contains a methyl group, an hydroxymethyl derivative thereof (-CH 3 -> -CH 2 OH): 15 (ii) where the compound of formula (I) contains an alkoxy group, an hydroxy derivative thereof (-OR -> -OH), (iii) where the compound of formula (I) contains a tertiary amino group, a secondary amino derivative thereof (-NR 1
R
2 -> -NHR' or -NHR 2 ), (iv) where the compound of formula (I) contains a secondary amino 20 group, a primary derivative thereof (-NHR' -> -N H 2 ), (v) where the compound of formula (I) contains a phenyl moiety, a phenol derivative thereof (-Ph -> -PhOH), and (vi) where the compound of formula (I) contains an amide group, a carboxylic acid derivative thereof (-CONH 2 > COOH). 25 Preferred Embodiments Variable substituents present in compounds (I) will now be further described. It is to be understood in the further description that any disclosed substituent or substituent class may be present in any combination with any of the other disclosed substituent classes. Specific examples of the variable substituents 30 include those present in the compounds of the Examples herein. Preferably, the group "alk" is (C 1 to C 6 ) alkylene or (C 2 to C 6 ) alkenylene. Preferably, at least one of the "Z" groups is located on either the 4- or 5- position of the pyridine ring. More preferably, at least one Z group is located on the 5- WO 2013/114113 PCT/GB2013/050212 8 position of the ring. Most preferably, the Z groups are located on the 4- and 5 positions of the ring. Preferably, X and/or Z is a solubilising group. Many such solubilising groups are known in medicinal chemistry. Examples of solubilising groups are morpholinyl, 5 piperidinyl, piperazinyl, pyrrolidinyl, ethylamino, isopropylamino, diethylamino, cyclohexylamino, cyclopentylamino, methoxyethylamino, piperidin-4-yl, N acetylpiperazinyl, methylsulfonylamino, thiomorpholinyl, thiomorpholinyldioxide, 4-hydroxyethylpiperidinyl, and 4-hydroxypiperidinyl. In a preferred embodiment Y is phenyl or heteroaryl optionally substituted with 10 C1 to C alkyl, ORA, halogen or C1 to C alkoxy. More preferably Y is pyridyl, pyrrolyl, phenyl, or phenyl substituted with methyl, 0-methyl, bromine or chlorine. In a yet further preferred embodiment, Y is optionally substituted aryl. Preferably, Y is optionally substituted phenyl. More preferably, Y is 15 unsubstituted phenyl. Preferably, a compound of the invention is according to one of the specific examples, or a pharmaceutically acceptable salt thereof.
R
1 is preferably H or Me. More preferably, R 1 is H. RA is preferably is H or C1-C alkyl. In an embodiment RA is -C1-C6 20 alkyl(cycloalkyl) such as -CH 2 -cyclopropyl, -CH 2 -cyclopentyl or -CH 2 cyclohexyl. In an embodiment at least one Z is H, halogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted nitrogen-containing heterocycle, C1 to C alkyl or ORA. In a particularly preferred embodiment the 25 optional substituent on the nitrogen-containing heterocycle is NRA A In a preferred embodiment one Z group is H, halogen, ORA or 1, to 06 alkyl, and the other Z group is optionally substituted aryl or optionally substituted nitrogen containing heterocycle. In a particularly preferred embodiment the optional substituent on the nitrogen-containing heterocycle is NRA A 30 In a preferred embodiment Z is (Alk)n-optionally substituted arylene-(Alk)n optionally substituted heterocycle. In an alternative preferred embodiment Z is optionally substituted heteroaryl or optionally substituted nitrogen-containing heterocycle.
WO 2013/114113 PCT/GB2013/050212 9 In a preferred embodiment, the compounds of the invention are according to formula (Ia): H N Y_
R
1 (Ia) 5 or a pharmaceutically acceptable salt thereof, wherein:
Z
1 and Z 2 are independently (Alk)n-Rn-(Alk)n-X, and Alk, n, R, X, Y, RA and R 1 are as defined in claim 1. Preferably in the compound of formula (Ia) Z 1 is halogen, phenyl, ORA orC to 06 alkyl, and Z 2 is optionally substituted aryl or optionally substituted heterocycle. 10 Preferably in the compound of formula (Ia) Z 2 is halogen, CF 3 , cyclopropyl, phenyl, ORA or C1 to 06 alkyl, and Z 1 is optionally substituted aryl or optionally substituted heterocycle. Preferably the terms "heterocycle" or "nitrogen-containing heterocycle" when used in the context of compounds of formula (I) or (Ia) represent an optionally 15 substituted piperidine, piperazine or morpholine ring. In an embodiment Z 1 is R-X, and Z 2 is X. In an alternative embodiment Z 2 is R-X, and Z 1 is X. In a further embodiment Z 1 is R-Alk-X, and Z 2 is X. In a yet further embodiment Z 2 is R-Alk-X, and Z 1 is X. 20 Utility The present invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.
WO 2013/114113 PCT/GB2013/050212 10 As used herein, the term "treatment" as used herein includes prophylactic treatment. Compounds of the invention may be used alone in the treatment of cancers and autoimmune disorders such as organ transplant rejection, lupus, multiple 5 sclerosis, rheumatoid arthritis and osteoarthritis. Inhibitors of CHK1 have demonstrated utility in improving the efficacy of current DNA-damage inducing radiotherapy or chemotherapeutic regimens for cancer treatment. The compound of formula (I) can be used in combination for the treatment of cancer with radiation therapy or one or more cytotoxic or cytostatic drugs, or drugs 10 which induce cytotoxicity or cytostasis. The compound of the invention and the other component (may be in the same pharmaceutical formulation or in separate formulations for administration simultaneously or sequentially. Non-limiting examples of chemotherapeutic agents, radiotheraputic agents and other active and ancillary agents are set forth below. 15 (i) Alkylating agents. (ii) Nitrogen mustards such as Chlorambucil Cyclophosphamide Ifosfamide Mechlorethamine Melphalan 20 (iii) Nitrosoureas such as carmustine (BCNU) lomustine (CCNU) semustine (methyl-CCNU) (iv) Ethylenimine/Methyl-melamine such as hexamethylmelamine (HMM / altetamine) thriethylenemelamine (TEM) trethylene thiophosphoramide (thiotepa) WO 2013/114113 PCT/GB2013/050212 11 (v) Alkyl sulphonates such as busulphan. (vi) Triazines such as dacarbazine (DTIC). 5 (vii) Antimetabolites such as the Folic acid analogues such as Methoxtrexate pemetrexed (multi-targeted antifolate) Trimetrexate (viii) Pyrimidine analogues such as 2,2'-difluorodeoxy-cytidine 5-azacytidine 5-fluorouracil cytosine arabinoside (araC / cytarabine) Fluorodeoxyuridine Gemcitabine 10 (ix) Purine analogues such as 2-chlorodeoxyadenosine (cladribine / 2-CdA) 2'-deoxycoformycin (pentostatin) 6-Mercaptopurine 6-thioguanine Azathioprine erthyrohydroxynonyl-adenine (EHNA) fludarabine phosphate (x) Type I Topoisomerase Inhibitors such as Camptothecin Irinotecan Topotecan (xi) Biological response modifiers such as G-CSF and GM-CSF.
WO 2013/114113 PCT/GB2013/050212 12 (xii) Differentiation agents such as retinoic acid derivatives. (xiii) Hormones and antagonists. 5 (xiv) Adrenocorticosteroids/antagonists such as Ainoglutethimide Dexamethasone prednisone and equivalents (xv) Progestins such as hydroxyprogesterone caproate medroxyprogesterone acetate megestrol acetate 10 (xvi) Estrogens such as Diethylstilbestrol ethynyl estradiol / equivalents (xvii) Antiestrogens such as tamoxifen. (xviii) Andogens such as testosterone propionate fluoxymesterone / equivalents 15 (xix) Anti-androgens such as Flutimide gonadotropin-releasing hormone analogues Leuprolide (xx) Nonsteroidal antiandrogens. 20 (xxi) Natural products.
WO 2013/114113 PCT/GB2013/050212 13 (xxii) Antimitotic drugs. (xxiii) Taxanes such as docetaxel (Taxotere) estramustine / estramustine phosphate Paclitaxel vinblastine (VLB) vinca alkaloids Vincristine Vinorelbine 5 (xxiv) Epipodophylotoxins such as etoposide or teniposide. (xxv) Antibiotics such as actimomycin D aphidicolin Bleomycin Dactinomycin daunomycin (rubidomycin) doxorubicin (adriamycin) mitomycin C Mitroxantroneidarubicin splicamycin (mithramycin) 10 (xxvi) Enzymes such as L-asparaginase and L-arginase. (xxvii) Radiosensitizers such as 5-bromodeozyuridine 5-idoddeoxyuridine Bromodeoxycytidine Desmethylmisonidazole E09 WO 2013/114113 PCT/GB2013/050212 14 Etanidazole Metronidazole Misonidazole Nicotinamide Nimorazole Pimonidazole RB 6145 RSU 1069 SR4233 (xxviii) Platinum coordination complexes such as Anthracenedione Carboplatin Cisplatin Mitoxantrone oxaliplatin (xxix) Substituted ureas such as hydroxyurea. 5 (xxx) Methyhydrazine derivatives such as N-methylhyrazine (MIH) and procarbazine. (xxxi) Adrenocortical suppressant mitocane (o,p'-DDD) ainoglutethimide. 10 (xxxii) Cytokines such as interferon (a, p, y) and interleukin-2. (xxxiii) Photosensitisers such as bacteriochlorophyll-a benzoporphyrin derivatives hematoporphyrin derivatives napthalocyanines Npe6 pheboride-a WO 2013/114113 PCT/GB2013/050212 15 photofrin phthalocyanines tin etioporphyrin (SnET2) zinc phthalocyanines (xxxiv) Radiation such as gamma radiation infrared radiation microwave radiation ultraviolet light visible light X-ray (xxxv) Molecular targeted therapeutics mTOR inhibitors P13 Kinase inhibitors MEK inhibitors Weel inhibitors 5 CHK1 inhibitors have recently shown preclinical activity as single agents in a diverse range of human cancers including but not limited to ovarian cancer, triple negative breast cancer, neuroblastoma, melanoma, pancreatic cancer, hematological cancers and cancers with defects in DNA repair pathways such as 10 Fanconi's Anaemia. It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the causative 15 mechanism and severity of the particular disease undergoing therapy. In general, a suitable dose for orally administrable formulations will usually be in the range of 0.1 to 3000 mg, once, twice or three times per day, or the equivalent daily amount administered by infusion or other routes. However, WO 2013/114113 PCT/GB2013/050212 16 optimum dose levels and frequency of dosing will be determined by clinical trials as is conventional in the art. The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. The 5 orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, 10 gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone, fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine, tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica, disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal 15 pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with H 2 0 or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, 20 glucose syrup, gelatin hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia, non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol, preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional 25 flavouring or colouring agents. For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia. 30 The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
WO 2013/114113 PCT/GB2013/050212 17 There are multiple synthetic strategies for the synthesis of the compounds (I) with which the present invention is concerned, but all rely on known chemistry, known to the synthetic organic chemist. Thus, compounds according to formula (I) can be synthesised according to procedures described in the standard 5 literature and are well-known to the one skilled in the art. Typical literature sources are "Advanced organic chemistry", 4 th Edition (Wiley), J March, "Comprehensive Organic Transformation", 2 nd Edition (Wiley), R.C. Larock , "Handbook of Heterocyclic Chemistry", 2 nd Edition (Pergamon), A.R. Katritzky), review articles such as found in "Synthesis", "Acc. Chem. Res." , "Chem. Rev", 10 or primary literature sources identified by standard literature searches online or from secondary sources such as "Chemical Abstracts" or "Beilstein". Such literature methods include those of the preparative Examples herein, and methods analogous thereto. Examples of methods known in the art of organic chemistry in general, by which 15 the compounds of the present invention may be prepared, are included in the following reaction schemes and procedures.
WO 2013/114113 PCT/GB2013/050212 18 Scheme I N N N H H H NNNN N N N BBr r Br Br
NO
2
NH
2 HN N'N Scheme 2 R
H
3 H3C CH 3 H 3 C CH 3 H 3 C H CH ~~ / Br / Br Br 2 B rH 2B Br NBrN N N Scheme- 3 Br Ir BrH2 Br NN N Br d /o N HN HN N N N N N Br Br Brr NO FH HN2 0 2 N H )N N N N N N OH N. NHN N1. NN N N NN WO 2013/114113 PCT/GB2013/050212 19 Scheme 4 HHH N N N HN H N N N N Br Br Br Br
NO
2
NH
2 HN V CH 3 HN N N ---- N Br O O- ~ HN HN N-N N'N
CH
3 N H N'N N HN- N HN- o NN N-N WO 2013/114113 PCT/GB2013/050212 20 Scheme 5 N H H N N NN N Br Br Br Br
NO
2 NH 2 HN
CH
3
CH
3 N'N NN N KN Br / HO HN HN N-N N'N
CH
3 s=O N N H N N N N' N'No WO 2013/114113 PCT/GB2013/050212 21 Scheme 6 N H N N N-/ ~ K N N N Br Br Br Br
NO
2
NH
2 IIN
CH
3 CH3 N'N N N N N Br
H
3 C B I HN H 3 CC 6 HN H3C CH3 N'N NN
CH
3 0 N N N N O N O N N N'N Scheme 7 H ss N N N N HO Br Br F F H N N H H H H N N N I0 0 0--
-
N NO 2 F F F NO 2 > O-"N H H H H N N N N N N 0 N NH 2 -- N HN- N MN H H N'N N' R R WO 2013/114113 PCT/GB2013/050212 22 Scheme 8
H
3 H3 CH3 CH O H HH F C F CN O N NO )CHO N N N H N H OH 0S~H NNH O IN N N N F ~ F K-/~ F.K F F F l F Fl F Cl NO 2 0 F N ON 2 H N N HN N 0 H)- H C oN" NN H 2 NO N N Scheme 9 NN -N NN > HO0 Br sr FF -- Si N N 0HN o N N_ 0N 0 0 0 0,11 / 0 F" F N0 2 F HH H 0 N N N N N0N 2 NH >K1 /N C~ 0'~~N"I N N 2 N H 0 0 N HN/ N
HN-N
WO 2013/114113 PCT/GB2013/050212 23 Examples The following examples illustrate the preparation of specific compounds of the invention and are not intended to be limiting of the full scope of the invention. Persons skilled in the art should recognize that the chemical syntheses 5 described here may be adapted to prepare other compounds of the invention. Indeed, alternative methods for preparing compounds of this invention are deemed to be within the scope of this invention. Example 1: 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-bromo-1H 10 pyrrolo[2,3-blpvridin-3-vi)-amide N NH HN N The title compound was prepared according to the route outlined in Scheme 1. Step 1: Preparation of 5-Bromo-3-nitro-1 H-pyrrolo[2,3-b]pyridine 15 5-Bromo-1H-pyrrolo[2,3-b]pyridine (470mg, 2.39mmol) was added in portions to a stirring solution of fuming nitric acid (2.5mL) at 0CC. After addition the reaction was stirred at 00C for 30 minutes and then carefully added to a mixture of ice/H 2 0 (25mL) and stirred for 30 minutes. The solids were separated via filtration and the filter cake washed with copious amounts of H 2 0 and then iso 20 hexane prior to drying in vacuo to afford the desired title compound, 484mg, 84%. Step 2: Preparation of 5-Bromo-1 H-pyrrolo[2,3-b]pyridin-3-ylamine 5-Bromo-3-nitro-1H-pyrrolo[2,3-b]pyridine was stirred in glacial acetic acid (6mL) 25 at 850C and to this, was added a solution of tin(II)chloride dihydrate (936mg, WO 2013/114113 PCT/GB2013/050212 24 4.15mmol) in conc. HCI (1 mL), drop wise. After addition the reaction was heated at 850C for a further 2 hours and then allowed to cool to room temperature. The reaction mixture was poured onto a mixture of rapidly stirring ice/H 2 0 (30mL) and the pH was adjusted to 9 by the careful addition of a 50% aqueous solution 5 of sodium hydroxide. This aqueous mixture was extracted with DCM (3x25mL) and the combined extracts were washed with H 2 0, saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo to yield the desired compound, 115mg, 66%. 10 Step 3: Preparation of Title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl)-amide 5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-ylamine (60mg, 0.28mmol), 1-benzyl-1H pyrazole-4-carboxylic acid (62mg, 0.31mmol) and triethylamine (57mg, 80uL, 0.56mmol) were stirred in dimethyl formamide (1mL). O-(7-azabenzotriazol-1-yl) 15 N,N,N',N'-tetramethyluroniumhexafluorophosphate (HATU) (106mg, 0.28mmol) was added and the reaction was stirred at room temperature for 4 hours. The reaction mixture was partitioned between EtOAc and saturated sodium hydrogen sulphate solution and the organics separated and washed with saturated aqueous sodium chloride (x4), dried (MgSO 4 ) and solvent removed in vacuo to 20 afford a brown solid. The residue was purified by flash chromatography on SiO 2 eluting first with 50% EtOAc/DCM and then 5% MeOH/DCM. The fractions containing pure product were combined and concentrated in vacuo to afford the title compound as a tan solid, 35mg, 31%. LC/MS: RT = 2.22 Min (270nm), m/z = 396 [M+H], 394 [M-H]. Total run time 3.75 25 min (short pos/neg), HP1 100. 'H NMR (de DMSO): 65.41 (s, 2H), 7.28-7.41 (m, 5H), 7.84 (d, 1H), 8.08 (s, 1H), 8.28 (d, 1 H), 8.45 (s, 1 H), 8.48 (d, 1 H), 9.88 (s, 1 H), 11.69 (br s, 1 H) WO 2013/114113 PCT/GB2013/050212 25 Example 2: 1-Benzvl-1H-pyrazole-4-carboxylic acid (1H-pvrrolo[2,3 blpyridin-3-vi)-amide N NH *0 HN N The title compound was prepared according to the route outlined in Scheme 1, 5 and using the methodology described for Example 1, Steps 1, 2 and 3, substituting 1H-pyrrolo[2,3-b]pyridine (150mg, 1.27mmol) for 5-bromo-11H pyrrolo[2,3-b]pyridine in Step 1. The title compound was isolated as a cream solid, 60.3mg, 35.8%. LC/MS: RT = 1.95 Min (270nm), m/z = 318 [M+H], 316 [M-H]. Total run time 3.75 10 min (short pos/neg), HP1 100. 1 H NMR (de DMSO): 65.41 (s, 2H), 7.06 (dd, 1H), 7.28-7.41 (m, 5H), 7.74 (d, 1H), 8.08 (s, 1H), 8.18 (dd, 1H), 8.22 (dd, 1H), 8.44 (s, 1H), 9.87 (s, 1H), 11.41 (br d, 1H) 15 WO 2013/114113 PCT/GB2013/050212 26 Example 3: 1-Benzyl-1H-pyrazole-4-carboxylic acid (4-bromo-1H Pyrrolo[2,3-blpvridin-3-vi)-amide N NH *0 (H N Br N The title compound was prepared by a similar route to that shown in Scheme 1. 5 Step 1: Preparation of 4-Bromo-3-nitro-1 H-pyrrolo[2,3-b]pyridine c.HNO 3 (0.93mL) was added drop wise to a solution of c.H 2
SO
4 (0.64mL) at 0C. 4-Bromo-1H-pyrrolo[2,3-b]pyridine (2g, 10.15mmol) in c.H 2
SO
4 (9mL) was added slowly, keeping the temperature at 0 C. After addition the reaction was stirred for 10 a further hour at 00C before pouring carefully onto rapidly stirring ice/H 2 0 (100mL). The suspension was stirred for 30mins and then the solids separated via filtration. The filter cake was washed with copious amounts of H 2 0 before drying in vacuo at 400C, to afford the desired compound, 1.9g, 77.3% Step 2: Preparation of 4-Bromo-1 H-pyrrolo[2,3-b]pyridin-3-ylamine 15 4-Bromo-3-nitro-1H-pyrrolo[2,3-b]pyridine (500mg, 2.07mmol) was heated in 48% aqueous hydrobromic acid (4mL) at 700C and then tin (II) chloride dihydrate (2.26g, 1Ommol) was added in portions. After addition the reaction was heated at 700C for a further 1 hour and then cooled before carefully adding to stirring ice/H 2 0 (15mL). This solution was basified to pHl12 using sodium hydroxide 20 solution, and the insoluble material separated via filtration. The filtrate was extracted with DCM (3x1OOmL) and the combined extracts were washed with
H
2 0 and saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. This afforded the desired compound, 230mg, 52.5%, which was used without further purification. 25 WO 2013/114113 PCT/GB2013/050212 27 Step 3: Preparation of Title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid (4-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl)-amide The title compound (cream solid, 145mg, 66.5%) was prepared as described in 5 Example 1, Step3, substituting 4-Bromo-1H-pyrrolo[2,3-b]pyridin-3-ylamine (117mg, 0.55mmol) for 5-Bromo-1 H-pyrrolo[2,3-b]pyridin-3-ylamine. LC/MS: RT = 2.12 Min (270nm), m/z = 396 [M+H], 394 [M-H]. Total run time 3.75 min (short pos/neg), HP1100. 10 'H NMR (de DMSO): 65.39 (s, 2H), 7.28-7.41 (m, 6H), 7.61 (d, 1H), 8.03 (s, 1H), 8.07 (d, 1H), 8.39 (s, 1H), 9.43 (s, 1H), 11.99 (br s, 1H) Example 4: 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-phenyl-1H Dvrrolof2.3-blpvridin-3-vi)-amide N NH HN NN 15 The title compound was prepared from Example 1. 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl) amide (50mg, 0.13mmol), phenylboronic acid (16.9mg, 0.14mmol), K 2 CO3 (53.9mg, 0.39mmol) and Pd(dppf)Cl 2 (9.5mg, 0.01 mmol) were combined in THF/ 20 H 2 0 (1.1mL : 0.12 mL) and thoroughly degassed. The reaction mixture was heated at 1200C for 1 hour under microwave irradiation and then it was diluted with EtOAc. The organic layer was separated and the aqueous extracted with another portion of EtOAc. The combined organics were washed with H 2 0, saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent removed in 25 vacuo to afford a brown gum. This crude material was purified by automated WO 2013/114113 PCT/GB2013/050212 28 column chromatography, eluting with DCM to 5% MeOH / DCM. Fractions found to contain pure material were combined and solvent removed in vacuo to afford the desired product as a pale brown solid, 27mg, 54%. 5 LC/MS: RT = 1.23 Min (270nm), m/z = 394 [M+H]. Total run time 1.9 min (super short pos), HP1200 'H NMR (de DMSO): 65.41 (s, 2H), 7.28-7.41 (m, 6H), 7.5 (m, 2H), 7.71 (dd, 2H), 7.83 (d, 1H), 8.10 (s, 1H), 8.47 (s, 1H), 8.51 (d, 1H), 8.54 (d, 1H), 9.92 (s, 1H), 11.51 (br d, 1H). 10 Example 5: 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-piperidin-1-yi-11H Dvrrolof2.3-blpvridin-3-vi)-amide N NH N HNN N N The title compound was prepared from Example 1. 15 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl) amide (75mg, 0.19mmol), piperidine (0.03mL, 0.28mmol), 2 dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (8.83mg, 0.02 mmol), chloro (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1 '-biphenyl)[2-(2 aminoethyl)phenyl]palladium(II) -methyl-t-butyl ether adduct (15.5 mg, 0.02 20 mmol) were added to a 0.5 - 2.0 mL microwave vial. The vial was sealed, evacuated and backfilled with nitrogen. Lithium bis(trimethylsilyl)amide solution, 1.OM in THF, (0.45mL, 0.45mmol) was added and reaction mixture was heated at 65 OC for 18 hours. The reaction was allowed to cool and the mixture was quenched with 1N HCI, diluted with DCM, washed with H 2 0, dried (phase 25 separator) and solvent removed in vacuo to afford a brown solid. This crude WO 2013/114113 PCT/GB2013/050212 29 material was purified by automated column chromatography, eluting with DCM 10% MeOH/DCM (gradient). Fractions found to contain product were combined and solvent removed in vacuo to afford a brown solid, 11mg, 14%. LC/MS: RT = 1.02 Min (270nm), m/z = 401 [M+H]. Total run time 1.9 min (super 5 short pos), HP1200. 'H NMR (de DMSO): 61.49-1.51 (m, 2H), 1.65-1.73 (m, 4H), 3.01-3.07 (m, 4H), 5.41 (s, 2H), 7.28-7.41 (m, 5H), 7.69 (s, 1H), 7.76 (s, 1H), 8.05 (d, 1H), 8.07 (s, 1H), 8.44 (s, 1H), 9.75 (s, 1H), 11.11 (br d, 1H) 10 Example 6: N-{4-[(3R)-3-aminopiperidin-1 -vil-5-bromo-1 H-pyrrolo[2,3 bipyridin-3-yil-1 -benzyl-1 H-pyrazole-4-carboxamide N NH N
H
2 N N The title compound was prepared according to the route outlined in Scheme 2. Step 1: Preparation of 4-bromo-1 -[tris(propan-2-yl)silyl]-1 H-pyrrolo[2,3-b]pyridine 15 Sodium hydride, 60% dispersion in mineral oil (0.49g, 12.18mmol) was added in portions to 4-bromo-1H-pyrrolopyridine (2g, 10.15mmol) in THF (45mL) at 00C and stirred for 15 minutes. Triisopropylsilyl chloride (2.31g, 2.57mL, 12mmol) was then added to the reaction mixture drop wise at 0CC. After addition the cooling was removed and the reaction mixture allowed toattain RT, where it was 20 stirred for a further 1 hour. The suspension was then cooled to about 0-50C and quenched with saturated aqueous ammonium chloride (30mL). The aqueous phase was extracted with EtOAc (3x3OmL) and the combined organic phases were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent removed in vacuo to afford a yellow oil. The crude material was purified 25 by flash chromatography, eluting with iso-hexane. Fractions found to contain WO 2013/114113 PCT/GB2013/050212 30 pure product were combined and solvent removed in vacuo to afford the desired compound as an oil, 3.5g, 97.6%. Step 2: Preparation of 4-fluoro-1 -[tris(propan-2-yl)silyl]-1 H-pyrrolo[2,3-b]pyridine n-Butyllithium solution, 2.5M in hexanes (2.52mL, 11.3mmol) was added drop 5 wise to a solution of 4-bromo-1-[tris(propan-2-yl)silyl]-1H-pyrrolo[2,3-b]pyridine (2.0g, 5.66mmol) in Et 2 0 (60mL) at -780C under a nitrogen atmosphere, and the mixture stirred for 30 minutes at -780C and for 45mins at -50C to give a pale yellow solution. The resulting solution was cooled to -780C, and a solution of N fluorobis(phenylsulphonyl)amine (2.05g, 6.51mmol) in THF (10mL) was added 10 drop wise. The mixture stirred for a further 3 hours at -780C, and then quenched by the addition of saturated aqueous ammonium chloride solution. The organic layer was separated and the aqueous layer was extracted with Et 2 0 (2x5OmL) and the combined extracts washed with saturated aqueous sodium chloride solution. The solution was dried over anhydrous MgSO 4 and concentrated to a 15 yellow gum. The crude material was purified by flash chromatography, eluting with iso-hexane. Fractions found to contain pure product were combined and solvent removed in vacuo to afford the desired compound as a colourless oil, 1.3g, 78.5%. Step 3: Preparation of 5-Bromo-4-fluoro-1-[tris(propan-2-yl)silyl]-1H-pyrrolo[2,3 20 b]pyridine 4-fluoro-1-[tris(propan-2-yl)silyl]-1H-pyrrolo[2,3-b]pyridine (833.0 mg, 2.85mmol) in THF (34 mL) at -78 0C was treated drop wise with sec-butyllithium solution, 1.4M in cyclohexane (4.48 mL, 6.27 mmol). The reaction was stirred at -78 0C for 1 hour. A solution of carbon tetrabromide (2.36g, 7.12mmol) in THF (6.3mL) 25 was added drop wise and the reaction was stirred at -78 0C for a further 1 hour. The reaction was quenched by the addition of saturated aqueous ammonium chloride. The mixture was extracted with iso-hexane (x2) and the combined extracts washed with saturated aqueous sodium chloride. The solution was dried over anhydrous MgSO4 and concentrated to a brown oil. The crude material was 30 purified by automated column chromatography, eluting with iso hexane. Fractions found to contain pure product were combined and solvent removed in vacuo to afford the desired compound as a yellow gum that solidified on standing, 0.97g, 91.7%. Step 4: Preparation of 5-Bromo-4-fluoro-1 H-pyrrolo[2,3-b]pyridine WO 2013/114113 PCT/GB2013/050212 31 Tetrabutylammonium fluoride solution, 1.OM in THF (2.61 mL, 2.61mmol) was added to a solution of 5-bromo-4-fluoro-1-[tris(propan-2-yl)silyl]-1H-pyrrolo[2,3 b]pyridine (970mg, 2.61mmol) in THF (16.5mL) at RT. The reaction mixture was stirred at RT for 20 minutes and then partitioned between H 2 0 and Et 2 0. The 5 organic layer was separated and the aqueous was extracted with more Et 2 0 (2x25mL). The combined organic phases were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo to afford a brown gum. The crude material was purified by automated chromatography, eluting with iso 10 hexane to 40% EtOAc / iso-hexane (gradient). Fractions found to contain pure product were combined and solvent removed in vacuo to afford the desired compound as an off white solid, 0.323g, 57.5%. Step 5: Preparation of 5-Bromo-4-fluoro-3-nitro-1 H-pyrrolo[2,3-b]pyridine 5-Bromo-4-fluoro-1 H-pyrrolo[2,3-b]pyridine (0.323g, 1.50mmol) was added in 15 portions to fuming nitric acid (1.6 mL) at 0 C. After addition the reaction mixture was stirred at 0 OC for 30 minutes and then added carefully to rapidly stirring ice/H 2 0 (25mL). The suspension was stirred for a further 30 minutes and then the solids were collected via filtration and the filter cake washed with copious amounts of H 2 0 and then iso-hexane, prior to drying in vacuo at 600C. This 20 yielded the desired compound as an off white solid, 0.335g, 85.8%. Step 6: Preparation of 5-Bromo-4-fluoro-1 H-pyrrolo[2,3-b]pyridin-3-ylamine Tin (II) chloride dihydrate (2.62 g, 13.8mmol) was added in portions to 5-Bromo 4-fluoro-3-nitro-1H-pyrrolo[2,3-b]pyridine (0.717g, 2.76 mmol) in 6N HCI (21mL) at 0 0C and then the cooling was removed and the reaction stirred at RT for 1 25 hour. The reaction mixture was cooled and poured onto a mixture of ice/ H 2 0 (50 mL) and basified to pH 8 by the careful addition of 50% sodium hydroxide solution. This was extracted with DCM / isopropyl alcohol (3:1, v:v) (3 x 100 mL) and the combined extracts were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo to afford a brown solid. This 30 yielded the desired compound as a brown solid, 0.613g, 96.5%. Step 7: Preparation of 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-bromo-4 fluoro-1 H-pyrrolo[2,3-b]pyridin-3-yl)-amide This was prepared using the methodology described for Example 1, Step 3, 0.85g, 77.0%.
WO 2013/114113 PCT/GB2013/050212 32 Step 8: Preparation of Title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 -yl)-5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid (5-bromo-4-fluoro-1 H-pyrrolo[2,3 b]pyridin-3-yl)-amide (40mg, 0.10mmol), (R)-piperidin-3-yl-carbamic acid tert 5 butyl ester (97mg, 0.48mmol) and n-butanol(2 mL) were combined in a 2-5mL microwave vial. The contents were heated at 1600C for 8hours under microwave irradiation and then the reaction mixture was concentrated in vacuo. The residue was taken up in DCM (3mL) then TFA (3 mL) was added at RT and stirring continued for 3 hours. The solvent was removed in vacuo and the residue taken 10 up in EtOAc (20 mL), that was washed with saturated aqueous sodium hydrogen carbonate (3 x 20 mL) and saturated aqueous sodium chloridesaturated aqueous sodium chloride (50 mL). The organics were dried (MgSO 4 ) and concentrated in vacuo to afford a dark yellow gum. This crude material was purified by automated chromatography, eluting with DCM to 10% MeOH/DCM 15 (gradient). Fractions found to contain pure product were combined and concentrated in vacuo to afford the title compound as a pale yellow solid, 10.2mg, 21.4%. LC/MS: RT = 1.77 Min (270nm), m/z = 494.4 [M+H]. Total run time 3.75 min (short pos/neg),HP1 100. 20 'H NMR (de DMSO): 6 1.13-1.20 (m, 1H), 1.44-1.53 (m, 1H), 1.62-1.77 (m, 2H), 2.88-2.98 (m, 2H), 3.10-3.19 (m, 2H), 5.42 (s, 2H), 7.26-7.40 (m, 5H), 7.71 (s, 1H), 8.04 (s, 1H), 8.19 (s, 1H), 8.52 (s, 1H), 9.77 (br s, 1H), 11.71 (s, 1H) 3 protons not seen 25 WO 2013/114113 PCT/GB2013/050212 33 Example 7: 1-Benzvl-1H-pyrazole-4-carboxylic acid [4-{(R)-3-amino Pyrrolidin-1-vI)-5-bromo-1H-pVrrolo[2,3-blpVridin-3-vIl-amide N NH Br 0 HN NN
H
2 N N The title compound (cream solid, 50.6mg, 54.5%) was prepared as described in 5 Example 6, substituting (R)-pyrrolidin-3-yl-carbamic acid tert-butyl ester (180mg, 0.97mmol) for (R)-piperidin-3-yl-carbamic acid tert-butyl ester in Step 8. LC/MS: RT = 1.73 Min (254nm), m/z = 480.4 [M+H]. Total run time 3.75 min (short pos/neg), HP 1100. 1 H NMR (de DMSO): 6 1.68-1.75 (m, 1H), 1.78-1.87 (brs, 2H), 2.12-2.21 (m, 1H), 10 3.00-3.03 (m, 1H), 3.39-3.45 (m, 1H), 3.52-3.58 (m, 2H), 3.66-3.70 (m, 1H), 5.39 (s, 2H), 7.28-7.40 (m, 5H), 7.78 (s, 1H), 8.10 (s, 1H), 8.25 (s, 1H), 8.67 (s, 1H), 9.81 (br s, 1 H), 11.63 (s, 1 H) Example 8 : 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-bromo-4-(R)-3 15 methylamino-piperidin-1-vi)-1H-pvrrolof2.3-blpvridin-3-vil-amide HN N U1H 3 WO 2013/114113 PCT/GB2013/050212 34 The title compound (cream solid, 63.4mg, 51.7%) was prepared as described in Example 6, substituting carbamic acid, N-methyl-N-(3R)-3-piperidinyl-, 1,1 dimethylethyl ester (259mg, 1.21mmol) for (R)-piperidin-3-yl-carbamic acid tert butyl ester in Step 8. 5 LC/MS: RT = 1.78 Min (270nm), m/z = 510.4 [M+H]. Total run time 3.75 min (short pos/neg), HP 1100. 'H NMR (de DMSO): 6 1.28-1.35 (m, 1H), 1.47-1.52 (m, 1H), 1.62-1.68 (m, 1H), 1.72-1.79 (m, 1H), 2.10 (s, 3H), 2.56-2.61 (m, 1H), 2.95-2.99 (m, 1H), 3.09-3.18 (m, 1H), 3.21-3.27 (m, 1H), 3.45-3.52 (m, 1H), 5.42 (s, 2H), 7.26-7.39 (m, 5H), 10 7.79 (s, 1H), 8.07 (s, 1H), 8.19 (s, 1H), 8.47 (s, 1H), 9.82 (br s, 1H), 11.70 (s, 1 H) 1 proton not seen Example 9 : 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-bromo-4-((R)-3 ethylamino-piperidin-1-vI)-1H-pyrrolof2.3-blpvridin-3-vIl-amide 15 N N
H
3 C The title compound (cream solid, 34.8mg, 39.4%) was prepared as described in 20 Example 6, substituting carbamic acid, N-ethyl-N-(3R)-3-piperidinyl-, 1,1 dimethylethyl ester (116mg, 0.51 mmol) for (R)-piperidin-3-yl-carbamic acid tert butyl ester in Step 8. LC/MS: RT = 1.81 Min (270nm), m/z = 524.5 [M+H]. Total run time 3.75 min (short pos/neg),HP 1100.
WO 2013/114113 PCT/GB2013/050212 35 'H NMR (de DMSO): 60.87 (t, 3H), 1.23-1.28 (m, 1H), 1.50-1.56 (m, 1H), 1.71 1.73 (m, 2H), 2.45 (q, 2H), 2.72-2.78 (m, 1H), 2.99-3.05 (m, 1H), 3.14-3.21 (m, 2H), 5.42 (s, 2H), 7.26-7.39 (m, 5H), 7.71 (s, 1H), 8.06 (s, 1H), 8.20 (s, 1H), 8.45 (s, 1 H), 9.70 (br s, 1 H), 11.73 (s, 1 H) 2 protons not seen 5 Example 10 : 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-bromo-4-(R)-3 hydroxy-pyrrolidin-1-vI)-1H-pyrrolof2,3-blpvridin-3-vil-amide N NH B r-kHN N N HO N The title compound (pale orange solid, 47mg, 51.0%) was prepared as 10 described in Example 6, substituting (R)-pyrrolidin-3-ol (84mg, 0.97mmol) for (R)-piperidin-3-yl-carbamic acid tert-butyl ester in Step 8. LC/MS: RT = 2.30 Min (270nm), m/z = 483.4 [M+H]. Total run time 3.75 min (short pos/neg),HP 1100. 1 H NMR (de DMSO): 6 1.94-1.99 (m, 1H), 2.24-2.33 (m, 1H), 3.14-3.17 (m, 1H), 15 3.43-3.49 (m, 1H), 3.53-3.60 (m, 1H), 3.64-3.68 (m, 1H), 4.54 (br s, 1H), 5.37 (s, 2H), 5.50 (d, 1H), 7.29-7.39 (m, 5H), 7.85 (s, 1H), 8.14 (s, 1H), 8.27 (s, 1H), 8.60 (s, 1 H), 9.72 (br s, 1 H), 11.63 (s, 1 H) WO 2013/114113 PCT/GB2013/050212 36 Example 11 : 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-bromo-4-(R)-3 hydroxy-piperidin-1-vI)-1H-pyrrolo[2,3-blpvridin-3-vil-amide HC The title compound (pale yellow solid, 3.6mg, 6.0%) was prepared as described 5 in Example 6, substituting (R)-3-hydroxypiperidine hydrochloride (83mg, 0.6mmol) for (R)-piperidin-3-yl-carbamic acid tert-butyl ester and using potassium carbonate (83mg, 0.6mmol) as base in Step 8. LC/MS: RT = 2.35 Min (270nm), m/z = 495.4 [M+H]. Total run time 3.75 min (short pos/neg),HP 1100. 10 1 H NMR (de DMSO): 6 1.48-1.54 (m, 2H), 1.63-1.68 (m, 1H), 1.78-1.87 (m, 1H), 2.97-3.07 (m, 2H), 3.54-3.63 (m, 1 H), 3.84-3.90 (m, 1 H), 5.33 (br s, 1 H), 5.39 (s, 2H), 7.26-7.39 (m, 5H), 7.88 (s, 1H), 8.18 (s, 1H), 8.20 (s, 1H), 8.62 (s, 1H), 9.91 (br s, 1 H), 11.69 (s, 1 H) 1 proton not seen 15 WO 2013/114113 PCT/GB2013/050212 37 Example 12 : 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-bromo-4-(3 dimethylamino-piperidin-1-vI)-1H-pyrrolo[2,3-blpvridin-3-vil-amide N N
H
3 C The title compound (pale yellow solid, 51.9mg, 54.9%) was prepared as 5 described in Example 6, substituting dimethyl-piperidin-3-yl-amine (116mg, 0.91mmol) for (R)-piperidin-3-yl-carbamic acid tert-butyl ester in Step 8. LC/MS: RT = 1.78 Min (270nm), m/z = 524.5 [M+H]. Total run time 3.75 min (short pos/neg), HP1 100. 1 H NMR (de DMSO):6 1.31-1.37 (m, 1H), 1.54-1.58 (m, 1H), 1.63-1.75 (m, 2H), 10 1.99 (s, 6H), 2.21-2.25 (m, 1H), 3.10-3.19 (m, 3H), 4.26-4.46 (m, 1H), 5.41 (s, 2H), 7.25-7.27 (m, 2H), 7.30-7.39 (m, 3H), 7.70 (s, 1H), 8.07 (s, 1H), 8.20 (s, 1 H), 8.42 (s, 1 H), 9.61 (br s, 1 H), 11.73 (s, 1 H) WO 2013/114113 PCT/GB2013/050212 38 Example 13 : 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-bromo-4-[(R)-3 (cyclopentvlmethyl-amino)-piperidin-1-vil-1H-pyrrolo[2,3-blpvridin-3-vIl amide N NH Ni N7 N N 5 The title compound was prepared from Example 6 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl) amide (40.0 mg, 0.08 mmol), acetic acid (0.01mL, 0.17mmol) and cyclopentanecarbaldehyde (10.8mg, 0.11 mmol) were stirred in MeOH (0.5 mL). Reaction mixture was stirred at RT for 10 minutes before addition of 10 NaBH(OAc) 3 (42.4mg, 0.2mmol) and reaction mixture was left to stir at RT 18 hours. The reaction mixture was basified with sodium bicarbonate solution and extracted with EtOAc (3x30mL). The organic phases were combined, washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The residue was purified by automated column chromatography, eluting 15 with DCM to5% MeOH/DCM (gradient). Fractions found to contain pure product were combined and concentrated in vacuo to afford the title compound as a yellow solid, 5.6mg, 12.1%. LC/MS: RT = 2.00 Min (230nm), m/z = 576.6 [M+H]. Total run time 3.75 min (short pos/neg), HP1 100. 20 1 H NMR (de DMSO): 6 0.94-1.80 (m, 14H), 2.24-2.32 (m, 2H), 2.59-2.66 (m, 1H), 2.93-3.68 (m, 3H), 5.41 (s, 2H), 7.25-7.26 (m, 2H), 7.30-7.39 (m, 3H), 7.68 (d, 1H), 8.03 (s, 1H), 8.19 (s, 1H), 8.42 (s, 1H), 9.66 (br s, 1H), 11.72 (d, 1H) WO 2013/114113 PCT/GB2013/050212 39 Example 14 : 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-bromo-4-(R)-3 isobutylamino-piperidin-1-vI)-1H-pyrrolo[2,3-blpvridin-3-vil-amide HH NN N H N
CH
3 The title compound (cream solid, 38.1mg, 68.4%) was prepared as described in 5 Example 13, substituting isobutyraldeyhyde (9.9mg, 0.14mmol) for cyclopentanecarbaldehyde. LC/MS: RT = 1.91 Min (254nm), m/z = 552.5 [M+H]. Total run time 3.75 min (short pos/neg), HP 1100. 1 H NMR (de DMSO): 60.74 (d, 6H), 1.14-1.20 (m, 1H), 1.40-1.50 (m, 1H), 1.52 10 1.58 (m, 1H), 1.69-1.71 (m, 2H), 2.13-2.22 (m, 2H), 2.58-2.62 (m, 1H), 2.95-3.00 (m, 1H), 3.10-3.15 (m, 1H), 3.21-3.27 (m, 1H), 5.42 (s, 2H), 7.25-7.27 (m, 2H), 7.30-7.39 (m, 3H), 7.66 (d, 1H), 8.02 (s, 1H), 8.19 (s, 1H), 8.41 (s, 1H), 9.62 (br s, 1 H), 11.73 (br s, 1 H) 2 protons not seen 15 WO 2013/114113 PCT/GB2013/050212 40 Example 15 : 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-bromo-4-[(R)-3 (2,2-dimethyl-propylamino)-piperidin-1-vil-1H-pVrrolo[2,3-blpvridin-3-vIl amide N NH i3 r HN .N
H
3 C H
HH
3 CH3 5 The title compound (cream solid, 38.1mg, 68.4%) was prepared as described in Example 13, substituting isobutyraldeyhyde (9.9mg, 0.14mmol) for cyclopentanecarbaldehyde. LC/MS: RT = 1.96 Min (270nm), m/z = 566.5 [M+H]. Total run time 3.75 min (short pos/neg),HP1 100. 10 1 H NMR (de DMSO): 60.75 (s, 9H), 1.08-1.13 (m, 2H), 1.53-1.58 (m, 1H), 1.63 1.74 (m, 2H), 2.10-2.17 (m, 2H), 2.97-3.08 (m, 2H), 5.41 (s, 2H), 7.23-7.26 (m, 2H), 7.30-7.39 (m, 3H), 7.58 (s, 1H), 8.00 (s, 1H), 8.19 (s, 1H), 8.39 (s, 1H) 9.52 (br s, 1 H), 11.74 (s, 1 H) 3 protons not seen 15 WO 2013/114113 PCT/GB2013/050212 41 Example 16 : 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-bromo-4-[(R)-3 (cyclopropylmethyl-amino)-piperidin-1 -vIl-1 H-pyrrolo[2,3-blpyridin-3-vil amide H-N N N N HN 5 The title compound (cream solid, 18.4mg, 41.9%) was prepared as described in Example 13, substituting cyclopropylcarboxaldehyde (7.7mg, 0.14mmol) for cyclopentanecarbaldehyde. LC/MS: RT = 1.88 Min (254nm), m/z = 550.5 [M+H]. Total run time 3.75 min (short pos/neg), HP 1100. 10 1 H NMR (de DMSO): 6 0.09- 0.02 (m, 2H), 0.23-0.26 (m, 2H), 0.64-0.71 (m, 1H), 1.25-1.30 (m, 1H), 1.51-1.56 (m, 1H), 1.68-1.77 (m, 2H), 2.18-2.29 (m, 2H), 2.71-2.77 (m, 1H), 2.96-3.03 (m, 1H), 3.16-3.28 (m, 2H), 5.42 (s, 2H), 7.25-7.27 (m, 2H), 7.30-7.39 (m, 3H), 7.73 (s, 1H), 8.05 (s, 1H), 8.19 (s, 1H), 8.47 (s, 1H), 9.74 (br s, 1 H), 11.71 (s, 1 H) 2 protons not seen 15 WO 2013/114113 PCT/GB2013/050212 42 Example 17: 1-(4-Fluoro-benzvl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-bromo-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH Br HN N
H
2 N N F The title compound was prepared as described in Example 6, substituting 1-(4 5 fluoro-benzyl)-1H-pyrazole-4-carboxylic acid (157mg, 0.715mmol) for 1-benzyl 1 H-pyrazole-4-carboxylic acid, in Step 7. Preparation of 1-(4-fluoro-benzyl)-1 H-pyrazole-4-carboxylic acid Ethyl 4-pyrazolecarboxylate (1.5 g, 10.7mmol) and K 2
CO
3 (4.44 g, 32.1mmol) were stirred in acetone (45mL). To this was added 4-fluorobenzyl bromide 10 (1.38mL, 11.24mmol) and the reaction mixture was heated at 500C for 18 hours.The reaction was cooled to RT and the solids separated via filtration. The filter cake ws washed through with EtOAc and the filtrate concentrated in vacuo. The residue was taken up in MeOH (36mL) and a solution of KOH (1.20g, 21.4mmol) in water (7.2mL) was added. The reaction was refluxed for 2 hours, 15 cooled and the solvent removed in vacuo. The residue was diluted with a little
H
2 0, cooled to 50C, and acidified by the careful addition of 1M HCI solution to precipitate the product. After stirring for 10 minutes the solids were collected via filtration, washed well with water, iso-hexane and dried in vacuo at 400C for 18 hours to afford 1-(4-fluoro-benzyl)-1H-pyrazole-4-carboxylic acid as a white 20 solid, 2.35g, 99.6%. The title compound was isolated as a pale yellow solid, 20.5mg, 17.3%. LC/MS: RT = 1.80 Min (254nm), m/z = 514.4 [M+H]. Total run time 3.75 min (short pos/neg),HP 1100. 1 H NMR (de DMSO): 6 1.12-1.25 (m, 1H), 1.43-1.53 (m, 1H), 1.65-1.75 (m, 2H), 25 1.95-2.30 (br s, 2H), 2.87-3.00 (m, 2H), 3.01-3.20 (m, 2H), 5.41 (s, 2H), 7.21 (dd, WO 2013/114113 PCT/GB2013/050212 43 2H), 7.33 (dd, 2H), 7.71 (s, 1H), 8.04 (s, 1H), 8.19 (s, 1H), 8.51 (br s, 1H), 9.75 (br s, 1 H), 11.70 (br s, 1 H) 1 proton not seen Example 18: 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 5 amino-piperidin-1-vI)-5-bromo-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH Br HN N
H
2 N N C I c 11 The title compound (pale yellow solid, 19.6mg, 17.3%) was prepared as described in Example 6, substituting 1-(4-chloro-benzyl)-1H-pyrazole-4 carboxylic acid (163mg, 0.715mmol), prepared in a similar manner to that 10 described for 1-(4-fluoro-benzyl)-1H-pyrazole-4-carboxylic acid, for 1-benzyl-1H pyrazole-4-carboxylic acid, in Step 7. LC/MS: RT = 1.87 Min (254nm), m/z = 530.4 [M+H]. Total run time 3.75 min (short pos/neg), HP 1100. 1 H NMR (de DMSO): 6 1.11-1.20 (m, 1H), 1.43-1.79 (m, 5H), 2.86-2.98 (m, 2H), 15 3.09-3.20 (m, 2H), 5.42 (s, 2H), 7.28 (d, 2H), 7.44 (d, 2H), 7.71 (s, 1H), 8.05 (s, 1H), 8.19 (s, 1H), 8.53 (br s, 1H), 9.77 (br s, 1H), 11.72 (br s, 1H) 1 proton not seen WO 2013/114113 PCT/GB2013/050212 44 Example 19: 1-(4-Methyl-benzvl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-bromo-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH Br HN N
H
2 N N
H
3 C The title compound (tan solid, 22mg, 18.5%) was prepared as described in 5 Example 6, substituting 1-(4-methyl-benzyl)-1H-pyrazole-4-carboxylic acid (155mg, 0.715mmol), prepared in a similar manner to that described for 1-(4 fluoro-benzyl)-1 H-pyrazole-4-carboxylic acid, for 1 -benzyl-1 H-pyrazole-4 carboxylic acid, in Step 7. LC/MS: RT = 1.85 Min (254nm), m/z = 508.4 [M+H]. Total run time 3.75 min (short pos/neg), HP1 100. 10 1 H NMR (de DMSO): 6 1.11-1.25 (m, 1H), 1.43-1.53 (m, 1H), 1.65-1.77 (m, 2H), 2.13-2.70 (br s, 2H), 2.29 (s, 3H), 2.88-3.01 (m, 2H), 3.08-3.20 (m, 2H), 5.36 (s, 2H), 7.15-7.21 (m, 4H), 7.70 (s, 1H), 8.02 (s, 1H), 8.19 (s, 1H), 8.47 (br s, 1H), 9.74 (br s, 1 H), 11.70 (br s, 1 H) 1 proton not seen 15 WO 2013/114113 PCT/GB2013/050212 45 Example 20: 1-(4-Methoxy-benzvl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-bromo-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH Br HN N
H
2 N N
H
3 CO The title compound (tan solid, 16.2mg, 13.7%) was prepared as described in 5 Example 6, substituting 1-(4-methoxy-benzyl)-1H-pyrazole-4-carboxylic acid (166mg, 0.715mmol) , prepared in a similar manner to that described for 1-(4 fluoro-benzyl)-1 H-pyrazole-4-carboxylic acid, for 1-benzyl-1H-pyrazole-4 carboxylic acid, in Step 7. LC/MS: RT = 1.79 Min (254nm), m/z = 524.4 [M+H]. Total run time 3.75 min 10 (short pos/neg), HP1 100. 1 H NMR (de DMSO): 6 1.10-1.27 (m, 1H), 1.43-1.53 (m, 1H), 1.64-1.95 (m, 4H), 2.87-2.99(m, 2H), 3.09-3.21 (m, 2H), 3.74 (s, 3H), 5.32 (s, 2H), 6.92 (d, 2H), 7.25 (d, 2H), 7.72 (s, 1H), 8.01 (s, 1H), 8.19 (s, 1H), 8.44 (br s, 1H), 9.73 (br s, 1 H), 11.69 (br s, 1 H) 1 proton not seen 15 WO 2013/114113 PCT/GB2013/050212 46 Example 21: 1-Pyridin-2-vImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-bromo-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH Br HN N
H
2 N N N The title compound (yellow solid, 40mg, 68.7%) was prepared as described in 5 Example 6, substituting 1-pyridin-2-ylmethyl-1H-pyrazole-4-carboxylic acid (150mg, 0.74mmol) , prepared in a similar manner to that described for 1 pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid in Example 81, Step 1, for 1 benzyl-1 H-pyrazole-4-carboxylic acid, in Step 7. It was isolated as a formate salt following purification by preparative HPLC at pH4. 10 LC/MS: RT = 0.87 Min (270nm), m/z = 497 [M+H]. Total run time 1.9 min (super short pos),HP1200. 1 H NMR (de DMSO): d D1.21-1.34 (br m, 1H), 1.40-1.53 (br m, 1H), 1.59-1.68 (br m, 1H), 1.78-1.86 (br m, 1H), 2.98-3.08 (br m, 1H), 3.13-3.29 (br m, 3H), 3.33-3.44 (br m, 1H),5.52 (s, 2H), 7.10 (d, 1H), 7.31-7.35 (m, 1H), 7.54 (s, 1H), 15 7.78-7.82 (m, 1H), 8.06 (s, 1H), 8.20 (s, 1H), 8.49-8.56 (m, 2H), 9.77 (br s, 1H) 3 protons not seen WO 2013/114113 PCT/GB2013/050212 47 Example 22: 1-Pyridin-3-vImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-bromo-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH Br HN N
H
2 N The title compound (tan solid, 9.5mg, 38%) was prepared as described in 5 Example 6, substituting 1-pyridin-3-ylmethyl-1H-pyrazole-4-carboxylic acid (150mg, 0.74mmol) prepared in a similar manner to that described for 1-pyridin 4-ylmethyl-1H-pyrazole-4-carboxylic acid in Example 81, Step 1, for 1-benzyl 1 H-pyrazole-4-carboxylic acid, in Step 7. LC/MS: RT = 0.83 Min (270nm), m/z = 497 [M+H]. Total run time 1.9 min (super 10 short pos),HP1200. 1 H NMR (de DMSO): d 1.43-1.55 (br m, 1H), 1.61-1.69 (br m, 1H), 1.72-1.79 (br m, 1 H), 3.03-3.22 (br m, 4H), 5.48 (s, 2H), 7.39-7.43 (m, 1 H), 7.61 (s, 1 H), 7.66 7.69 (m, 1 H), 8.05 (s, 1 H), 8.22 (s, 1 H), 8.50-8.55 (m, 3H), 9.61 (br s, 1 H), 11.81 (br s, 1 H) 4 protons not seen 15 WO 2013/114113 PCT/GB2013/050212 48 Example 23: 1-Pyridin-4-vImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-bromo-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH Br HN N
H
2 N N N The title compound (tan solid, 25mg, 24%) was prepared as described in 5 Example 6, substituting 1-pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid (225mg, 1.1mmol), described in Example 81, Step 1, for 1-benzyl-1H-pyrazole 4-carboxylic acid, in Step 7. LC/MS: RT = 0.74 Min (254nm), m/z = no mass [M+H]. Total run time 1.9 min (super short pos),HP1200. 10 1 H NMR (de DMSO): d D 1.10-1.20 (br m, 1H), 1.44-1.54 (br m, 1H), 1.61-1.80 (br m, 2H), 2.87-2.99 (br m, 2H), 3.09-3.23 (br m, 2H),5.51 (s, 2H), 7.15 (d, 2H), 7.72 (s, 1H), 8.10 (s, 1H), 8.20 (s, 1H), 8.55 (d, 2H), 8.59 (s, 1H), 9.82 (s, 1H), 11.72 (br s, 1 H) 4 protons not seen 15 WO 2013/114113 PCT/GB2013/050212 49 Example 24: N-{4-[(3R)-3-aminopiperidin-1-vIl-5-chloro-1 H-pyrrolof2.3 bipyridin-3-yil-1 -benzyl-1 H-pyrazole-4-carboxamide N NH cr HN N
H
2 N N The title compound was prepared according to an analogous route to that 5 outlined in Scheme 2. The title compound was prepared as described in Example 6, Steps 1 and 2. Step 3: 5-Chloro-4-fluoro-1 H-pyrrolo[2,3-b]pyridine 4-Fluoro-1-[tris(propan-2-yl)silyl]-1H-pyrrolo[2,3-b]pyridine (2g, 6.84mmol) in 10 THF (80mL) at -78 OC was treated drop wise with sec-butyllithium solution, 1.4M in cyclohexane (4.48 mL, 6.27 mmol). The reaction was stirred at -780C for 0.5 hours. A solution of hexachloroethane (4.05g, 17.1mmol) in THF (20mL) was added drop wise and the reaction was stirred at -780C for a further 0.5 hours. The reaction was quenched by the addition of saturated aqueous ammonium 15 chloride. The mixture was extracted with iso-hexane (x2) and the combined extracts washed with saturated aqueous sodium chloride. The solution was dried over anhydrous MgSO4 and concentrated to a yellow gum. The crude material was stirred in THF (50mL) and tetrabutylammonium fluoride solution, 1.OM in THF (6.84 mL, 6.84 mmol) was added drop wise at RT. The 20 reaction was stirred at RT for a further 1 hour before H 2 0 and EtOAc were added. The organic layer was separated and the aqueous phase was extracted with another portion of EtOAc. The combined organic phases were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo to afford a pale orange solid. The crude residue was purified by automated flash 25 chromatography eluting with iso-hexane to 40% EtOAc / iso-hexane. Fractions WO 2013/114113 PCT/GB2013/050212 50 containing pure material were combined and solvent removed in vacuo to afford the desired product as a white solid 1.0g, 85.7%. Step 4: Preparation of 5-chloro-4-fluoro-3-nitro-1 H-pyrrolo[2,3-b]pyridine This was prepared using the methodology described for Example 6, Step 5, 5 substituting 5-chloro-4-fluoro-1H-pyrrolo[2,3-b]pyridine (1g, 5.86mmol) for 5 bromo-4-fluoro-1 H-pyrrolo[2,3-b]pyridine. The title compound was isolated as a white solid, 1.15g, 91.1%. Step 5: Preparation of 5-Chloro-4-fluoro-1 H-pyrrolo[2,3-b]pyridin-3-ylamine This was prepared using the methodology described for Example 6, Step 6, 10 substituting 5-chloro-4-fluoro-3-nitro-1 H-pyrrolo[2,3-b]pyridine (202.9mg, 0.94mmol) for 5-bromo-4-fluoro-3-nitro-1 H-pyrrolo[2,3-b]pyridine. The title compound was isolated as a solid, 167.4mg, 95.8%. Step 6: Preparation of 1 -benzyl-1 H-pyrazole-4-carboxylic acid (5-chloro-4-fluoro 15 1 H-pyrrolo[2,3-b]pyridin-3-yl)-amide 5-Chloro-4-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylamine (167.4 mg, 0.90mmol) was stirred in DMF (9.0 mL) with Et 3 N (0.25 mL, 1.80 mmol) and 1-benzyl-1H pyrazole-4-carboxylic acid (200.6 mg, 0.99 mmol). HATU (342.2 mg, 0.90 mmol) was added and the reaction was stirred at RT for 2 hours. The reaction mixture 20 was diluted with H 2 0, and extracted with EtOAc (3 x 30 mL). The combined extracts were washed with saturated aqueous sodium bicarbonate, saturated aqueous sodium chloride (4 x 60 mL), dried (MgSO 4 ) and solvent removed in vacuo to afford a brown gum. This was triturated with Et 2 0, filtered and washed with Et 2 0 prior to drying in vacuo at 400C. This afforded the title compound as an 25 off white solid, 240.5mg, 72.1%. Step 7: Preparation of title compound: N-{4-[(3R)-3-aminopiperidin-1-yl]-5 chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl}-1 -benzyl-1 H-pyrazole-4-carboxamide A solution of 1-benzyl-1H-pyrazole-4-carboxylic acid (5-chloro-4-fluoro-1H 30 pyrrolo[2,3-b]pyridin-3-yl)-amide (100.0 mg, 0.27 mmol) in n-BuOH (5.4 mL) was treated with (R)-piperidin-3-yl-carbamic acid tert-butyl ester (270.8 mg, 1.35 mmol) and heated under microwave irradiation at 1600C for 6 hours. The solvent was removed in vacuo and residue was taken up in DCM (5 mL). TFA (5 mL) was added and the reaction stirred at RT for 18hours. The reaction mixture was WO 2013/114113 PCT/GB2013/050212 51 concentrated in vacuo, the residue taken up in EtOAc (40mL), washed with aqueous ammonia solution (2 x 50mL), saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The crude material was purified by automated column chromatography, eluting with DCM to 10% MeOH/DCM 5 (gradient). The fractions containing pure product were combined and concentrated in vacuo to afford the title compound as a cream solid, 53.6mg, 44.1%. LC/MS: RT = 1.77 Min (270nm), m/z = 450.4 [M+H]. Total run time 3.75 min (short pos/neg),HP1 100. 10 'H NMR (de DMSO): 6 1.16-1.21 (m, 1H), 1.45-1.49 (m, 1H), 1.66-1.74 (m, 4H), 2.90-2.94 (m, 2H), 3.13-3.16 (m, 2H), 5.42 (s, 2H), 7.26-7.39 (m, 5H), 7.73 (s, 1H), 8.04 (s, 1H), 8.08 (s, 1H), 8.53 (s, 1H), 9.73 (br s ,1H), 11.68 (s, 1H) 1 proton not seen 15 Example 25: 1-(4-Methyl-benzvl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-chloro-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH cr / N
H
2 N N
H
3 C The title compound (cream solid, 24mg, 28.4%) was prepared as described in Example 24, substituting 1-(4-methyl-benzyl)-1H-pyrazole-4-carboxylic acid 20 (256.3mg, 1.19mmol) for 1-benzyl-1H-pyrazole-4-carboxylic acid, in Step 6. LC/MS: RT = 1.82 Min (254nm), m/z = 464 [M+H]. Total run time 3.75 min (short pos)HP 1100. 1 H NMR (de DMSO): E D, 1.18 (m, 1H), 1.52 (m, 2H), 1.68 (m, 2H), 2.33 (2, 3H), 2.91 (m, 2H), 3.14 (m, 2H), 3.33 (m, 2H), 5.36 (s, 2H), 7.19 (m, 4H), 7.75(s, 1H), 25 8.03(s, 1 H), 8.09(s, 1 H), 8.50 (s, 1 H), 9.73(s, 1 H), 11.69 (s, 1 H) WO 2013/114113 PCT/GB2013/050212 52 Example 26: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-chloro-1H-pyrrolof2.3-blpvridin-3-vil-amide N NH cr N N
H
2 N N F 5 The title compound (cream solid, 24.2mg, 20.1%) was prepared as described in Example 24, substituting 1-(4-fluoro-benzyl)-1H-pyrazole-4-carboxylic acid (261 mg, 1 .1 9mmol) for 1 -benzyl-1 H-pyrazole-4-carboxylic acid, in Step 6. LC/MS: RT = 1.77 Min (270nm), m/z = 468.5 [M+H]. Total run time 3.75 min (short pos/neg),HP 1100. 10 1 H NMR (de DMSO): 6 1.18-1.23 (m, 1H), 1.45-1.50 (m, 1H), 1.68-1.70 (m, 2H), 2.94-2.99 (m, 2H), 3.11-3.13 (m, 2H), 5.41 (s, 2H), 7.19-7.23 (m, 2H), 7.32-7.36 (m, 2H), 7.71 (s, 1H), 8.04 (s, 1H), 8.09 (s, 1H), 8.51 (s, 1H), 9.69 (br s, 1H), 11.71 (br s, 1 H) 3 protons not seen 15 WO 2013/114113 PCT/GB2013/050212 53 Example 27: 1-(4-Chloro-benzvl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-chloro-1H-pyrrolo[2,3-blpvridin-3-vIl-amide N NH cr N
H
2 N N cr The title compound (cream solid, 22.1mg, 18.4%) was prepared as described in 5 Example 24, substituting 1-(4-chloro-benzyl)-1H-pyrazole-4-carboxylic acid (280.5mg, 1.19mmol) for 1-benzyl-1H-pyrazole-4-carboxylic acid, in Step 6. LC/MS: RT = 1.84 Min (270nm), m/z = 484.4 [M+H]. Total run time 3.75 min (short pos/neg),HP1 100. 1 H NMR (de DMSO): 61.15-1.20 (m, 1H), 1.45-1.49 (m, 1H), 1.66-1.72 (m, 2H), 10 2.92-2.96 (m, 2H), 3.13-3.16 (m, 2H), 5.42 (s, 2H), 7.29 (d, 2H), 7.44 (d, 2H), 7.72 (s, 1 H), 8.05 (s, 1 H), 8.09 (s, 1 H), 8.53 (s, 1 H), 9.72 (br s, 1 H), 11.70 (br s, 1 H) 3 protons not seen Example 28: 1-(4-Methoxy-benzvl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 15 amino-piperidin-1-vI)-5-chloro-1H-pyrrolof2.3-blpvridin-3-vIl-amide N N H cr' N
H
2 N N
H
3
CO
WO 2013/114113 PCT/GB2013/050212 54 The title compound (white solid, 24mg, 19.8%) was prepared as described in Example 24, substituting 1-(4-methoxy-benzyl)-1H-pyrazole-4-carboxylic acid (275.3mg, 1.19mmol) for 1-benzyl-1H-pyrazole-4-carboxylic acid, in Step 6. LC/MS: RT = 1.77 Min (254nm), m/z = 480 [M+H]. Total run time 3.75 min (short 5 pos/neg),HP1100. 'H NMR (de DMSO): 6 1.17 (m, 1H), 1.49 (m, 2H), 1.71 (m, 2H), 2.91 (m, 2H), 3.14 (m, 2H), 3.33 (m, 2H), 3.75 (s, 3H), 5.33 (s, 2H), 6.94 (d, J 8.68, 2H), 7.27(d, J 8.65, 2H), 7.75 (s, 1H), 8.01(s, 1H), 8.08 (s, 1H), 8.46(s, 1H), 9.71 (s, 1H), 11.65 (s, 1H) 10 Example 29: 1-Benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino Pyrrolidin-1-vI)-5-chloro-1H-pyrrolof2.3-blpvridin-3-vIl-amide N NH cr' 0 N NN
H
2 N N The title compound (white solid, 42.5mg, 60.1%) was prepared as described in 15 Example 24, substituting (R)-pyrrolidin-3-yl-carbamic acid tert-butyl ester (151.1mg, 0.81mmol) for (R)-piperidin-3-yl-carbamic acid tert-butyl ester, in Step 7. LC/MS: RT = 1.71 Min (254nm), m/z = 436.4 [M+H]. Total run time 3.75 min (short pos/neg),HP 1100. 20 1 H NMR (de DMSO): 6 1.66-1.72 (m, 1H), 2.09-2.17 (m, 1H), 3.02-3.05 (m, 1H), 3.37-3.43 (m, 1H), 3.51-3.58 (m, 2H), 3.63-3.68 (m, 1H), 5.39 (s, 2H), 7.28-7.39 (m, 5H), 7.76 (s, 1H), 8.10 (s, 1H), 8.14 (s, 1H), 8.66 (s, 1H), 9.78 (s, 1H), 11.60 (br s, 1 H) 2 protons not seen WO 2013/114113 PCT/GB2013/050212 55 Example 30: N-{4-[(3R)-3-aminopiperidin-1-vIl-5-cyclopropyl-1 H Pyrrolo[2,3-blpvridin-3-vIl-1-benzyl-1 H-pyrazole-4-carboxamide N NH HN N
H
2 N N The title compound was prepared from ((R)-1-{3-[(1-benzyl-1H-pyrazole-4 5 carbonyl)-amino]-5-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester, the product of Step 1, Example 53. ((R)-1 -{3-[(1 -benzyl-1 H-pyrazole-4-carbonyl)-amino]-5-bromo-1 H-pyrrolo[2,3 b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester (29mg, 0.05mmol), 10 cyclopropylboronic acid (8.4 mg, 0.1mmol), Pd(dppf)C1 2 (5.1mg, 0.01 mol) and
K
2
CO
3 (27.6mg, 0.20mmol) and THF (4.5 mL)/ H 2 0H 2 0 (0.5 mL) were charged to a microwave vial and degassed. The contents were heated under microwave irradiation at 1200C for 1 hour. The reaction mixture was partitioned between EtOAc and H 2 0H 2 0, then the organic layer was separated and the aqueous 15 extracted with another portion of EtOAc. The combined organics were washed with saturated aqueous sodium hydrogen bicarbonate, H 2 0H 2 0, saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent removed in vacuo to give crude ((R)-1 -{3-[(1 -benzyl-1 H-pyrazole-4-carbonyl)-amino]-5-cyclopropyl-1 H pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester as a 20 yellow oil. This material was taken up in hydrochloric acid solution, 1.25 M in MeOH (5mL) and irradiated in a microwave for 1 hour at 800C. The volatiles were removed in vacuo and the residue was taken up in the minimum volume of MeOH and loaded onto a SCX2 ion exchange column that had been primed with MeOH. 25 The column was washed with DCM, MeOH and the title compound was eluted WO 2013/114113 PCT/GB2013/050212 56 using ammonia solution, 3.5M in MeOH. This solution was concentrated in vacuo and the residue was purified by preparative HPLC at pH4 and then at pH9. The material was taken up in acetone and filtered through a plug of potassium carbonate. The filtrate was concentrated in vacuo to afford the title 5 compound as a solid, 1.5mg, 6.8%. LC/MS: RT = 1.56 Min (270nm), m/z = 456 [M+H]. Total run time 3.75 min (short pos/neg), HP1 100. 'H NMR (d 4 MeOH): 60.72-1.07 (m, 4H), 1.20-2.18 (m, 5H), 3.16-3.24 (m, 1H), 3.37-3.52 (m, 3H), 5.41 (s, 2H), 7.28-7.42 (m, 5H), 7.66 (s, 1H), 7.96 (s, 1H), 10 8.10 (s, 1H), 8.32 (s, 1H) 5 protons not seen Example 31: 1-Benzvl-1H-pyrazole-4-carboxylic acid [4-{(R)-3-amino piperidin-1-vI)-5-hydroxy-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH HO0 H N H NN H2N N 15 The title compound was prepared according to the route outlined in Scheme 9. The title compound was prepared as described in Example 6. In Step 3, (2R,8aS)-(+)-(camphorylsulfonyl)oxaziridine (2.55g, 11.1 mmol) was used as the electrophile instead of carbon tetrabromide. Following the usual work up, purification by flash column chromatography eluting with iso-hexane and then 20 5%EtOAc / iso-hexane, the desired intermediate, 4-fluoro-1-triisopropylsilanyl 1H-indol-5-ol, was isolated as a pale yellow oil, 0.91g, 66.5%. Step 4: Preparation of 2,2-dimethyl-propionic acid 4-fluoro-1-triisopropylsilanyl 1 H-pyrrolo[2,3-b]pyridin-5-yl ester To a solution of 4-fluoro-1-triisopropylsilanyl-1H-indol-5-o (1 g, 3.24mmol) and 25 Et 3 N (0.45mL, 3.24mmol) in DCM (1mL) was added pivaloyl chloride (0.8 mL, 6.5 mmol) and stirred at RT for 3 hours. The mixture was diluted with DCM (30 WO 2013/114113 PCT/GB2013/050212 57 mL) and washed with H 2 0, saturated aqueous sodium chloride, dried over anhydrous Na 2
SO
4 and concentrated in vacuo. The crude material was purified by flash column chromatography to give the title compound as a clear oil, 0.55g, 43.2%. 5 Step 5: Preparation of 2,2-dimethyl-propionic acid 4-fluoro-1 H-pyrrolo[2,3 b]pyridin-5-yl ester Tetrabutylammonium fluoride solution, 1.OM in THF (2.8mL, 2.8mmol) was added drop wise to a solution of 2,2-dimethyl-propionic acid 4-fluoro-1 triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-5-y ester (550mg, 1.4mmol) in THF 10 (10mL) at 0CC. After addition, stirring was continued for a further 1.5hours at RT. EtOAc was added and the mixture washed with H 2 0 and saturated aqueous sodium chloride. The organics were dried over MgSO 4 , concentrated in vacuo and the crude material obtained was purified by flashchromatography eluting with 33% EtOAc / iso-hexane. Fractions containing pure product were combined 15 and concentrated in vacuo to afford the title compound as a white solid, 270mg, 81.6%. Step 6: Preparation of 2,2-dimethyl-propionic acid 4-fluoro-3-nitro-1H pyrrolo[2,3-b]pyridin-5-yl ester 20 This was prepared using the methodology described for Example 6, Step 5, substituting 2,2-dimethyl-propionic acid 4-fluoro-1 H-pyrrolo[2,3-b]pyridin-5-yl ester (270mg, 1.14mmol) for 5-bromo-4-fluoro-1H-pyrrolo[2,3-b]pyridine. The title compound was isolated as a pale yellow solid, 321mg, 99.9%. Step 7: Preparation of 2,2-dimethyl-propionic acid 4-((R)-3-tert 25 butoxycarbonylamino-piperidin-1 -yl)-3-nitro-1 H-pyrrolo[2,3-b]pyridin-5-yl ester 2,2-Dimethyl-propionic acid 4-fluoro-3-nitro-1H-pyrrolo[2,3-b]pyridin-5-yl ester (95mg, 0.34 mmol), (R)-piperidin-3-yl-carbamic acid tert-butyl ester (81mg, 0.4mmol), DIPEA (89uL, 0.51mmol) and 1-butanol (2 mL) were combined in a microwave vial and then heated at 1200C for 2 hours under microwave 30 irradiation. The mixture was concentrated in vacuo and the residue purified by flashchromatography eluting with 25% EtOAc / iso-hexane. Fractions containing product were combined and concentrated in vacuo to give the title compound as a yellow solid 73mg, 46.5%.
WO 2013/114113 PCT/GB2013/050212 58 Step 8: Preparation of 2,2-dimethyl-propionic acid 3-amino-4-((R)-3-tert butoxycarbonylamino-piperidin-1 -yl)-1 H-pyrrolo[2,3-b]pyridin-5-yl ester To a mixture of 2,2-dimethyl-propionic acid 4-((R)-3-tert-butoxycarbonylamino piperidin-1-yl)-3-nitro-1H-pyrrolo[2,3-b]pyridin-5-yl ester (73mg, 0.158mmol) and 5 Et 3 N (0.2mL) in MeOH (20mL) was added Raney Nickel, 50% slurry in H 2 0 (10 mg). The reaction was stirred at RT an atmosphere of hydrogen for 18hours. The catalyst was removed via filtration and the filtrate concentrated in vacuo to afford the title compound as a brown solid, 68 mg, 100%. Step 9: Preparation of 2,2-dimethyl-propionic acid 3-[(1-benzyl-1H-pyrazole-4 10 carbonyl)-amino]-4-((R)-3-tert-butoxycarbonylamino-piperidin-1 -yl)-1 H pyrrolo[2,3-b]pyridin-5-yl ester 2,2-Dimethyl-propionic acid 3-amino-4-((R)-3-tert-butoxycarbonylamino piperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl ester (68mg, 0.158mmol) and 1 benzyl-1H-pyrazole-4-carboxylic acid (32mg, 0.158mmol) were stirred in DMF 15 (5mL) at RT. To this was added triethylamine (0.04mL, 5.74mmol) followed by HATU (60mg, 0.158mmol) and the mixture was stirred at room temperature for 5 hours. The resulting solution was concentrated in vacuo and the resultant brown gum was taken up in EtOAc (100mL). It was washed with H 2 0 (2x6OmL), saturated aqueous sodium chloride (20mL), dried (MgSO 4 ) and concentrated in 20 vacuo. The crude material was purified by flash column chromatography to afford the title compound as a brown solid, 63mg, 64.8%. Step 10: Preparation of ((R)-1-{3-[(1-benzyl-1H-pyrazole-4-carbonyl)-amino]-5 hydroxy-1 H-pyrro 25 lo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester To a solution of 2,2-dimethyl-propionic acid 3-[(1-benzyl-1H-pyrazole-4 carbonyl)-amino]-4-((R)-3-tert-butoxycarbonylamino-piperidin-1 -yl)-1 H pyrrolo[2,3-b]pyridin-5-yl ester (382mg, 0.62mmol, in ethanol (15mL) was added 30 aqueous NaOH, 4N (1.5 mL, 6mmol) and the reaction was stirred at RT for 2 hours. The solvent was removed in vacuo and the residue was carefully neutralized to pH7 with HCI, 6N. The mixture was extracted with EtOAc (3x4OmL) and the combined extracts washed with saturated aqueous sodium chloride (x3), dried over Na 2
SO
4 and concentrated in vacuo. The crude material WO 2013/114113 PCT/GB2013/050212 59 was purified twice by flash column chromatography eluting with 6% MeOH / DCM and the fractions containing pure product were combined and concentrated in vacuo to give the title compound as a pale brown solid 115mg, 34.9%. 5 Step 11: Preparation of title compound: 1-benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 -yl)-5-hydroxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide ((R)-1 -{3-[(1 -Benzyl-1 H-pyrazole-4-carbonyl)-amino]-5-hydroxy-1 H-pyrrolo[2,3 b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester (115mg, 0.216mmol) 10 was stirred in MeOH (4mL) and hydrochloric acid solution, 4N in MeOH (1 mL) was added. The mixture was stirred at RT for 18hours and then neutralized (pH 7) by the careful addition of ammonium hydroxide solution. DCM (70mL) was added and the mixture washed with H 2 0 (2x20 mL), saturated aqueous sodium chloride (2x20 mL), dried over Na 2
SO
4 and concentrated in vacuo to afford the 15 title compound as the hydrochloride salt, 75 mg, 80.5%. LC/MS: RT = 2.02 Min (270nm), m/z = 432 [M+H]. Total run time 7.5min (long pos), HP 1100. 'H NMR (de DMSO): E 1.35-1.48 (m, 2H), 1.59-1.69 (m, 1H), 1.84-1.91 (m, 1H), 2.99-3.11 (m, 2H), 3.17-3.38 (m, 2H), 5.42 (s, 2H), 7.24-7.28 (m, 2H), 7.30-7.40 20 (m, 3H), 7.50 (d, 1H), 7.88 (s, 1H), 7.99 (br s, 3H), 8.02 (s, 1H), 8.42 (s, 1H), 9.31 (br s, 1 H), 9.52 (s, 1 H), 11.39 (s, 1 H) 1 proton not seen Example 32: 1-Benzvl-1H-pyrazole-4-carboxylic acid [4-{(R)-3-amino piperidin-1-vI)-5-methoxy-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH
H
3 C.O NN
H
2 N N 25 WO 2013/114113 PCT/GB2013/050212 60 The title compound was prepared from 4-fluoro-1-triisopropylsilanyl-1H-indol-5 ol, the product of Step 3, in Example 31. Step 1: Preparation of 4-Fluoro-5-methoxy-1-triisopropylsilanyl-1H-pyrrolo[2,3 5 b]pyridine Diisopropyl azodicarboxylate (688mg, 3.4mmol) was added drop wise to a solution of 4-fluoro-1-triisopropylsilanyl-1H-indol-5-ol (805mg, 2.61mmol) and triphenylphosphine (892mg, 3.44mmol) in THF (25mL) at 00C and the reaction stirred for 10mins. MeOH (1mL, 24.7mmol) was added and the mixture stirred 10 for a further 1 hour at 00C and then RT for hour. The solution was concentrated in vacuo to a dark yellow gum. The crude material was purified by column chromatography eluting with iso-hexane to 3% EtOAc / iso-hexane. Fractions containing pure product were combined and concentrated in vacuo to afford the title compound as a pale yellow oil, 680mg, 80.8%. 15 Step 2: Preparation of 4-Fluoro-5-methoxy-1 H-pyrrolo[2,3-b]pyridine This was prepared using the methodology described for Example 31, Step 5, substituting 4-fluoro-5-methoxy-1 -triisopropylsilanyl-1 H-pyrrolo[2,3-b]pyridine (630mg, 1.95mmol) for 2,2-dimethyl-propionic acid 4-fluoro-1-triisopropylsilanyl 20 1 H-pyrrolo[2,3-b]pyridin-5-yl ester. The title compound was isolated as a pale yellow solid, 285mg, 87.8%. Step 3: Preparation of 4-Fluoro-5-methoxy-3-nitro-1 H-pyrrolo[2,3-b]pyridine This was prepared using the methodology described for Example 6, Step 5, substituting 4-fluoro-5-methoxy-1 H-pyrrolo[2,3-b]pyridine (280mg, 1.69mmol) for 25 5-bromo-4-fluoro-1H-pyrrolo[2,3-b]pyridine. The title compound was isolated as a pale yellow solid, 325mg, 91.3%. Step 4: Preparation of [(R)-1-(5-methoxy-3-nitro-1H-pyrrolo[2,3-b]pyridin-4-yl) piperidin-3-yl]-carbamic acid tert-butyl ester This was prepared using the methodology described for Example 31, Step 7, 30 substituting 4-fluoro-5-methoxy-3-nitro-1 H-pyrrolo[2,3-b]pyridine (270mg, 1.28mmol) for 2,2-dimethyl-propionic acid 4-fluoro-3-nitro-1H-pyrrolo[2,3 b]pyridin-5-yl ester. The title compound was isolated as a yellow solid, 385mg, 76.9%.
WO 2013/114113 PCT/GB2013/050212 61 Step 5: Preparation of [(R)-1-(3-amino-5-methoxy-1H-pyrrolo[2,3-b]pyridin-4-yl) piperidin-3-yl]-carbamic acid tert-butyl ester This was prepared using the methodology described for Example 31, Step 8, substituting [(R)-1 -(5-methoxy-3-nitro-1 H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-3 5 yl]-carbamic acid tert-butyl ester (130mg, 0.332mmol) for 2,2-dimethyl-propionic acid 4-((R)-3-tert-butoxycarbonylamino-piperidin-1 -yl)-3-nitro-1 H-pyrrolo[2,3 b]pyridin-5-yl ester. The title compound was isolated as a brown oil, 120mg, 100%. 10 Step 6: Preparation of ((R)-1-{3-[(1-benzyl-1H-pyrazole-4-carbonyl)-amino]-5 methoxy-1 H-pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester This was prepared using the methodology described for Example 31, Step 9, substituting [(R)-1-(3-amino-5-methoxy-1H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-3 15 yl]-carbamic acid tert-butyl ester (120mg, 0.332mmol) for 2,2-dimethyl-propionic acid 3-amino-4-((R)-3-tert-butoxycarbonylamino-piperidin-1 -yl)-1 H-pyrrolo[2,3 b]pyridin-5-yl ester. The title compound was isolated as a pale brown solid, 68mg, 37.5%. Step 7: Preparation of title compound: 1-benzyl-1H-pyrazole-4-carboxylic acid 20 [4-((R)-3-amino-piperidin-1 -yl)-5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide To a solution of ((R)-1-{3-[(1-benzyl-1H-pyrazole-4-carbonyl)-amino]-5-methoxy 1 H-pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester (320 mg, 0.58mmol) in MeOH (10mL) was added hydrochloric acid solution, 3.0 M in MeOH (2mL) at 0CC. After addition the reaction mixture was stirred at 500C for 3 25 hours and then concentrated in vacuo. The residue was partitioned between saturated aqueous sodium carbonate (15 mL) and 20% MeOH in DCM (100 mL). The organics were separated, washed with H 2 0, saturated aqueous sodium chloride and dried over anhydrous Na 2
SO
4 . The solvent was removed in vacuo and the crude material purified by flash column chromatography to give 30 the title compound as an off white solid, 105 mg, 73%. LC/MS: RT = 2.14 Min (270nm), m/z = 446 [M+H]. Total run time 7.5 min (long pos), HP 1100. 'H NMR (de DMSO): 6 1.15-1.25 (m, 1H), 1.40-1.51 (m, 1H), 1.67-1.76 (m, 2H), 2.25 (br s, 2H), 2.82-2.94 (m, 2H), 3.00-3.08 (m, 2H), 3.19-3.25 (m, 1H), 3.85 (s, WO 2013/114113 PCT/GB2013/050212 62 3H), 5.41 (s, 2H), 7.25-7.40 (m, 5H), 7.71 (s, 1H), 8.01 (s, 1H), 8.07 ( s, 1H), 8.54 (s, 1 H), 9.71 (br s, 1 H), 11.22 (br s, 1 H). Example 33: 1-Benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino 5 piperidin-1-vI)-5-methyl-1H-pyrrolof2,3-blpvridin-3-vil-amide N NH
H
3 C 0 N
H
2 N N The title compound was prepared from ((R)-1-{3-[(1-benzyl-1H-pyrazole-4 carbonyl)-amino]-5-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester, the product of Step 1, Example 53. 10 ((R)-1 -{3-[(1 -benzyl-1 H-pyrazole-4-carbonyl)-amino]-5-bromo-1 H-pyrrolo[2,3 b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester (48.0mg, 0.08mMmol), methylboronic acid (8.70mg, 0.15mMmol), Pd(dppf)C1 2 (7.0 mg, 0.01mMmol) and K 2
CO
3 (22.1mg, 0.16mMmol) and THF (4.5 mL)/ H 2 0 (0.5 mL) 15 were charged to a microwave vial and degassed. The contents were heated under microwave irradiation at 1200C for 2 hours. The reaction mixture was partitioned between EtOAc and H 2 0, then the organic layer was separated and the aqueous extracted with another portion of EtOAc. The combined organics were washed with H 2 0, saturated aqueous sodium chloride, dried (MgSO 4 ) and 20 solvent removed in vacuo. The crude product was purified by automated column chromatography eluting with iso-hexane to 15 % EtOAc/iso-hexane (gradient). Fractions found to contain pure material were combined and solvent removed in vacuo to afford ((R)-1-{3-[(1-benzyl-1H-pyrazole-4-carbonyl)-amino]-5-methyl 1 H-pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester.
WO 2013/114113 PCT/GB2013/050212 63 This was taken up in DCM (5mL) and trifluoroacetic acid (0.05mL, 0.6 mMmol) was added drop wise and the reaction was allowed to stir for 2 hours at RT. Trifluoroacetic acid (0.05 mL, 0.6mMmol) was added and the reaction was stirred for a further 1 hour at RT. The volatiles were removed in vacuo and 5 residue was partitioned between DCM and H 2 0. The organic layer was separated and washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and the volatiles removed in vacuo. The residue was purified by preparative HPLC at pH9, taken up in acetone and filtered through a plug of potassium carbonate. The filtrate was concentrated in vacuo to afford the title compound as 10 a solid, 4mg, 11.5%. LC/MS: RT = 1.61 Min (270nm), m/z = 430 [M+H]. Total run time 3.75 min (short pos/neg), HP 1100. 'H NMR (d 4 MeOH) 6 1.11-1.23 (m, 1H), 1.50-1.64 (m, 1H), 1.69-1.76 (m, 1H), 1.78-1.87 (m, 1H), 2.44 (s, 3H), 2.83-2.97 (m, 2H), 3.08-3.23 (m, 2H), 5.42 (s, 15 2H), 7.28-7.41 (m, 5H), 7.62 (s, 1H), 7.93 (s, 1H), 8.04 (s, 1H), 8.24 (s, 1H) 5 protons not seen Example 34: 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-(4-piperidin-1 ylmethyl-phenyl)-1 H-pyrrolo[2,3-blpvridin-3-vil-amide N ,NH N N N 20 The title compound was made according to the route outlined in Scheme 3. The title compound was prepared from Example 1. Step 1: Preparation of 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4-formyl 25 phenyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide WO 2013/114113 PCT/GB2013/050212 64 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl) amide (100mg, 0.25mmol), 4-formylphenylboronic acid (41.6mg, 0.28mmol),
K
2
CO
3 (103.7mg, 0.75mmol) and Pd(dppf)C1 2 (18.3mg, 0.025mmol) were 5 combined in THF/ H 2 0 (2.1mL : 0.23 mL) and thoroughly degassed. The reaction mixture was heated at 120 OC for 1 hour under microwave irradiation. The reaction was diluted with EtOAc, washed with H 2 0, the aqueous was extracted again with EtOAc and the combined organics were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent removed in 10 vacuo to afford a brown gum. This crude material was purified by automated column chromatography, eluting with DCM to 7% MeOH / DCM (gradient). Fractions found to contain pure material were combined and solvent removed in vacuo to afford the desired product as a pale yellow solid, 76.5mg, 71.9%. 15 Step 2: Preparation of Title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4-piperidin-1 -ylmethyl-phenyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(4-formyl-phenyl)-1 H-pyrrolo[2,3 20 b]pyridin-3-yl]-amide (76.5 mg, 0.18 mmol) and piperidine (0.05 mL, 0.54 mmol) were stirred in THF (6 mL) at RT for 10 minutes. NaBH(OAc) 3 (190.8 mg, 0.90 mmol) was added and the reaction was stirred at RT 18 hours. The reaction mixture was quenched by the addition of saturated aqueous NaHCO 3 and extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed 25 with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo to afford a yellow gum. Crude material was purified by automated column chromatography, eluting with DCM to 16% MeOH / DCM (gradient). Fractions found to contain product were combined and solvent removed in vacuo to afford the title compound as a cream 30 solid, 35.2mg, 39.5%. LC/MS: RT = 1.90 Min (270nm), m/z = 491.5 [M+H]. Total run time 3.75 min (short pos/neg),HP 1100. 'H NMR (de DMSO): 6 1.39-1.41 (m, 2H), 1.48-1.52 (m, 4H), 2.32-2.35 (m, 4H), 3.47 (s, 2H), 5.41 (s, 2H), 7.29-7.34 (m, 3H), 7.36-7.41 (m, 4H), 7.64 (d, 2H), WO 2013/114113 PCT/GB2013/050212 65 7.82 (d, 1H), 8.10 (s, 1H), 8.47 (s, 1H), 8.49 (d, 1H), 8.53 (d, 1H), 9.90 (s, 1H), 11.49 (d, 1H) Example 35: 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4-{[(2-methoxy 5 ethyl)-methyl-aminol-methyll-phenvl)-1 H-pyrrolo[2,3-blpvridin-3-vil-amide H3C O'l N NH NN H3CN N N The title compound was prepared as described in Example 34, Step 1 and the following change to the described protocol for Step 2. 10 Step 2: 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(4-{[(2-methoxy-ethyl)-methyl amino]-methyl}-phenyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(4-formyl-phenyl)-1 H-pyrrolo[2,3 b]pyridin-3-yl]-amide (50 mg, 0.12 mmol) was dissolved in DMF (5mL) at rtp. To this was added (2-methoxy-ethyl)-methyl-amine (158.6mg, 1.78mmol) and AcOH 15 (0.050mL). The solution was then evacuated and backfilled with N2. 10% Palladium on charcoal (25.3mg) was added then the reaction was evacuated and backfilled with N2 once more, then evacuated and backfilled with H 2 . The reaction was then stirred under H 2 at 450C for 16 hours. To the reaction mixture was added a further 15eq of amine and 50uL of AcOH and the reaction was 20 heated at 450C under H 2 for a further 24 hours.The catalyst was separated via filtration and the filter cake washed with a further portion of DMF (1mL). The filtrate was concentrated in vacuo and the residue purified by preparative HPLC first at pH4 and then pH9 to furnish the title compound, 7.9mg, 13.5% as a brown solid.
WO 2013/114113 PCT/GB2013/050212 66 LC/MS: RT = 1.91 Min (254nm), m/z = 495 [M+H]. Total run time 3.75 min (short pos/neg), HP1 100. 'H NMR (de DMSO): 6 2.19 (s, 3H), 2.54 (t, 2H), 3.24 (s, 3H), 3.47 (t, 2H), 3.55 (s, 2H), 5.41 (s, 2H), 7.27-7.35 (m, 7H), 7.66 (m, 2H), 7.82 (d, 1H), 8.10 (d, 1H), 5 8.47 (s, 1 H), 8.50 (d, 1 H), 8.53 (d, 1 H), 9.91 (s, 1 H), 11.49 (br d, 1 H) Example 36: 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4-pyrrolidin-1 ylmethyl-phenyl)-1 H-pyrrolo[2,3-blpvridin-3-vil-amide N -NH |) HN N 10 The title compound was prepared as described in Example 34, substituting pyrrolidine (25.6mg, 0.36mmol) for piperidine in Step2. It was isolated as a formate salt, 21mg, 37.1%, following purification by preparative HPLC at pH 4. LC/MS: RT = 1.87 Min (270nm), m/z = 477 [M+H]. Total run time 3.75 min (short pos/neg), HP 1100. 15 1 H NMR (de DMSO): 6 1.69-1.76 (m, 4H), 5.41 (s, 2H), 7.28-7.45 (m, 7H), 7.65 7.68 (m, 2H), 7.82 (d, 1H), 8.10 (s, 1H), 8.23 (s, 1H), 8.47 (s, 1H), 8.49-8.51 (m, 1 H), 8.53-8.55 (m, 1 H), 9.92 (s, 1 H), 11.49 (br d, 1 H) 6 protons not seen WO 2013/114113 PCT/GB2013/050212 67 Example 37: 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-[4-(4-fluoro piperidin-1-vimethyl)-phenvll-1H-pyrrolo[2,3-blpvridin-3-vIl-amide N
NH
HN NN The title compound was prepared as described in Example 34, substituting 4 5 fluoro-piperidine hydrochloride (99.4mg, 0.71mmol) for piperidine in Step2. It was isolated as a white solid, 21mg, 34%, following purification by automated column chromatography eluting with DCM to 8% MeOH / DCM (gradient) and trituration with acetonitrile. LC/MS: RT = 1.93 Min (270nm), m/z = 509 [M+H]. Total run time 3.75 min (short 10 pos),HP1100. 1 H NMR (de DMSO): 61.67-1.92 (m, 4H), 2.32 (m, 2H), 2.52 (m, 2H), 3.52 (s, 2H), 4.61-4.76 (m, 1H), 5.41 (s, 2H), 7.29-7.42 (m, 7H), 7.66 (m, 2H), 7.82 (s, 1H), 8.10 (s, 1H), 8.47-8.53 (m, 3H), 9.90 (s, 1H), 11.49 (br s, 1H) 15 WO 2013/114113 PCT/GB2013/050212 68 Example 38: 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(4 dimethylaminomethyl-phenyl)-1 H-pyrrolo[2,3-blpvridin-3-vil-amide N NH cH3 HN H3CN N N The title compound was prepared as described in Example 35, substituting 5 dimethylamine solution, 2.OM in THF (1.07mL, 2.14mmol) for (2-methoxy-ethyl) methyl-amine in Step 2. It was isolated as a yellow solid, containing 0.5 equivalents of formate salt, 4.4mg, 13.7%, following purification by preparative HPLC at pH 9. LC/MS: RT = 1.84 Min (254nm), m/z = 451 [M+H]. Total run time 3.75 min (short 10 pos/neg),HP1100. 1 H NMR (de DMSO): 6 2.18 (s, 6H), 3.45 (s, 2H), 5.41 (s, 2H), 7.28-7.42 (m, 7H), 7.67 (m, 2H), 7.82 (d, 1H), 8.10 (d, 1H), 8.22 (s, 0.5H - formate), 8.47 (s, 1H), 8.50 (d, 1 H), 8.54 (d, 1 H), 9.91 (s, 1 H), 11.49 (br d, 1 H) 15 WO 2013/114113 PCT/GB2013/050212 69 Example 39: 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-[4-(3-fluoro piperidin-1-vimethyl)-phenvll-1H-pyrrolo[2,3-blpvridin-3-vIl-amide N ,NH F NN N N The title compound was prepared as described in Example 34, substituting 3 5 fluoro-piperidine hydrochloride (99.4mg, 0.71mmol) for piperidine in Step2. It was isolated as a white solid, 17mg, 28%, following purification by automated column chromatography eluting with DCMto 10% MeOH / DCM (gradient) and trituration with acetonitrile. LC/MS: RT = 1.91 Min (270nm), m/z = 509 [M+H]. Total run time 3.75 min (short 10 pos),HP1100. 1 H NMR (de DMSO): 6 1.44-1.56 (m, 2H), 1.68-1.87 (m, 2H), 2.24-2.44 (m, 2H), 2.66-2.75 (m, 2H), 3.56 (s, 2H), 4.55-4.71 (m, 1H), 5.41 (s, 2H), 7.29-7.42 (m, 7H), 7.66 (m, 2H), 7.82 (s, 1H), 8.10 (s, 1H), 8.47-8.53 (m, 3H), 9.90 (s, 1H), 11.49 (br s, 1H) 15 WO 2013/114113 PCT/GB2013/050212 70 Example 40: 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(4 methylaminomethyl-phenyl)-1 H-pyrrolo[2,3-blpvridin-3-vIl-amide N NH H HN
H
3 C N N The title compound was prepared as described in Example 35, substituting 5 methylamine solution, 2.OM in THF (1.07mL, 2.14mmol) for (2-methoxy-ethyl) methyl-amine in Step 2. It was isolated as a pink solid, 4mg, 12.9%, following purification by preparative HPLC at pH 4. LC/MS: RT = 1.83 Min (254nm), m/z = 437 [M+H]. Total run time 3.75 min (short pos/neg), HP1 100. 10 1 H NMR (de DMSO): 6 2.37 (s, 3H), 3.83 (s, 2H), 5.41 (s, 2H), 7.28-7.41 (m, 5H), 7.48 (m, 2H), 7.69 (m, 2H), 7.82 (d, 1H), 8.10 (s, 1H), 8.36 (s, 1H), 8.49 (s, 1H), 8.52 (d, 1 H), 8.55 (d, 1 H), 9.96 (s, 1 H), 11.52 (br d, 1 H) Example 41: 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-(4-morpholin-4 15 vlmethyl-phenvl)-1 H-pyrrolof2.3-blpvridin-3-vIl-amide N N H 0 N
NN
WO 2013/114113 PCT/GB2013/050212 71 The title compound was prepared as described in Example 34, substituting morpholine (51.7mg, 0.59mmol) for piperidine in Step2. It was isolated as an off white solid, 28.4mg, 48.6%, following purification by column chromatography eluting with DCM - 5% MeOH / DCM (gradient) and preparative HPLC at pH4. 5 LC/MS: RT = 1.86 Min (254nm), m/z = 493 [M+H]. Total run time 3.75 min (short pos/neg), HP1 100. 'H NMR (de DMSO): 6 2.38 (m, 4H), 3.51 (s, 2H), 3.59 (m, 4H), 5.41 (s, 2H), 7.28-7.45 (m, 7H), 7.67 (m, 2H), 7.81 (d, 1H), 8.09 (s, 1H), 8.47 (s, 1H), 8.49 (d, 1 H), 8.53 (d, 1 H), 9.91 (s, 1 H), 11.49 (br d, 1 H) 10 Example 42: 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[4-(3,3-difluoro Pyrrolidin-1-vimethyl)-phenvll-1H-pyrrolof2.3-blpvridin-3-vIl-amide N NH F N NN The title compound was prepared as described in Example 34, substituting 3,3 15 difluoropyrrolidine hydrochloride (102.2mg, 0.71 mmol) for piperidine in Step 2. It was isolated as a white solid, 22mg, 36.2%, following purification by automated column chromatography eluting with DCMto 10% MeOH / DCM (gradient) and trituration with acetonitrile. LC/MS: RT = 2.17 Min (270nm), m/z = 513 [M+H]. Total run time 3.75 min (short 20 pos),HP1100. 1 H NMR (de DMSO): 6 2.26 (m, 2H), 2.72 (t, 2H), 2.88 (t, 2H), 3.67 (s, 2H), 5.41 (s, 2H), 7.29-7.44 (m, 7H), 7.69 (m, 2H), 7.82 (s, 1H), 8.10 (s, 1H), 8.47-8.53 (m, 3H), 9.90 (s, 1H), 11.50 (br s, 1H) WO 2013/114113 PCT/GB2013/050212 72 Example 43: 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(3 dimethylaminomethyl-phenyl)-1 H-pyrrolo[2,3-blpvridin-3-vil-amide N NH
H
3 CN HN N -1N The title compound was prepared according to the route outlined in Scheme 4. 5 The title compound was prepared from Example 1. Step 1: Preparation of 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-bromo-1 (toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide To a solution of 1-benzyl-1 H-pyrazole-4-carboxylic acid (5-bromo-1 H-pyrrolo[2,3 10 b]pyridin-3-yl)-amide 93.5g, 8.83mmol) in DCM (75ml) was added tetrabutylammonium hydrogen sulphate 0.45g, 1.32mmol), aqueous sodium hydroxide solution (50%, w/v, 7mL) and tosyl chloride (2.02g, 10.6mmol). The reaction mixture was stirred at RT for 4 hours and then diluted with DCM. It was washed with aqueous 1 M HCI, saturated aqueous bicarbonate, saturated 15 aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The residue was purified via automated column chromatography eluting with iso hexane to 75% EtOAc / iso-hexane (gradient). This furnished the desired compound as a brown foam, 3.51 g, 61.4%. Step 2: Preparation of 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(3-formyl 20 phenyl)-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-1 -(toluene-4-sulfonyl)-1 H pyrrolo[2,3-b]pyridin-3-yl]-amide (595mg, 1.08mmol), 3-formylphenylboronic acid (195mg, 1.3mmol), K 2
CO
3 (448mg, 3.24mmol) and Pd(dppf)C 2 (39.6mg, 25 0.05mmol) were combined in THF/ H 2 0(1OmL / 1 mL) and thoroughly WO 2013/114113 PCT/GB2013/050212 73 degassed. The reaction mixture was heated at 1200C for 1 hour under microwave irradiation. The reaction was diluted with EtOAc, washed with H 2 0, the aqueous was extracted again with EtOAc and the combined organics were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent 5 removed in vacuo to afford a brown gum. This crude material was purified by automated column chromatography, eluting with iso-hexane to 50% EtOAc / iso hexane to EtOAc (gradient). Fractions found to contain pure material were combined and solvent removed in vacuo to afford the desired product as a yellow solid, 420mg, 67.5%. 10 Step 3: Preparation of 1-benzyl-1H-pyrazole-4-carboxylic acid [5-(3 dimethylaminomethyl-phenyl)-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3 yl]-amide To a solution of 1-benzyl-1H-pyrazole-4-carboxylic acid [5-(3-formyl-phenyl)-1 15 (toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-amide (100mg, 0.17mmol) in MeOH (1mL) was added 4A molecular sieves followed by dimethylamine, 2.OM solution in THF (4mL, 8mmol) and the reaction stirred for 3 hours at RT. Sodium triacetoxyborohydride (72.1mg, 0.34mmol) was added and the reaction stirred 18 hours at RT. The inorganic material was separated via filtration and the 20 filtrate was diluted with DCM. The solution was washed with aqueous saturated sodium bicarbonate solution, dried (MgSO 4 ) and concentrated in vacuo. The residue was purified using automated column chromatography eluting with DCM to 10% MeOH/DCM. Fractions containing pure compound were combined and concentrated in vacuo to give the desired compound as a colourless glass, 25 61mg, 58.0%. Step 4: Preparation of Title compound: 1-benzyl-1H-pyrazole-4-carboxylic acid [5-(3-dimethylaminomethyl-phenyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(3-dimethylaminomethyl-phenyl)-1 30 (toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-amide (61mg, 0.10mmol) was dissolved in a mixture of THF (2mL) and MeOH (1mL) and potassium hydroxide (26.6mg, 0.474mmol) in the minimum volume of H 2 0 was added. After stirring at RT for 18hours the reaction mixture was diluted with H 2 0 and stirring continued. After 1 hour the solids were separated via filtration and the filter cake was WO 2013/114113 PCT/GB2013/050212 74 washed with H 2 0 prior to drying in vacuo at 400C. This furnished the title compound as a yellow solid, 15mg, 33.2%. LC/MS: RT = 0.99 Min (230nm), m/z = 451 [M+H]. Total run time 1.9 min (super short pos),HP1200. 5 'H NMR (de DMSO): 6 2.18(s, 6H), 3.47 (s, 2H), 5.42 (s, 2H), 7.25-7.46 (m, 7H), 7.58-7.63 (m, 2H), 7.84 (s, 1H), 8.10 (s, 1H), 8.47 (s, 1H), 8.50-8.53 (m, 2H), 9.95 (br s, 1 H), 11.50 (br s, 1 H) Example 44: 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro 10 piperidin-1-vimethyl)-phenvll-1H-pyrrolo[2,3-blpvridin-3-vl}-amide N NH |HN N N The title compound was prepared as described in Example 43, substituting 3 fluoropiperidine hydrochloride (47.5mg, 0.34mmol) for piperidine in Step 3. It was isolated as a yellow powder, 11.7mg, 18.1%, following purification by 15 preparative HPLC at pH9. LC/MS: RT = 1.04 Min (230nm), m/z = 509 [M+H]. Total run time 1.9 min (super short pos),HP1200. 1 H NMR (de DMSO): 6 1.40-1.60 (m, 2H), 1.67-1.90 (m, 2H), 2.24-2.32 (m, 1H), 2.36-2.48 (m, 2H), 2.66-2.76 (m, 1H), 3.60 (s, 2H), 4.54-4.74 (m, 1H), 5.42 (s, 20 2H), 7.28-7.40 (m, 6H), 7.45(dd, 1H), 7.58-7.62 (m, 2H), 7.84 (d, 1H), 8.10 (s, 1H), 8.47 (s, 1H), 8.50 (d, 1H), 8.52 (d, 1H), ), 9.96 (s, 1H), 11.51 (br d, 1H) WO 2013/114113 PCT/GB2013/050212 75 Example 45: 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-[3-(3,3-difluoro piperidin-1-vimethyl)-phenvll-1H-pyrrolo[2,3-blpvridin-3-vIl-amide N
NH
F N NN The title compound was prepared as described in Example 43, substituting 3,3 5 difluoropiperidine hydrochloride(124mg, 0.79mmol) for piperidine and sodium cyanoborohydride (13.1mg, 0.21mmol) for sodium triacetoxyborohydride in Step 3. Step 4: Preparation of Title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid 10 {5-[3-(3,3-difluoro-piperidin-1 -ylmethyl)-phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl} amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-[3-(3,3-difluoro-piperidin-1-ylmethyl) phenyl]-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide (100mg, 0.147mmol), potassium carbonate (138mg, 1mmol) and MeOH (4mL) were 15 combined in a microwave vial and heated under microwave irradiation at 1000C for 30 minutes. The reaction mixture was diluted with H 2 0 and extracted with a mixture of DCM/IPA (3:1). The organics were washed with saturated aqueous sodium chloride, dried (MgSO4) and concentrated in vacuo. The residue was taken up in the minimum amount of MeOH and then Et 2 0 was added until the 20 solution started to go cloudy. This was left to stand for 1 hour then the crystals were filtered off and dried in vacuo at 400C to furnish the title compound as yellow crystals, 30.3mg, 38.6%. LC/MS: RT = 1.17 Min (230nm), m/z = 527 [M+H]. Total run time 1.9 min (super short pos),HP1200.
WO 2013/114113 PCT/GB2013/050212 76 'H NMR (de DMSO): 61.62-1.71 (m, 2H), 1.80-1.95 (m, 2H), 2.42-2.48 (m, 2H), 2.61-2.70 (m, 2H), 3.67 (s, 2H), 5.41 (s, 2H), 7.28-7.40 (m, 6H), 7.47 (dd, 1H), 7.59-7.63 (m, 2H), 7.83 (d, 1H), 8.10 (s, 1H),8.47 (s, 1H), 8.49 (d, 1H), 8.52 (d, 1H), 9.94 (s, 1H), 11.52 (br d, 1H) 5 Example 46: 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-(3-azetidin-1 ylmethyl-phenyl)-1 H-pyrrolo[2,3-blpvridin-3-vil-amide N -NH N O HNN The title compound was prepared as described in Example 45, substituting 10 azetidine (38.7mg, 0.68mmol) for piperidine in Step 3. In Step 4 the product precipitated after diluting with H 2 0 and was collected via filtration, washed with
H
2 0, Et 2 0 and dried in vacuo at 400C to furnish the title compound as an off white solid, 26.7mg, 25.6%. LC/MS: RT = 1.00 Min (230nm), m/z = 463.2 [M+H]. Total run time 1.9 min 15 (super short pos),HP1200. 1 H NMR (de DMSO): 61.94-2.02 (m, 2H), 3.12-3.18 (m, 4H), 3.60 (s, 2H), 5.42 (s, 2H), 7.22-7.46 (m, 7H), 7.54-7.60 (m, 2H), 7.83 (s, 1H), 8.10 (s, 1H), 8.46 8.53 (m, 3H), 9.8-10.2 (brs, 1H), 11-12 (brs, 1H) 20 WO 2013/114113 PCT/GB2013/050212 77 Example 47: 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-[3-(3,3-difluoro azetidin-1-vimethyl)-phenvll-1H-pyrrolo[2,3-blpvridin-3-vIl-amide N ,NH F N HNN N N 5 The title compound was prepared as described in Example 45, substituting 3,3 difluoroazetidine hydrochloride(1 14mg, 0.88mmol) for piperidine and sodium cyanoborohydride (13.1mg, 0.21mmol) for sodium triacetoxyborohydride in Step 3. In Step 4 the product precipitated after diluting with H 2 0 and was collected via filtration, washed with H 2 0, Et 2 0 and dried in vacuo at 400C to furnish the title 10 compound as a cream powder, 23.4mg, 38.8%. LC/MS: RT = 1.15 Min (230nm), m/z = 499.2 [M+H]. Total run time 1.9 min (super short pos),HP1200. 1 H NMR (de DMSO): 6 3.64 (t, 4H), 3.81 (s, 2H), 5.42 (s, 2H), 7.28-7.41 (m, 6H), 7.45 (dd, 1H), 7.59-7.65 (m, 2H), 7.84 (s, 1H), 8.10 (s, 1H), 8.47 (s, 1H), 8.50 (d, 15 1H), 8.53 (d, 1H), 9.95 (br s, 1H), 11.51 (br s, 1H) WO 2013/114113 PCT/GB2013/050212 78 Example 48: 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-{5-pyrrolidin-1 ylmethyl-thiophen-2-v)-1 H-pyrrolo[2,3-blpvridin-3-vil-amide N NH r-NN N N The title compound was prepared as described in Example 43, substituting 5 5 formyl-2-thiopheneboronic acid 67.1mg, 0.43mmol) for 3-formylphenylboronic acid, 2M aqueous sodium carbonate 76.3mg, 0.72mmol) for K 2
CO
3 , tetrakis (19.6mg, 0.017mmol) for Pd(dppf)C1 2 and 1,4-dioxane / THF (4mL:2mL) for
THF/H
2 0 (10:1) in Step 2. The reaction mixture was heated at 1500C for 2 hours under microwave irradiation. The reaction was diluted with 3:1 DCM/IPA, 10 washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The residue was dissolved in the minimum amount of DCM and Et 2 0 was added to precipitate the desired, deprotected, Suzuki product, 1-benzyl-1H-pyrazole-4-carboxylic acid [5-(5-formyl-thiophen-2-yl)-1H pyrrolo[2,3-b]pyridin-3-yl]-amide, 68mgs, 43.8%. In Step 3 pyrrolidine (45.3mg, 15 0.64mmol) was substituted for piperidine and sodium cyanoborohydride (15mg, 0.24mmol) for sodium triacetoxyborohydride. The title compound was isolated as a white solid, 5mg, 6.5%, following purification by automated column chromatography eluting with DCM to 20% MeOH/DCM (gradient), preparative HPLC at pH4 and finally trituration with Et 2 0. 20 LC/MS: RT = 0.94 Min (230nm), m/z = 483 [M+H]. Total run time 1.9 min (super short pos),HP1200. 1 H NMR (de DMSO): 61.68-1.76 (m, 4H), 3.79 (s, 2H), 5.42 (s, 2H), 6.95 (d, 1H), 7.27-7.41 (m, 6H), 7.82 (s, 1H), 8.10 (s, 1H), 8.44 (d, 1H), 8.48 (s, 1H), 8.55 (d, 1 H), 9.94 (br s, 1 H), 11.53 (br s, 1 H) 4 protons not seen 25 WO 2013/114113 PCT/GB2013/050212 79 Example 49: 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-{5-pyrrolidin-1 ylmethyl-thiophen-3-v)-1 H-pyrrolo[2,3-blpvridin-3-vil-amide N NH HN N The title compound was prepared as described in Example 43, substituting 5 5 formyl-3-thiopheneboronic acid (67.1mg, 0.43mmol) for 3-formylphenylboronic acid, 2M aqueous sodium carbonate (76.3mg, 0.72mmol) for K 2
CO
3 , tetrakis (19.6mg, 0.017mmol) for Pd(dppf)Cl 2 and 1,4-dioxane (4mL) for THF/H 2 0 (10:1) in Step 2. The reaction mixture was heated at 1500C for 20 minutes under microwave irradiation. The reaction was diluted with DCM washed with saturated 10 aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The residue was dissolved in the minimum amount of DCM and Et 2 0 was added to precipitate the desired Suzuki product, 142mgs, 64.9% as a brown powder. In Step 3 pyrrolidine (34.2mg, 0.48mmol) was substituted for piperidine and sodium cyanoborohydride (11.3mg, 0.18mmol) for sodium triacetoxyborohydride. In Step 15 4 potassium carbonate (83.2mg, 0.6mmol) and MeOH (4mL) were combined in a microwave vial and heated under microwave irradiation at 100 C for 30 minutes. The reaction mixture was diluted with H 2 0 and the precipitate was collected via filtration, washed with H 2 0, Et 2 0 and dried in vacuo at 400C to furnish the title compound as a cream powder, 12.8mg, 22%. 20 LC/MS: RT = 0.94 Min (230nm), m/z = 483 [M+H]. Total run time 1.9 min (super short pos),HP1200. 1 H NMR (de DMSO): 61.68-1.76 (m, 4H), 3.82 (s, 2H), 5.42 (s, 2H), 7.28-7.42 (m, 6H), 7.68 (d, 1H), 7.78 (s, 1H), 8.10 (s, 1H), 8.46 (d, 1H), 8.48 (s, 1H), 8.59 (d, 1 H), 9.83 (br s, 1 H), 11-12 (br s, 1 H) 4 protons not seen 25 WO 2013/114113 PCT/GB2013/050212 80 Example 50: 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-[5-(3,3-difluoro azetidin-1 -vimethyl)-thiophen-3-vil-1 H-pyrrolo[2,3-blpvridin-3-vIl-amide N NH Fs HN F N The title compound was prepared as described in Example 49, substituting 3,3 5 difluoro-azetidine hydrochloride (94.5mg, 0.73mmol) for pyrrolidine in Step 3. It was isolated as a cream powder, 27.5mg, 53.4%, following the same procedure described in Step 4. LC/MS: RT = 1.19 Min (230nm), m/z = 505 [M+H]. Total run time 1.9 min (super short pos),HP1200. 10 1 H NMR (de DMSO): 6 3.67 (t, 4H), 3.96 (s, 2H), 5.42 (s, 2H), 7.28-7.41 (m, 5H), 7.44-7.46 (m, 1H), 7.72 (d, 1H), 7.78 (d, 1H), 8.10 (d, 1H), 8.45 (d, 1H), 8.47 (s, 1 H), 8.59 (d, 1 H), 9.88 (br s, 1 H), 11.47 (br d, 1 H) Example 51: 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-(3-pyrrolidin-1 15 vimethyl-phenvl)-1 H-pyrrolof2,3-blpvridin-3-vIl-amide N ,NH NO | H
NN
WO 2013/114113 PCT/GB2013/050212 81 The title compound was prepared as described in Example 43, substituting pyrrolidine (30mg, 0.45mmol) for dimethylamine, 2.0M solution in THF in Step 3. In Step 4 potassium carbonate (71.9mg, 0.52mmol) and MeOH (3mL) were combined in a microwave vial and heated under microwave irradiation at 1000C 5 for 30 minutes. The reaction mixture was concentrated to half volume in vacuo.
H
2 0 was added to the residue and the precipitate was collected via filtration, washed with H 2 0, Et 2 0 and dried in vacuo at 400C to furnish the title compound as a cream powder, 38mg, 76.8%. LC/MS: RT = 1.04 Min (230nm), m/z = 477 [M+H]. Total run time 1.9 min (super 10 short pos),HP1200. 'H NMR (de DMSO): 61.66-1.74 (m, 4H), 2.42-2.50 (m, 4H), 3.65 (s, 2H), 5.42 (s, 2H), 7.28-7.45 (m, 7H), 7.56-7.64 (m, 2H), 7.83 (s, 1H), 8.10 (s, 1H), 8.47 (s, 1H), 8.49-8.52 (m, 2H), 9.8-10.12 (br s, 1H), 11.12 (br s, 1H) 15 Example 52: 1-Benzvl-1H-pyrazole-4-carboxylic acid [4-{(R)-3-amino piperidin-1-vI)-5-fluoro-1H-pyrrolof2,3-blpvridin-3-vil-amide N NH F N
H
2 N N The title compound was prepared according to an analogous route to that outlined in Scheme 2. 20 The title compound was prepared as described in Example 6, substituting N fluorobis(phenylsulphonyl)amine (1.08g, 3.42mmol) for carbon tetrabromide in Step 3, and the desired intermediate was isolated as a white solid, 134mg, 63.4%. The crude material from Step 8 was purified by automated column chromatography, eluting with DCM - 16% MeOH/DCM (gradient) and then WO 2013/114113 PCT/GB2013/050212 82 preparative HPLC at pH 4. The title compound was isolated as a white solid, 34.3mg, 46.6%. LC/MS: RT = 1.70 Min (270nm), m/z = 434.5 [M+H]. Total run time 3.75 min (short pos/neg),HP1 100. 5 'H NMR (de DMSO): 6 1.33-1.38 (m, 2H), 1.60-1.63 (m, 1H), 1.74-1.76 (m, 1H), 2.98-3.14 (m, 4H), 3.46-3.48 (m, 1H), 5.41 (s, 2H), 7.24-7.26 (m, 2H), 7.31-7.39 (m, 3H), 7.52 (s, 1 H), 8.07 (s, 1 H), 8.09 (d, 1 H), 8.48 (s, 1 H), 9.70 (s, 1 H), 11.70 (br s, 1 H) 2 protons not seen 10 Example 53: 1-Benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino piperidin-1-vI)-5-phenyl-1H-pyrrolof2,3-blpvridin-3-vil-amide N NHl HN
H
2 N N The title compound was prepared according to the route outlined in Scheme 3. The title compound was prepared from 1 -benzyl-1 H-pyrazole-4-carboxylic acid 15 (5-bromo-4-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-amide, the product of Step 7 in Example 6. Step 1: Preparation of ((R)-1-{3-[(1-Benzyl-1H-pyrazole-4-carbonyl)-amino]-5 bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester 1 -Benzyl-1 H-pyrazole-4-carboxylic acid (5-bromo-4-fluoro-1 H-pyrrolo[2,3 20 b]pyridin-3-yl)-amide (0.445g, 1.07mmol), (R)-piperidin-3-yl-carbamic acid tert butyl ester (1.08g, 5.37mmol) and n-butanol(15 mL) were combined in a microwave vial. The contents were heated at 1600C for 6 hours under microwave irradiation and then the reaction mixture was diluted with EtOAc. The solution was washed with H 2 0, saturated aqueous sodium chloride, dried 25 (MgSO 4 ) and concentrated in vacuo to afford a brown gum. This crude material WO 2013/114113 PCT/GB2013/050212 83 was purified by automated column chromatography, eluting with iso-hexane 50% EtOAc/iso-hexane-EtOAc (gradient). Fractions found to contain pure product were combined and concentrated in vacuo to afford the desired compound as a yellow powder, 443.2mg, 69.4%. 5 Step 2: Preparation of Title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 -yl)-5-phenyl-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide. Phenylboronic acid (17.9 mg, 0.15 mmol), ((R)-1-{3-[(1-Benzyl-1H-pyrazole-4 carbonyl)-amino]-5-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic 10 acid tert-butyl ester (48.4 mg, 0.08 mmol), K 2 C0 3 (34.6 mg, 0.25 mmol), Pd(dppf)C1 2 (8.0 mg, 0.01 mmol) and THF/ H 2 0 (4.5 mL : 0.5 mL) were combined in a microwave vial and thoroughly degassed. The reaction mixture was heated at 100 C for 1 hour under microwave irradiation and then it was diluted with EtOAc. The organic layer was separated and the aqueous extracted 15 with another portion of EtOAc. The combined organics were washed with H 2 0, saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent removed in vacuo to afford a brown gum. This material was taken up in DCM (10mL) and cooled in an ice bath followed by drop wise addition of TFA (0.03 mL, 0.4 mmol). Stirring was continued for 4 hours at RT and the solvents removed in vacuo. The 20 crude material was purified by automated column chromatography, eluting with DCM - 15% MeOH / DCM. Fractions found to contain pure material were combined and solvent removed in vacuo to afford the title compound as a solid, 22mg, 55%. LC/MS: RT = 1.82 Min (270nm), m/z = 492 [M+H]. Total run time 3.75 min (short 25 pos/neg),HP1100. 'H NMR (de DMSO): 6 D1.35-1.45 (m, 2H), 1.56-1.67 (m, 1H), 2.25-2.37 (m, 1H), 2.76-3.04 (m, 3H), 3.13-3.22 (m, 1H), 5.40 (s, 2H), 7.18-7.82 (m, 11H), 7.89 (br s, 1 H), 8.05 (s, 1 H), 8.42 (s, 1 H), 9.53 (s, 1 H), 11.74 (s, 1 H) 30 WO 2013/114113 PCT/GB2013/050212 84 Example 54: 1-Benzvl-1H-pyrazole-4-carboxylic acid [4-{(R)-3-amino piperidin-1-vI)-5-cyano-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH I/ *0 NHN N
H
2 N N The title compound was prepared from ((R)-1-{3-[(1-benzyl-1H-pyrazole-4 5 carbonyl)-amino]-5-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester, the product of Step 1, Example 53. ((R)-1 -{3-[(1 -benzyl-1 H-pyrazole-4-carbonyl)-amino]-5-bromo-1 H-pyrrolo[2,3 b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester (21 mg, 0.04mmol), 10 dicyanozinc (7.5 mg, 0.06 mmol), Pd(PPh 3
)
4 (6.1 mg, 0.01 mmol) and DMF (5mL) were combined in a microwave vial and degassed. The contents were heated under microwave irradiation at 1200C for 1 hour. A further portion of dicyano zinc (2.1mg, 0.018mmol) and Pd(PPh 3
)
4 (2.0mg) were added and degassed. The contents were heated under microwave irradiation at 1200C for 2 15 hours. The reaction mixture was partitioned between EtOAc and H 2 0, then the organic layer was separated and the aqueous extracted with another portion of EtOAc. The combined organics were washed with H 2 0, saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent removed in vacuo to afford a brown gum. The crude product was purified by automated column chromatography 20 eluting with iso-hexane - 50% EtOAc/iso-hexane-EtOAc (gradient). Fractions found to contain pure material were combined and solvent removed in vacuo to afford ((R)-1 -{3-[(1 -benzyl-1 H-pyrazole-4-carbonyl)-amino]-5-cyano-1 H pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester. This material was taken up in hydrochloric acid solution, 1.25 M in MeOH (5mL) 25 and irradiated in a microwave for 1 hour at 800C. The volatiles were removed in WO 2013/114113 PCT/GB2013/050212 85 vacuo and the residue was taken up in the minimum volume of MeOH and loaded onto a SCX2 ion exchange column that had been primed with MeOH. The column was washed with DCM, MeOH and the title compound was eluted using ammonia solution, 3.5M in MeOH. This solution was concentrated in 5 vacuo to afford the title compound as a white solid, 3mg, 19.3%. LC/MS: RT = 1.67 Min (270nm), m/z = 441 [M+H]. Total run time 3.75 min (short pos/neg), HP1 100. 'H NMR (d 4 MeOH): 61.35-1.98 (m, 4H), 3.18-3.26 (m, 1H), 3.47-3.56 (m, 1H), 3.84-3.90 (m, 1H), 5.41 (s, 2H), 7.24-7.40 (m, 5H), 7.43 (s, 1H), 8.08 (s, 1H), 10 8.26 (s, 1 H), 8.36 (s, 1 H) 6 protons not seen Example 55: 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-[3-(2-morphollin-4 vi-ethoxy)-phenvll-1 H-pyrrolo[2,3-blpvridin-3-vIl-amide N NH N O , O 00 N 15 The title compound was prepared according to the route outlined in Scheme 5. The title compound was prepared from 1 -benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-amide, the product of Step 1, Example 43. 20 Step 1: Preparation of 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4,4,5,5 tetramethyl-[1,3,2]dioxaborolan-2-yl)-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3 b]pyridin-3-yl]-amide 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (408mg, 1.85mmol), 1 25 benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-1 -(toluene-4-sulfonyl)-1 H- WO 2013/114113 PCT/GB2013/050212 86 pyrrolo[2,3-b]pyridin-3-yl]-amide (850mg, 1.54mmol), K 2 C0 3 (640mg, 4.63mmol), Pd(dppf)C1 2 (56.5mg, 0.077mmol) and THF/ H 2 0 (12mL: 1.2mL) were combined in a microwave vial and thoroughly degassed. The reaction mixture was heated at 1200C for 1 hour under microwave irradiation and then it was diluted with 5 EtOAc. The organic layer was separated and the aqueous extracted with another portion of EtOAc. The combined organics were washed with H 2 0, saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent removed in vacuo. The crude product was purified by automated column chromatography eluting with iso-hexane to 50% EtOAc/iso-hexane to EtOAc (gradient). Fractions 10 found to contain pure material were combined and solvent removed in vacuo to afford the desired compound as a yellow glass, 518mg, 59.5%. Step 2: Preparation of 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-[3-(2 morpholin-4-yl-ethoxy)-phenyl]-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3 15 yl]-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(3-hydroxy-phenyl)-1 -(toluene-4 sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-amide (80mg, 0.14mmol) and 4-(2 chloroethyl)morpholine hydrochloride (37.0mg, 0.2mmol) were combined in 20 anhydrous DMF (3mL) and to this was added CS2CO3 (138.7mg, 0.43mmol). The reaction was heated at 600C for 3 hours and then allowed to cool to RT. The reaction mixture was diluted with H 2 0 and extracted with DCM (x2). The combined organic phases were washed saturated aqueous sodium chloride (x4), dried (MgSO 4 ) and concentrated in vacuo. The crude material was purified via 25 automated column chromatography eluting with DCM to 10% MeOH/DCM (gradient) to furnish the desired compound as a yellow glass, 50mg, 52.1%. Step 3: Preparation of title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 30 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-[3-(2-morpholin-4-yl-ethoxy)-phenyl] 1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide (50mg, 0.07mmol) potassium carbonate (51.1mg, 037mmol) and MeOH (4mL) were combined in a microwave vial and heated under microwave irradiation at 100 C for 30 minutes. The reaction mixture was reduced to half volume in vacuo and diluted with H 2 0.
WO 2013/114113 PCT/GB2013/050212 87 The mixture was stirred for hour at RT and the precipitate was collected via filtration, washed with H 2 0, Et 2 0 and dried in vacuo at 400C. This afforded the title compound as a pale yellow powder, 20mg, 51.8%. LC/MS: RT = 1.02 Min (230nm), m/z = 523 [M+H]. Total run time 1.9 min (super 5 short pos),HP1200. 'H NMR (de DMSO): 62.72 (t, 2H), 3.56-3.61 (m, 4H), 4.18 (t, 2H), 5.42 (s, 2H), 6.92-6.96 (m, 1H), 7.24-7.42 (m, 8H), 7.83 (s, 1H), 8.10 (s, 1H), 8.47 (s, 1H), 8.51 (d, 1H), 8.55 (d, 1H), 9.90 (br s, 1H), 11.3-11.7 (br s, 1H) 4 protons not seen. 10 Example 56: 1 -Benzyl-1 H-pyrazole-4-carboxylic acid {5-[3-(3 dimethylamino-2,2-dimethyl-propoxv)-phenvl1-1 H-Pyrrolof2.3-b1Pyridin-3 vil-amide CH3 ~ s N NH
CH
3 cH3 I/ I N 0
H
3 H 0 N 15 Preparation of (3-chloro-2,2-dimethyl-propyl)-dimethyl-amine hydrochloride To a solution of 3-dimethylamino-2,2-dimethyl-propan-1-o (5g, 38.1mmol) in toluene (100mL) was added DMF (1 drop) followed by thionyl chloride (5g, 41.9mmol) drop wise at RT. After addition the reaction was heated at reflux for 3 20 hours and then allowed to cool to RT. The solvent was removed in vacuo and toluene (50mL) was added and removed in vacuo. This process was repeated three more times. Toluene (50mL) was added and the solids broken up by sonication for 10 minutes. The solid was collected via filtration, washed well with toluene, iso-hexane and dried in vacuo. This afforded the desired compound as 25 a light brown solid, 6.68g, 94%.
WO 2013/114113 PCT/GB2013/050212 88 The title compound was prepared as described in Example 55, substituting (3 chloro-2,2-dimethyl-propyl)-dimethyl-amine hydrochloride (30.1mg, 0.16mmol) for 4-(2-chloroethyl)morpholine hydrochloride in Step 2, except heating was 5 conducted for 18hours at 600C. It was isolated as a pale yellow powder, 6.5mg, 33.7%, following the same procedure described in Step 3. LC/MS: RT = 1.10 Min (230nm), m/z = 523.2 [M+H]. Total run time 1.9 min (super short pos),HP1200. 'H NMR (de DMSO): 6 0.98 (s, 6H), 2.22 (s, 6H), 2.26 (s, 2H), 3.78 (s, 2H), 5.42 10 (s, 2H), 6.92-6.96 (m, 1H), 7.22-7.42 (m, 8H), 7.85 (s, 1H), 8.10 (s, 1H), 8.47 (s, 1H), 8.51-8.56 (m, 2H), 9.92 (br s, 1H), 11.50 (br s, 1H) Example 57: 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(3-morpholin-4 vI-propoxv)-phenvil-1 H-pyrrolof2.3-blpvridin-3-vIl-amide e,- N NH 0 N 0 | H N 15 The title compound was prepared as described in Example 55, substituting 4-(3 chloropropyl)morpholine (31.9mg, 0.195mmol) for 4-(2-chloroethyl)morpholine in Step 2, except heating was conducted for 18 hours at 600C. It was isolated as a powder, 8mg, 20.2%, following the same procedure described in Step 3 and 20 extra purification via preparative HPLC at pH4. LC/MS: RT = 1.06 Min (230nm), m/z = 537.2 [M+H]. Total run time 1.9 min (super short pos),HP1200. 1 H NMR (de DMSO): 61.91 (quintet, 2H), 2.33-2.40 (m, 4H), 2.44 (t, 2H), 3.53 3.60 (m, 4H), 4.10 (t, 2H), 5.42 (s, 2H) 6.90-6.96 (m, 1H), 7.20-7.42 (m, 8H), WO 2013/114113 PCT/GB2013/050212 89 7.84 (s, 1H), 8.10 (s, 1H), 8.48 (s, 1H), 8.51-8.56 (m, 2H), 9.92 (brs, 1H), 11.51 (br s, 1H) Example 58: 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(1-methyl 5 piperidin-3-vimethoxy)-phenyll-1 H-pyrrolo[2,3-blpvridin-3-vIl-amide H3CN ON NH N .0 H 3 H N N 11N The title compound was prepared as described in Example 55, substituting 3 bromomethyl-1 -methyl-piperidine (40.7mg, 0.21 mmol) for 4-(2 chloroethyl)morpholine hydrochloride in Step 2, except heating was conducted 10 for 18 hours at 700C. It was isolated as a white powder, 8.8mg, 38%, following the same procedure described in Step 3. LC/MS: RT = 1.01 Min (230nm), m/z = 521 [M+H]. Total run time 1.9 min (super short pos),HP1200. 1 H NMR (de DMSO): 6 1.03-1.14 (m, 1H), 1.44-1.56 (m, 1H), 1.60-1.68 (m, 1H), 15 1.70-1.84 (m, 2H), 1.84-1.94 (m, 1H), 1.98-2.06 (m, 1H), 2.15 (s, 3H), 2.59-2.66 (m, 1H), 2.80-2.86 (m, 1H), 3.88-3.98 (m, 2H), 5.42 (s, 2H), 6.90-6.96 (m, 1H), 7.22-7.42 (m, 8H), 7.83 (s, 1H), 8.10 (s, 1H), 8.48 (s, H), 8.53(dd, 2H), 9.91 (br s, 1H), 11.5 (br s, 1H) 20 WO 2013/114113 PCT/GB2013/050212 90 Example 59: 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-[3-{oxetan-3-vloxy) phenvll-1 H-pyrrolo[2,3-blpvridin-3-vIl-amide N NH 10 c HN N The title compound was prepared as described in Example 55, substituting 3 5 iodo-oxetane (35.9mg, 0.195mmol) for 4-(2-chloroethyl)morpholine hydrochloride in Step 2, except heating was conducted for 18 hours at 600C. It was isolated as a beige powder, 4mg, 10.9%, following the same procedure described in Step 3, and extra purification via automated column chromatography eluting with DCM to 10% MeOH/DCM (gradient). 10 LC/MS: RT = 1.17 Min (230nm), m/z = 466.2 [M+H]. Total run time 1.9 min (super short pos),HP1200. 1 H NMR (de DMSO): 64.59 (dd, 2H), 4.97 (dd, 2H), 5.37-5.43 (m, 3H) 6.74-6.78 (m, 1H), 7.12-7.14 (m, 1H), 7.28-7.44 (m, 7H), 7.82 (d, 1H), 8.10 (s, 1H), 8.47 (s, 1H), 8.51 (d, 1H), 8.54 (d, 1H), 9.90 (br s, 1H), 11.52 (br d, 1H) 15 WO 2013/114113 PCT/GB2013/050212 91 Example 60: 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-[3-(2-pyrrolidin-1-yl ethoxy)-phenvll-1 H-pyrrolo[2,3-blpvridin-3-vIl-amide N NH N O HNs N I-,N The title compound was prepared according to the route outlined in Scheme 6. 5 The title compound was prepared from 1 -benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-amide, the product of Step 1 in Example 43. Step 1: Preparation of 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4,4,5,5 tetramethyl-[1,3,2]dioxaborolan-2-yl)-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3 10 b]pyridin-3-yl]-amide 1 -benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-1 -(toluene-4-sulfonyl)-1 H pyrrolo[2,3-b]pyridin-3-yl]-amide (215mg, 0.39mmol), bis(pinacolato)diboron (218.2mg, 0.86mmol), sodium acetate (96.1mg, 1.17mmol) and DMF (2mL) 15 were combined in a microwave vial. The contents were degassed by sparging with N 2 then Pd(dppf)Cl 2 (14.3mg, 0.02mmol) was added and the mixture heated under microwave irradiation at 1400C for 1 hour. Bis(pinacolato)diboron (78.9mg, 0.31mmol) was added and the contents were degassed by sparging with N 2 . Pd(dppf)Cl 2 (7.1mg, 0.01 mmol) was added and the reaction was heated 20 under microwave irradiation at 1400C for 30 minutes. The reaction mixture was diluted with DCM and washed with saturated aqueous sodium chloride (x4), dried (MgSO 4 ) and solvent removed in vacuo. The crude product was purified by automated column chromatography eluting with iso-hexane to 50% EtOAc/iso hexane to EtOAc (gradient) to afford the desired compound as a yellow gum, 25 185mg, 79.3%.
WO 2013/114113 PCT/GB2013/050212 92 Step 2: Preparation of 1-[2-(3-Bromo-phenoxy)-ethyl]-pyrrolidine 3-Bromophenol (5g, 28.9mmol), 1-(2-chloroethyl)pyrrolidine hydrochloride (5.9g, 34.7mmol) were stirred in DMF (1OOmL). Cesium carbonate (18.83g, 57.8mmol) 5 was added and the reaction was heated at 1000C for 4 hours. The reaction was cooled and the solvent removed in vacuo. The residue was taken up in EtOAc, washed with H 2 0, saturated aqueous sodium chloride (x4), dried (MgSO 4 ) and concentrated in vacuo. The crude material was purified via flash chromatography eluting with 50% EtOAc/iso-hexane and then 67% EtOAc/iso-hexane to afford 10 the desired compound as a brown oil, 1.24g, 15.9%. Step 3: Preparation of 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-[3-(2-pyrrolidin 1 -yl-ethoxy)-phenyl]-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 15 The title compound was prepared as described in Example 55, substituting 1 benzyl-1 H-pyrazole-4-carboxylic acid [5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan 2-yl)-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide (72mg, 0.12mmol) for 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol and 1-[2-(3 20 bromo-phenoxy)-ethyl]-pyrrolidine 65.1mg, 0.24mmol) for 1-benzyl-1H-pyrazole 4-carboxylic acid [5-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl] amide, in Step 1. The crude product was purified by automated column chromatography eluting with DCM to 10% MeOH/DCM (gradient) to afford the desired compound as a beige glass, 38mg, 47.9%. 25 Step 4: Preparation of Title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(2-pyrrolidin-1 -yl-ethoxy)-phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide The title compound was prepared as described in Example 55, substituting 1 30 benzyl-1H-pyrazole-4-carboxylic acid [5-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-1 (toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-amide (38mg, 0.058mmol) for 1-benzyl-1H-pyrazole-4-carboxylic acid [5-[3-(2-morpholin-4-yl-ethoxy)-phenyl] 1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-amide, in Step 3. Following WO 2013/114113 PCT/GB2013/050212 93 the usual work up, and trituration of the solid obtained with acetonitrile, the title compound was isolated as a beige powder, 8.6mg, 29.5%. LC/MS: RT = 0.99 Min (230nm), m/z = 507 [M+H]. Total run time 1.9 min (super short pos),HP1200. 5 'H NMR (de DMSO): 61.64-1.73 (m, 4H), 2.82 (t, 2H), 4.15 (t, 2H), 5.42 (s, 2H), 6.92-6.96 (m, 1H), 7.24-7.42 (m, 8H), 7.83 (s, 1H), 8.10 (s, 1H), 8.48 (s, 1H), 8.51 (d, 1 H), 8.55 (d, 1 H), 9.91 (br s, 1 H), 11.34-11.64 (br s, 1 H) 4 protons not seen 10 Example 61: 1-Benzyl-1H-pyrazole-4-carboxylic acid [4-((3R,4R)-3-amino-4 cyclopropyl-piperid in-1 -v)-5-bromo-1 H-pyrrolo[2,3-blpyridin-3-vil-amide N NH N
H
2 N N The title compound was prepared according to the route outlined in Scheme 2. The title compound was prepared from the product of Step 7, in Example 6, 1 15 benzyl-1 H-pyrazole-4-carboxylic acid (5-bromo-4-fluoro-1 H-pyrrolo[2,3-b]pyridin 3-yl)-amide and ((3R,4R)-4-cyclopropyl-piperidin-3-yl)-phosphoramidic acid diethyl ester. Preparation of ((3R,4R)-4-Cyclopropyl-piperidin-3-yl)-phosphoramidic acid diethyl ester 20 Step 1: Preparation of 3,6-dihydro-2H-pyridine-1-carboxylic acid benzyl ester 1,2,3,6-tetrahydropyridine (5.24g, 63mmol) was stirred in DCM (30mL) and cooled to OC. Et 3 N (9.6g, 95mmol) was added followed by benzyl chloroformate (11.3g, 66.2mmol) drop wise. After addition the reaction was stirred at 50C for 30 minutes and then at RT for 2 hours. The reaction mixture was washed with 25 saturated aqueous Na 2
CO
3 , dried (MgSO 4 ) and concentrated in vacuo. Crude WO 2013/114113 PCT/GB2013/050212 94 material was purified by automated column chromatography, eluting with iso Hexane to 10% EtOAc /iso-Hexane (gradient). Fractions found to contain product were combined and solvent removed in vacuo to afford the title compound as a colourless oil, 9.8g, 71.6%. 5 Step 2: Preparation of 7-Oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acid benzyl ester To a solution of 7-Oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acid benzyl ester (6.86g, 31.6mmol) in DCM (65mL) at 00C was added m-CPBA (8.28g, 48mmol) portion wise. After addition the reaction was maintained at 50C for 20 10 minutes and then at RT for 4 hours. The reaction mixture was diluted with Et 2 0 (150 mL), washed with 1N NaOH solution (2 x 50mL), sat sodium thiosulphate solution (2 x 50mL) and saturated aqueous sodium chloride. The organics were dried (MgSO 4 ) and concentrated in vacuo. Crude material was purified by automated column chromatography, eluting with iso-hexane to 10% EtOAc /iso 15 Hexane (gradient). Fractions found to contain product were combined and solvent removed in vacuo to afford the desired compound as a colourless gum, 5.88g, 79.8% Step 3: Preparation of 4-Azido-3-hydroxy-piperidine-1-carboxylic acid benzyl ester and 3-azido-4-hydroxy-piperidine-1 -carboxylic acid benzyl ester 20 7-Oxa-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acid benzyl ester (3.35g, 14.3mmol) was dissolved in MeOH/H 2 0 5:1 (48mL) and ammonium chloride (0.77g, 14.3mmol) was added followed by sodium azide (1.87g, 28.7mmol). The reaction mixture was heated at 650C for 18 hours. The MeOH was removed in vacuo and the residue diluted with H 2 0 (15mL) and extracted with Et 2 0 (x2). The 25 combined organics were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo to give the desired mixture of regioisomers, 3.84g, 96.9%, as a colourless oil. The mixture contained a 3:1 ratio (3:1) of 4 azido-3-hydroxy-piperidine-1-carboxylic acid benzyl ester to 3-azido-4-hydroxy piperidine-1-carboxylic acid benzyl ester. 30 Step 4: Preparation of 4-Azido-3-(toluene-4-sulfonyloxy)-piperidine-1-carboxylic acid benzyl ester and 3-azido-4-(toluene-4-sulfonyloxy)-piperidine-1-carboxylic acid benzyl ester 4-Azido-3-hydroxy-piperidine-1-carboxylic acid benzyl ester and 3-azido-4 hydroxy-piperidine-1-carboxylic acid benzyl ester (3.84g, 13.9mmol) were WO 2013/114113 PCT/GB2013/050212 95 dissolved in DCM (18mL) and pyridine (2.97g, 37.53mmol) was added. The solution was cooled to 00C and p-toluenesulfonyl chloride (5.56g, 29.2mmol) in DCM (7mL) was added drop wise. The reaction was allowed to stir at RT for 68 hours. Pyridine (1.96g, 24.8mmol) and p-toluenesulfonyl chloride (1g, 5.25mmol) 5 were added and the reaction was stirred at RT for 24hrs. The reaction mixture was concentrated in vacuo to give a white solid that was dissolved in EtOAc and washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The crude material was purified via automated column chromatography eluting with iso-hexane to 50% EtOAc/iso-hexane (gradient) to 10 give the desired mixture of regioisomers, 5.62g, 94%, as a colourless oil. The mixture contained a ratio (77:23) of 4-azido-3-(toluene-4-sulfonyloxy)-piperidine 1-carboxylic acid benzyl ester to 3-azido-4-(toluene-4-sulfonyloxy)-piperidine-1 carboxylic acid benzyl ester. 15 Step 5: Preparation of 4-Amino-3-(toluene-4-sulfonyloxy)-piperidine-1-carboxylic acid benzyl ester and 3-amino-4-(toluene-4-sulfonyloxy)-piperidine-1-carboxylic acid benzyl ester Sodium borohydride (300mg, 7.93mmol) was added in portions to a solution of copper(II)sulphate pentahydrate (1.04g, 4.15mmol) in MeOH (20mL) at 20 0*C. After 5 minutes a solution of 4-azido-3-(toluene-4-sulfonyloxy)-piperidine-1 carboxylic acid benzyl ester and 3-azido-4-(toluene-4-sulfonyloxy)-piperidine-1 carboxylic acid benzyl ester (3.57g, 8.29mmol) in MeOH (10mL) was added drop wise, followed by sodium borohydride (600mg, 15.86mmol) in portions. After addition stirring was continued at 00C for 1 hour. The reaction mixture was 25 filtered through a plug of celite and concentrated in vacuo. The residue was taken up in DCM then washed with H 2 0, saturated aqueous ammonium chloride, saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The desired mixture of regioisomers was obtained as a colourless oil, 2.77g, 83.3%. 30 Step 6: Preparation of 4-(Diethoxy-phosphorylamino)-3-(toluene-4-sulfonyloxy) piperidine-1-carboxylic acid benzyl ester and 3-(diethoxy-phosphorylamino)-4 (toluene-4-sulfonyloxy)-piperidine-1 -carboxylic acid benzyl ester WO 2013/114113 PCT/GB2013/050212 96 To a solution of 4-amino-3-(toluene-4-sulfonyloxy)-piperidine-1-carboxylic acid benzyl ester and 3-amino-4-(toluene-4-sulfonyloxy)-piperidine-1-carboxylic acid benzyl ester 2.77g, 6.84mmol) in DCM (22mL) was added triethylamine (1.38g, 13.68mmol) and the solution cooled to 0*C. Diethyl chlorophosphate (1.3g, 5 7.52mmol) was added and the mixture allowed to attain RT over 30 minutes. Diethyl chlorophosphate (0.24g 1.38mmol) was added and stirred for 30 minutes at RT. The reaction was diluted with H 2 0 and the organics separated, washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. EtOAc was added to the residue and the crystals formed were collected 10 via filtration and dried in vacuo to afford the desired compound, 0.604g, 16.4%. The filtrate was concentrated in vacuo and the residue purified via automated column chromatography eluting with EtOAc to afford more of the desired compound, 2.76g, 74.8%, as a colurless oil. Step 7: Preparation of 7-(Diethoxy-phosphoryl)-3,7-diaza-bicyclo[4.1.0]heptane 15 3-carboxylic acid benzyl ester To a solution of 4-(diethoxy-phosphorylamino)-3-(toluene-4-sulfonyloxy) piperidine-1-carboxylic acid benzyl ester and 3-(diethoxy-phosphorylamino)-4 (toluene-4-sulfonyloxy)-piperidine-1 -carboxylic acid benzyl ester (2.6g, 4.81 mmol) in THF (25mL) at 0*C was added sodium hydride, 60% dispersion in 20 mineral oil, (288.6mg, 7.21mmol) in portions. The reaction was stirred for 30 minutes then diluted with H 2 0. The mixture was extracted with EtOAc (x2) and the combined organics were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The residue was purified via automated column chromatography eluting with EtOAc to give the desired 25 compound as a colourless oil, 1.34g, 76.5%. Step 8: Preparation of (3R,4R)-4-Cyclopropyl-3-(diethoxy-phosphorylamino) piperidine-1-carboxylic acid benzyl ester To a suspension of copper(I)iodide (38.8mg, 0.2mmol) in THF (10mL) at -30*C was added cyclopropylmagnesium bromide, 0.5M in THF (16.3mL, 8.15mmol) 30 drop wise. This was stirred for 15 minutess, then 7-(diethoxy-phosphoryl)-3,7 diaza-bicyclo[4.1.0]heptane-3-carboxylic acid benzyl ester (750mg, 2.04mmol) in THF (5mL) was added drop wise at -30*C. The reaction was warmed to RT over 2 hours, and diluted with EtOAc and H 2 0 and the resultant emulsion filtered through celite. The filtrate was transferred to a separating funnel. The organics WO 2013/114113 PCT/GB2013/050212 97 were separated and the aqueous extracted with EtOAc. The combined organics were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The resultant yellow oil was purified via automated column chromatography eluting with EtOAc, to afford the desired 5 compound as a gum, 321mg, 38.4%, that solidified on standing. Step 9: Preparation of ((3R,4R)-4-Cyclopropyl-piperidin-3-yl)-phosphoramidic acid diethyl ester (3R,4R)-4-Cyclopropyl-3-(diethoxy-phosphorylamino)-piperidine-1 -carboxylic acid benzyl ester (321mg, 0.78mmol) was dissolved in MeOH (5mL) and 10 palladium on charcoal, 10% (20mg) was added under a stream of N 2 . This was then evacuated and back filled with nitrogen three times, before finally evacuating and connecting to a hydrogen atmosphere. The reaction mixture was shaken under hydrogen for 5 hours. The reaction was evacuated and back filled with nitrogen three times. The mixture was filtered through a pad of celite 15 and the filtrate concentrated in vacuo to give the desired amine, ((3R,4R)-4 cyclopropyl-piperidin-3-yl)-phosphoramidic acid diethyl ester, as a colourless oil, 232mg. Preparation of title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid [4 ((3R,4R)-3-amino-4-cyclopropyl-piperidin-1 -yl)-5-bromo-1 H-pyrrolo[2,3-b]pyridin 20 3-yl]-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid (5-bromo-4-fluoro-1 H-pyrrolo[2,3 b]pyridin- 3-yl)-amide (90mg, 0.22mmol), ((3R,4R)-4-cyclopropyl-piperidin-3-yl) phosphoramidic acid diethyl ester (230mg, 0.83mmol) and 1-butanol (5mL) were combined in a sealed tube and heated at 3140-ES-085 at 1600C for 60 hours. 25 The reaction mixture was concentrated in vacuo and the residue was purified via automated column chromatography eluting with DCM to 25% MeOH/DCM (gradient). The material obtained was further purified by preparative HPLC at pH4. The material obtained was taken up in DCM/IPA (3:1), washed with saturated aqueous sodium hydrogen bicarbonate, dried (MgSO 4 ) and 30 concentrated in vacuo. The residue was dried in vacuo at 400C o/n to afford the desired title compound as a golden brown powder, 3.3mg, 2.84%. LC/MS: RT = 1.03 Min (230nm), m/z = 534 [M+H]. Total run time 1.9 min (super short pos),HP1200.
WO 2013/114113 PCT/GB2013/050212 98 'H NMR (de DMSO): 6 0.16-0.07 (m, 1H), 0.15-0.25 (m, 2H), 0.30-0.46 (m, 3H), 1.31-1.44 (m, 1H), 1.64-1.76 (m, 1H), 2.71-2.81 (m, 1H), 2.92-3.03 (m, 1H), 5.40 (s, 2H), 7.20-7.38 (m, 5H), 7.62 (s, 1H), 8.04 (s, 1H), 8.18 (s, 1H), 8.46 (s, 1H), 9.63 (br s, 1 H), 11.56-11.94 (br s, 1 H) 5 protons not seen 5 Example 62: 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(2-fluoro-4 Pyrrolidin-1-vimethyl-phenyl)-1 H-pyrrolo[2,3-blpvridin-3-vil-amide N NH C N F N N The title compound was prepared by an analogous route to the one outlined in 10 Scheme 4. The title compound was prepared as described in Example 43, substituting 2 fluoro-4-formyl boronic acid (109mg, 0.65mmol) for 3-formylphenylboronic acid, saturated aqueous sodium hydrogen carbonate (2mL) for K 2
CO
3 and MeCN (4mL) for THF/H 2 0 in Step 2. The reaction was heated at 1300C for 2 hours 15 under microwave irradiation. The reaction was diluted with DCM, washed with
H
2 0, the aqueous was extracted again with DCM and the combined organics were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent removed in vacuo to afford a brown gum. This crude material was purified by automated column chromatography, eluting with iso-hexane to 90% 20 EtOAc / iso-hexane - EtOAc (gradient). Fractions found to contain pure material were combined and solvent removed in vacuo to afford the desired Suzuki product as a yellow glass, 108mg, 50%. In Step 3, pyrrolidine 925.2mg, 0.35mmol) was substituted for dimethylamine, 2.OM solution in THF and sodium cyanoborohydride (16.7mg, 0.27mmol) was 25 substituted for sodium triacetoxyborohydride.
WO 2013/114113 PCT/GB2013/050212 99 The title compound was isolated as a white powder, 16.6mg, 68.1%, following the usual protocol for deprotection of the tosyl group. LC/MS: RT = 1.00 Min (230nm), m/z = 495 [M+H]. Total run time 1.9 min (super short pos),HP1200. 5 'H NMR (de DMSO): 61.69-1.75 (m, 4H), 2.45-2.49 (m, 4H), 3.64 (s, 2H), 5.45 (s, 2H), 7.24-7.40 (m, 7H), 7.59-7.55 (m, 1H), 7.83 (s, 1H), 8.08 (s, 1H), 8.37 8.39 (m, 1 H), 8.40-8.42 (m, 1 H), 8.46 (br s, 1 H), 9.93 (br s, 1 H), 11.56 (br s, 1 H) Example 63: 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-(3-pyrrolidin-1-yi 10 phenyl)-1 H-pyrrolof2,3-blpvridin-3-vil-amide N ,NH NN NN O | HN / b NN The title compound was prepared according to the route outlined in Scheme 4. The title compound was prepared as described in Example 43, substituting 1-[3 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrrolidine (59.6mg, 15 0.22mmol) for 3-formylphenylboronic acid in Step 2. Subsequent deprotection as described for Example 43, Step 4, furnished the title compound as a brown powder, 54.2mg, 62.4%. LC/MS: RT = 1.33 Min (230nm), m/z = 463 [M+H]. Total run time 1.9 min (super short pos),HP1200. 20 1 H NMR (de DMSO): 61.94-2.02 (m, 4H), 5.41 (s, 2H), 6.52-6.57 (dd, 1H), 6.77 6.80 (m, 1H), 6.87-6.91 (d, 1H), 7.24-7.41 (m, 6H), 7.82 (s, 1H), 8.10 (s, 1H), 8.45-8.48 (m, 2H), 8.50-8.52 (d, 1H), 9.91 (s, 1H), 11.47 (br s, 1H) 4 protons not seen WO 2013/114113 PCT/GB2013/050212 100 Example 64: 1-Benzvl-1H-pyrazole-4-carboxylic acid [5-(1-methyl-1 H Pyrazol-4-yl)-1 H-pyrrolo[2,3-blpvridin-3-vil-amide N ,NH H3C-N HNN N) The title compound was prepared according to the route outlined in Scheme 4. 5 The title compound was prepared as described in Example 43, substituting 1 methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-pyrazole (41.6mg, 0.2mmol) for 3-formylphenylboronic acid, aqueous sodium carbonate solution, 2M (0.18mL, 0.36mmol), tetrakis(triphenylphosphine)palladium(0) (10.5mg, 9.1 Mol) for Pd(dppf)C1 2 , 1,4-dioxane (2mL) for THF / H 2 0 (10:1) and heating at 10 1500C for 20 minutes under microwave irradiation, in Step 2. Subsequent deprotection as described for Example 43, Step 4, furnished the title compound as a yellow powder, 32.6mg, 52.6%. LC/MS: RT = 1.01 Min (230nm), m/z = 398 [M+H]. Total run time 1.9 min (super short pos),HP1200. 15 1 H NMR (de DMSO): 6 3.88 (s, 3H), 5.41 (s, 2H), 7.27-7.41 (m, 5H), 7.72 (s, 1H), 7.84 (d, 1H), 8.09 (s, 1H), 8.12 (s, 1H), 8.27-8.30 (d, 1H), 8.45-8.48 (m, 2H), 9.85 (s, 1 H), 11.40 (br s, 1 H) WO 2013/114113 PCT/GB2013/050212 101 Example 65: 1-Benzvl-1H-pyrazole-4-carboxylic acid (5-pyridin-4-yi-1 H Pyrrolo[2,3-blpvridin-3-vi)-amide N NH NN N N The title compound was prepared from Example 1. 5 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl) amide (75mg, 0.19mmol), pyridine-4-boronic acid (34.9mg, 0.28mmol), K 3
PO
4 , 2M aqueous solution (0.19mL, 0.38mmol) and Pd(dppf)C1 2 (13.3mg, 0.02mmol) were combined in 1,4-dioxane (2mL) and thoroughly degassed. The reaction mixture was heated at 1200C for 1 hour under microwave irradiation and then it 10 was partitioned between saturated aqueous sodium hydrogen carbonate and EtOAc. The organic layer was separated and the aqueous extracted with another portion of EtOAc. The combined organics were washed with H 2 0, saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent removed in vacuo. This crude material was purified by flash chromatography, eluting with 15 DCM then 4% MeOH / DCM then 7% MeOH / DCM. Fractions found to contain pure material were combined and solvent removed in vacuo to afford the desired product as a beige solid, 30.9mg, 41.4%. LC/MS: RT = 1.80 Min (254nm), m/z = 395 [M+H]. Total run time 3.75 min (short pos/neg), HP1 100. 20 1 H NMR (de DMSO): 6 5.42 (s, 2H), 7.29-7.41 (m, 5H), 7.78 (m, 2H), 7.85 (d, 1H), 8.10 (d, 1H), 8.48 (s, 1H), 8.63-8.80 (m, 4H), 9.96 (s, 1H), 11.67 (brd, 1H) WO 2013/114113 PCT/GB2013/050212 102 Example 66: 1-Benzvl-1H-pyrazole-4-carboxylic acid (5-pvridin-3-vI-1H Pyrrolo[2,3-blpvridin-3-vi)-amide N NH HN N N -1N The title compound was prepared from Example 1, using exactly the same 5 protocol as Example 65 but substituting pyridine-3-boronic acid (75mg, 0.19mmol) for pyridine-4-boronic acid. The title compound was isolated as a beige solid, 24.8mg, 33.2%. LC/MS: RT = 1.93 Min (254nm), m/z = 395 [M+H]. Total run time 3.75 min (short pos/neg), HP1 100. 10 1 H NMR (de DMSO): 6 5.41 (s, 2H), 7.28-7.41 (m, 5H), 7.49-7.54 (m, 1H), 7.85 (d, 1H), 8.10 (d, 1H), 8.11-8.15 (m, 1H), 8.47 (s, 1H), 8.55-8.60 (m, 3H), 8.94 (dd, 1H), 9.91 (s, 1H), 11.59 (br d, 1H) Example 67: 1-(3-Methoxy-benzvl)-1H-pyrazole-4-carboxylic acid (5-bromo 15 1 H-pyrrolo[2,3-blpvridin-3-vI)-amide N N H H N B , HNN N 0
HC-
WO 2013/114113 PCT/GB2013/050212 103 The title compound was prepared according to the route outlined in Scheme 1, and using the methodology described for Example 1, substituting 1-(3-methoxy benzyl)-1H-pyrazole-4-carboxylic acid (120.8mg, 0.52mmol) for 1-benzyl-1H pyrazole-4-carboxylic acid in Step 1. The title compound was isolated as a pale 5 brown solid, 73.6mg, 36.6%. LC/MS: RT = 2.35 Min (254nm), m/z = 426.3 [M+H]. Total run time 3.75 min (short pos/neg),HP1 100. 'H NMR (de DMSO): 6 3.75 (s, 3H), 5.37 (s, 2H), 6.83-6.90 (m, 3H), 7.29 (t, 1H), 7.84 (d, 1H), 8.08 (s, 1H), 8.28 (d, 1H), 8.44 (s, 1H), 8.48 (d, 1H), 9.88 (s, 1H), 10 11.69 (s, 1H) Example 68: 1-(2-Fluoro-benzvl)-1H-pyrazole-4-carboxylic acid (5-bromo 1 H-pyrrolo[2,3-blpvridin-3-vI)-amide N NH HN N NN F 15 The title compound was prepared according to the route outlined in Scheme 1, and using the methodology described for Example 1, substituting 1-(2-fluoro benzyl)-1 H-pyrazole-4-carboxylic acid (114.5mg, 0.52mmol), prepared in a similar way to 1-(-fluoro-benzyl)-1H-pyrazole-4-carboxylic acid as described in Example 17, for 1-benzyl-1H-pyrazole-4-carboxylic acid in Step 1. In Step 3, the 20 product precipitated following dilution of the reaction mixture with H 2 0. It was separated via filtration, washed well with H 2 0 and Et 2 0 then dried in vacuo at 400C to afford the title compound as a pale orange solid, 93.1mg, 47.7%. LC/MS: RT = 2.27 Min (254nm), m/z = 414.3 [M+H]. Total run time 3.75 min (short pos/neg),HP 1100.
WO 2013/114113 PCT/GB2013/050212 104 'H NMR (de DMSO): 6 5.47 (s, 2H), 7.20-7.32 (m, 3H), 7.41 (q, 1H), 7.84 (d, 1H), 8.07 (s, 1H), 8.28 (d, 1H), 8.44 (s, 1H), 8.48 (d, 1H), 9.89 (s, 1H), 11.70 (s, 1H) Example 69: 1-(2-Cyano-benzyl)-1H-pyrazole-4-carboxylic acid (5-bromo 5 1 H-pyrrolo[2,3-blpvridin-3-vI)-amide N NH HN N N)N The title compound was prepared according to the route outlined in Scheme 1, and using the methodology described for Example 1, substituting 1-(2-cyano benzyl)-1 H-pyrazole-4-carboxylic acid (118.2mg, 0.52mmol), prepared in a 10 similar way to 1-(-fluoro-benzyl)-1H-pyrazole-4-carboxylic acid as described in Example 17, for 1-benzyl-1H-pyrazole-4-carboxylic acid in Step 1. In Step 3, following the usual aqueous work up, the crude material was triturated in Et 2 0, filtered, washed with Et 2 0 and dried in vacuo at 400C to afford the title compound as a solid, 54.8mg, 27.7%. 15 LC/MS: RT = 2.20 Min (254nm), m/z = 423.3 [M+H]. Total run time 3.75 min (short pos/neg),(HP1 100. 1 H NMR (de DMSO): 65.62 (s, 2H), 7.36 (d, 1H), 7.56 (td, 1H), 7.73 (td, 1H), 7.84 (d, 1H), 7.91 (dd, 1H), 8.12 (s, 1H), 8.28 (d, 1H), 8.48 (d, 1H), 8.50 (s, 1H), 9.93 (s, 1H), 11.71 (br s, 1H) 20 WO 2013/114113 PCT/GB2013/050212 105 Example 70: 1-(1H-Pyrrol-2-vImethyl)-1H-pyrazole-4-carboxylic acid (5 bromo-1 H-pyrrolof2,3-blpvridin-3-vI)-amide N NH HN N / b H N The title compound was prepared according to the route outlined in Scheme 1, 5 and using the methodology described for Example 1, substituting potassium 1 (1H-pyrrol-2-ylmethyl)-1H-pyrazole-4-carboxylate (61.2mg, 0.32mmol) for 1 benzyl-1H-pyrazole-4-carboxylic acid in Step 1. In Step 3, following the usual aqueous work up, the crude material was purified via automated column chromatography eluting with DCM to 20%MeOH / DCM (gradient). Fractions 10 found to contain product were combined and solvent removed in vacuo and the residue further purified via preparative HPLC at pH 9 to afford the title compound as white solid, 15.4mg, 12.5%. Preparation of potassium 1-(1H-pyrrol-2-ylmethyl)-1H-pyrazole-4-carboxylate. 15 Step 1: Preparation of 1-methanesulfonyl-1H-pyrrole-2-carbaldehyde A solution of pyrrole carboxaldehyde (1.0g, 10.5mmol) in THF (20mL) was added drop wise to a suspension of sodium hydride, 60% dispersion in mineral oil (484mg, 12.1mmol) and THF (60mL) and the mixture stirred for 15 mins at 20 RT. Methane sulfonyl chloride (1.69g, 14.72mmol) was added drop wise and the reaction was stirred for a further 1 hour at RT. The reaction was diluted with
H
2 0 and concentrated under reduced pressure. The residual aqueous was extracted with DCM (x5) and the combined extracts were then washed successively with saturated aqueous sodium bicarbonate, H 2 0 and with 25 saturated aqueous sodium chloride. The organics were dried over MgSO 4 and WO 2013/114113 PCT/GB2013/050212 106 concentrated under reduced pressure to afford an oil that was purified by automated flash chromatography eluting with of iso-hexane to 30% EtOAc /iso hexane (gradient). Fractions found to contain pure product were combined and solvent removed in vacuo to afford the title compound as a colourless oil, 1.3g, 5 71.4%. Step 2: Preparation of (1-methanesulfonyl-1 H-pyrrol-2-yl)-MeOH 1-Methanesulfonyl-1H-pyrrole-2-carbaldehyde (1.3g, 7.51mmol) was stirred in a mixture of DCM (180mL) and MeOH (63ml) at 0*C. Sodium borohydride (428mg, 10 11.3mmol) was added in portions and the reaction mixture was left to stir at 00C for 1.5 hours. The reaction mixture was diluted with DCM (80mL) and oxalic acid, 5% aqueous solution (200mL) was added drop wise and stirring continued at 0*C for a further 15 minutes, before allowing the reaction mixture to warm to RT. The organic layer was separated, washed with H 2 0 (2x250ml), dried over 15 MgSO 4 and concentrated under reduced pressure to afford the title compound as pink crystals, 0.865g, 65.8%. Step 3: Preparation of 1-(1-methanesulfonyl-1H-pyrrol-2-ylmethyl)-1H-pyrazole 4-carboxylic acid ethyl ester 20 DIPEA (1.29mL, 7.41mmol) was added to a solution of (1-methanesulfonyl-1H pyrrol-2-yl)-MeOH (865mg, 4.94mmol) in DCM (27mL) and cooled to 0*C. Methanesulfonyl chloride (0.57mL, 7.41mmol) was added drop wise and the reaction was stirred at 0*C for 20 minutes and RT for 30 minutes. The reaction mixture was diluted with DCM and washed successively with ice cold H 2 0, cold 25 10% aqueous hydrochloric acid solution and followed by saturated aqueous sodium hydrogen bicarbonate. The organics were dried over MgSO 4 and concentrated under reduced pressure (low temperature) to afford 2 chloromethyl-1-methanesulfonyl-1H-pyrrole as an orange oil which was used immediately as the compound can polymerise on standing. A solution of 2 30 chloromethyl-1-methanesulfonyl-1H-pyrrole (1.02g, 5.27mmol) in acetone (11 mL) was added to a suspension of 1 H-pyrazole-4-carboxylic acid ethyl ester (703mg, 5.02mmol) and potassium carbonate (2.78g, 20.1mmol) in acetone (1OmL). Stirring was continued for 70 hours at RT and then the reaction mixture was filtered and the filter cake washed through with EtOAc. The filtrate was WO 2013/114113 PCT/GB2013/050212 107 concentrated under reduced pressure and the residue was taken up in EtOAc, washed with H 2 0, dried (MgSO 4 ) and concentrated under reduced pressure. The crude material was purified by automated flash chromatography eluting with iso hexane to EtOAc / iso-hexane to EtOAc (gradient). Fractions containing pure 5 product were combined and concentrated in vacuo to afford the desired compound as an orange oil that solidified on standing, 442mg, 29.6%. Fractions containing product and an impurity were combined and concentrated in vacuo and the residue further purified via SCX-2 ion exchange column giving a further 359mg, 24.1%, of title compound as an off white solid. 10 Step 4:Preparation of Potassium 1 -(1 H-pyrrol-2-ylmethyl)-1 H-pyrazole-4 carboxylate 1-(1-Methanesulfonyl-1H-pyrrol-2-ylmethyl)-1H-pyrazole-4-carboxylic acid ethyl ester (801mg, 2.69mmol) was dissolved in a mixture of MeOH:THF (1:1, 20mL) 15 and a solution of potassium hydroxide (301.8mg, 5.38mmol) in H 2 0 (2mL) was added. The reaction mixture was then refluxed for 4 hours, cooled and concentrated in vacuo. The residue was dried in a dessicator at 600C for 18 hours to give the title compound as a solid, 860mg, 93.5%. It was assumed by the recovery, and reaction stoichiometry to be predominantly the desired title 20 compound with 2 equivalents of KOH present and it was used without further purification. Step 5: Preparation of title compound: 1-(1H-pyrrol-2-ylmethyl)-1H-pyrazole-4 carboxylic acid (5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl)-amide 25 5-Bromo-1 H-pyrrolo[2,3-b]pyridin-3-ylamine (101.8mg, 0.48mmol) and potassium 1 -(1 H-pyrrol-2-ylmethyl)-1 H-pyrazole-4-carboxylate (61.2mg, 0.179mmol) were stirred in DMF (4mL) and triethylamine (97mg, 0.13ml, 0.96mmol) was added followed by HATU (183mg, 0.48mmol) . The reaction 30 mixture was left to stir at RT for 72 hours and diluted with EtOAc. The organics were separated and the aqueous extracted with a further portion of EtOAc. The combined extracts were washed with saturated aqueous sodium chloride (x3), dried (MgSO 4 ) and concentrated in vacuo. The crude material was purified automated flash chromatography eluting with DCM to 20% MeOH / DCM WO 2013/114113 PCT/GB2013/050212 108 (gradient). Fractions containing product were combined and concentrated in vacuo and the residue was further purified by preparative HPLC at pH9 to afford the title compound as a white solid, 15.4mg, 22.3%. LC/MS: RT = 1.09 Min (254nm), m/z = 386.0 [M+H]. Total run time 1.9 min 5 (super short pos),HP1200. 'H NMR (de DMSO): 6 5.28 (s, 2H), 6.00 (m, 1H), 6.13 (s, 1H), 6.75 (m, 1H), 7.83 (d, 1 H), 8.04 (s, 1 H), 8.23 (s, 1 H), 8.27 (d, 1 H), 8.47 (d, 1 H), 9.88 (s, 1 H), 11.03 (s, 1H), 11.69 (s, 1H) 10 Example 71: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic acid (5-bromo 1 H-pyrrolo[2,3-blpvridin-3-vI)-amide N NH Br HN N NN F The title compound was prepared according to the route outlined in Scheme 1, and using the methodology described for Example 1, substituting 1-(4-fluoro 15 benzyl)-1H-pyrazole-4-carboxylic acid (45.7mg, 0.21mmol), as described in Example 17, for 1-benzyl-1H-pyrazole-4-carboxylic acid in Step 1. The title compound was isolated as a brown solid, 26.7mg, 34.2%. LC/MS: RT = 2.26 Min (270nm), m/z = 416.3 [M+H]. Total run time 3.75 min (short pos/neg),HP 1100. 20 1 H NMR (de DMSO): 65.40 (s, 2H), 7.19-7.23 (m, 2H), 7.35-7.38 (m, 2H), 7.84 (d, 1H), 8.08 (s, 1H), 8.28 (d, 1H), 8.45 (s, 1H), 8.48 (d, 1H), 9.88 (s, 1H), 11.69 (br s, 1H) WO 2013/114113 PCT/GB2013/050212 109 Example 72: 1-Benzvl-1H-pyrazole-4-carboxylic acid (5-methyl-1 H Pyrrolo[2,3-blpvridin-3-vi)-amide N NH
H
3 C 0 HN N / NN The title compound was prepared according to an analogous route to that 5 outlined in Scheme 1, and using the methodology described for Example 1, substituting 5-methyl-1H-pyrrolo[2,3-b]pyridine (1.06g, 8.02mmol) for 5-bromo 1 H-pyrrolo[2,3-b]pyridine in Step 1. In Step 2, the methodology from Example 6, Step 6, substituting 5-methyl-3-nitro-1 H-pyrrolo[2,3-b]pyridine (1.42g, 8.02mmol) for 5-bromo-4-fluoro-3-nitro-1 H-pyrrolo[2,3-b]pyridine, was used. The title 10 compound was isolated as a cream solid, 22.7mg, 20.2%, following the protocol described for Example 1, Step 3, substituting 5-methyl-1H-pyrrolo[2,3-b]pyridin 3-ylamine (50mg, 0.34mmol) for 5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-ylamine. LC/MS: RT = 2.04 Min (270nm), m/z = 332.4 [M+H]. Total run time 3.75 min (short pos/neg),HP 1100. 15 1 H NMR (de DMSO): 62.38 (s, 3H), 5.40 (s, 2H), 7.29-7.40 (m, 5H), 7.69 (d, 1H), 7.97-7.98 (m, 1 H), 8.06-8.08 (m, 2H), 8.44 (s, 1 H), 9.80 (s, 1 H), 11.25 (br s, 1 H) WO 2013/114113 PCT/GB2013/050212 110 Example 73: 1 -Benzyl-1 H-pyrazole-4-carboxylic acid (5-chloro-1 H Pyrrolo[2,3-blpvridin-3-vi)-amide N NH cr'0 HN N NN The title compound was prepared according to an analogous route to that 5 outlined in Scheme 1, and using the methodology described for Example 1, in Steps 1 and 2, substituting 5-chloro-1H-pyrrolo[2,3-b]pyridine (400mg, 2.62mmol) for 5-bromo-1 H-pyrrolo[2,3-b]pyridine in Step 1. Step 3: Preparation of title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid 10 (5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl)-amide 5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylamine (37.4 mg, 0.22mmol), HATU(95.1 mg, 0.2mmol) and acetonitrile (5 mL) were combined in a microwave vial. 1 Benzyl-1 H-pyrazole-4-carboxylic acid (49.6 mg, 0.25mmol) and DIPEA (0.09 mL, 0.50mmol) were added, and contents degassed. The reaction was then heated 15 at 800C under microwave irradiation for 1 hour. The reaction was partitioned between EtOAc and H 2 0 and the organics separated. The aqueous was extracted with a further portion of EtOAc and the combined extracts were washed with H 2 0, saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The crude material was purified by automated column 20 chromatography eluting with 30% EtOAc/iso-hexane to 100% EtOAc. Fractions containing pure material were combined, concentrated in vacuo to afford the desired compound as a brown powder, 24 mg, 30.6%. LC/MS: RT = 2.19 Min (270nm), m/z = 352 [M+H]. Total run time 3.75 min (short pos/neg), HP 1100.
WO 2013/114113 PCT/GB2013/050212 111 'H NMR (de DMSO): 65.42 (s, 2H), 7.29-7.41 (m, 5H), 7.86 (s, 1H), 8.09 (s, 1H), 8.23 (s, 1 H), 8.35 (s, 1 H), 8.46 (s, 1 H), 9.89 (s, 1 H), 11.70 (s, 1 H) Example 74: 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic acid (5-chloro 5 1 H-pyrrolo[2,3-blpvridin-3-vi)-amide N NH cr' HN N NN F The title compound was prepared according to an analogous route to that outlined in Scheme 1, and using the methodology described for Example 73, in Step. 10 Step 2: Preparation of 5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylamine Tin (II) chloride dihydrate (8.57g, 38mmol) was added in portions to a mixture of 5-chloro-3-nitro-1 H-pyrrolo[2,3-b]pyridine (1.5g, 7.59mmol) in 6N HCI (60mL)at 5 15 OC and the reaction was stirred at RT for 2 hours. The reaction mixture was cooled and diluted with H 2 0 (300mL) then basified to pH8 by the careful addition of 50% aqueous NaOH solution. The mixture was then extracted with DCM/ IPA (3:1, 4 x 150mL) and the combined extracts were washed with saturated aqueous sodium chloride, dried (MgSO 4 )and solvent removed in vacuo to afford 20 the title compound as a green solid, 1.25g, 98.2%. Step 3: Preparation of title compound: 1-(4-fluoro-benzyl)-1H-pyrazole-4 carboxylic acid (5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl)-amide 5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylamine (40.0 mg, 0.24 mmol) was stirred in 25 DMF (3.0 mL), with Et 3 N (0.07 mL, 0.48 mmol) and 1-(4-fluoro-benzyl)-1H- WO 2013/114113 PCT/GB2013/050212 112 pyrazole-4-carboxylic acid (57.8 mg, 0.26 mmol), which was prepared in Example 17. HATU (91.3 mg, 0.24 mmol) was added and the reaction was stirred at RT for 2 hours. The reaction mixture was diluted with H 2 0, and extracted with EtOAc (3 x 30 mL). The combined extracts were washed with 5 saturated aqueous sodium bicarbonate, saturated aqueous sodium chloride (4 x 60 mL), dried (MgSO 4 ) and solvent removed in vacuo. The crude material was purified by automated column chromatography, eluting with DCM to 5% MeOH /DCM (gradient). Fractions containing pure product were combined and concentrated in vacuo to afford the title compound as a pale brown solid, 10 58.7mg, 66.5%. LC/MS: RT = 2.23 Min (270nm), m/z = 370.3 [M+H]. Total run time 3.75 min (short pos/neg),HP1 100. 'H NMR (de DMSO): 65.40 (s, 2H), 7.19-7.23 (m, 2H), 7.35-7.39 (m, 2H), 7.85 (d, 1 H), 8.08 (s, 1 H), 8.21 (d, 1 H), 8.33 (d, 1 H), 8.44 (s, 1 H), 9.88 (s, 1 H), 11.69 15 (br s, 1H) Example 75: 1-(3-methoxy-benzvl)-1H-pyrazole-4-carboxylic acid (5-chloro 1 H-pyrrolof2.3-blpvridin-3-vI)-amide N NH cr' o. HN N NN
H
3 C 20 The title compound was prepared according to an analogous route to that outlined in Scheme 1, and using the methodology described for Example 74, substituting 1-(3-methoxy-benzyl)-1 H-pyrazole-4-carboxylic acid (72.8mg, 0.31mmol) for 1-(4-fluoro-benzyl)-1H-pyrazole-4-carboxylic acid in Step 3. The title compound was isolated as a white solid, 24mg, 21.1% following trituration 25 with EtOAc.
WO 2013/114113 PCT/GB2013/050212 113 LC/MS: RT = 2.42 Min (254nm), m/z = 382 [M+H]. Total run time 3.75 min (short pos/neg), HP 1100. 'H NMR (de DMSO): 6 3.75 (s, 3H), 5.38 (s, 2H), 6.88 (m, 3H), 7.30(t, 7.83, 1H), 7.87(s, 1H), 8.09(s, 1H), 8.23(s, 1H), 8.35 (s, 1H), 8.44(s, 1H), 9.88 (s, 1H), 5 11.71 (s, 1H) Example 76: 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-((S)-1-methyl pyrrolidin-2-vimethoxy)-phenvll-1 H-pyrrolo[2,3-blpvridin-3-vil-amide ON NH (N0 HNH
H
3 C N NN) 10 The title compound was prepared according an analogous route to that outlined in Scheme 6. The title compound was prepared from 1 -benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-amide, the product of Step 1 in Example 43. 15 Step 1: Preparation of (S)-1 -methyl-2-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan 2-yl)-phenoxymethyl]-pyrrolidine To a solution of 4-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenol (150 mg, 0.68mmol), (S)-(-)-1-methyl-2-pyrrolidineMeOH( 117.8mg, 1.02mmol) and 20 triphenylphosphine (268.2mg, 1.02mmol) in THF (3mL) was added DIAD (206.7mg, 2mL, 1.02mmol) drop wise at 0CC. The resulting solution was stirred at room temperature for 36 hours and the reaction mixture concentrated in vacuo. The crude material was purified by automated column chromatography eluting iso-hexane to 50% EtOAc/iso-hexane (gradient). The title compound was 25 isolated as a white solid, 220mg, 100%.
WO 2013/114113 PCT/GB2013/050212 114 Step 2: Preparation of title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-((S)-1 -methyl-pyrrolidin-2-ylmethoxy)-phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl} amide 1 -benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-1 -(toluene-4-sulfonyl)-1 H 5 pyrrolo[2,3-b]pyridin-3-yl]-amide (115mg, 0.21mmol), (S)-1-methyl-2-[3-(4,4,5,5 tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenoxymethyl]-pyrrolidine (99.4mg, 0.31mmol), potassium carbonate (86.6mg, 0.63mmol), THF (4mL) and H 2 0 (0.4mL) were combined in a microwave vial/. The mixture was degassed, Pd(dppf)C1 2 (7.64mg, 0.01mmol) added and the reaction heated at 1300C for 1 10 hour under microwave irradiation. The reaction mixture was diluted with DCM and washed with saturated aqueous sodium chloride. The organics were separated, dried (MgSO 4 ) and concentrated in vacuo. The crude material was purified via automated column chromatography eluting with DCM to 10% MeOH/DCM (gradient). This afforded a mixture of two compounds, 1-benzyl-1H 15 pyrazole-4-carboxylic acid [5-[3-((S)-1-methyl-pyrrolidin-2-ylmethoxy)-phenyl]-1 (toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide and 1 -benzyl-1 H pyrazole-4-carboxylic acid [5-[3-(1-methyl-piperidin-3-yloxy)-phenyl]-1 -(toluene 4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide as a brown glass. This was taken up in MeOH (5mL) and transferred to a microwave vial. K 2
CO
3 (100.9mg, 20 0.73mmol) was added and the contents heated at 800C for 30 minutes under microwave irradiation. The reaction mixture was concentrated in vacuo to one quarter of volume and diluted with H 2 0. Upon standing a precipitate formed, which was filtered off and washed with H 2 0 and then Et 2 0. The powder was dried and purified via automated column chromatography eluting with DCM to 25 19% MeOH/DCM (gradient), to give the title compound as a white powder, 7mg, 6.6%. Example 77 (below), 1-benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(1 methyl-piperidin-3-yloxy)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-amide, was also isolated from the same column as a solid, 8mg, 7.6%. LC/MS: RT = 1.00 Min (230nm), m/z = 507 [M+H]. Total run time 1.9 min (super 30 short pos),HP1200. 'H NMR (de DMSO): 6 1.62-1.81 (m, 3H), 1.96-2.08 (m, 1H), 2.96-3.12 (m, 1H), 3.9-4.15 (m, 2H), 5.42 (s, 2H), 6.93-6.98 (m, 1H), 7.22-7.42 (m, 8H), 7.82-7.85 (m, 1H), 8.10 (s, 1H), 8.48 (s, 1H), 8.51-8.57 (m, 2H), 9.92 (br s, 1H), 11.51 (br s, 1 H) 5 protons not seen WO 2013/114113 PCT/GB2013/050212 115 Example 77: 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(1-methyl Piperidin-3-vloxv)-phenvl1-1 H-pyrrolof2.3-blpvridin-3-vIl-amide N NH
H
3 C Na O HN NN 5 The title compound was isolated from the crude reaction mixture as described in Example 76, Step 2, as a solid, 8mg, 7.6%. LC/MS: RT = 1.00 Min (230nm), m/z = 507 [M+H]. Total run time 1.9 min (super short pos),HP1200. 1 H NMR (de DMSO): 61.31-1.42 (m, 1H), 1.50-1.62 (s, 1H), 1.67-1.76 (m, 1H), 10 1.95-2.10 (m, 3H), 2.19 (s, 3H), 2.86-2.92 (m, 1H), 4.46-4.54 (m, 1H), 5.41 (s, 2H), 6.94-6.98 (m, 1H), 7.22-7.41 (m, 8H), 7.82-7.84 (d, 1H), 8.10 (s, 1H), 8.48(s, 1H), 8.51-8.55 (m, 2H), 9.91 (br s, 1H), 11.50 (br s, 1H) 1 proton not seen 15 Example 78: 1 -Benzyl-1 H-pyrazole-4-carboxylic acid f5-[4-(3 dimethylamino-propoxv)-phenvil-1 H-pyrrolof2.3-blpvridin-3-vIl-amide N ,NH H3C N O
CH
3
NN
WO 2013/114113 PCT/GB2013/050212 116 The title compound was prepared from 1 -benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-amide, the product of Step 1 in Example 43. 5 Step 1: Preparation of: 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4-hydroxy phenyl)-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-1 -(toluene-4-sulfonyl)-1 H pyrrolo[2,3-b]pyridin-3-yl]-amide (1.0g, 1.82mmol), 4-hydroxyphenylboronic acid 10 (0.3g, 2.18mmol) and K 2 C0 3 (0.75g, 5.45mmol) were combined in THF/ H 2 0 (14mL : 1.4mL) and thoroughly degassed. Pd(dppf)Cl 2 (0.067mg, 0.09mmol) was added and the mixture degassed again before heating at 1200C for 1 hour under microwave irradiation. 4-Hydroxyphenylboronic acid (0.15g, 1.09mmol) was added and the mixture degassed again before heating at 1200C 15 for 2 hours and at 1400C for 1 hour under microwave irradiation. The reaction was diluted with saturated aqueous sodium hydrogen bicarbonate (100mL) and extracted with EtOAc (2xlOOmL). The combined organics were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent removed in vacuo. The crude material was purified by flash chromatography, eluting with 20 DCM to 50% EtOAc/DCM (gradient). Fractions found to contain product were combined and solvent removed in vacuo. The residue was triturated using the minimum amount of ethanol to afford the desired compound as a as a white solid, 0.33g, 32.6%. 25 Step 2: Preparation of: 1-Benzyl-1 H-pyrazole-4-carboxylic acid [5-[4-(3-dimethylamino-propoxy)-phenyl]-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3 b]pyridin-3-yl]-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-1 -(toluene-4-sulfonyl)-1 H 30 pyrrolo[2,3-b]pyridin-3-yl]-amide (100mg, 0.18mmol) was stirred in DMF (4mL) with K 2 C0 3 (73.6mg, 0.53mmol). To this was added (3-chloro-propyl) dimethylamine hydrochloride (36.5mg, 0.23mmol) and the reaction was then heated at 500C for 16 hours. The reaction was then cooled, concentrated in vacuo, and the residue partitioned between saturated aqueous sodium hydrogen WO 2013/114113 PCT/GB2013/050212 117 carbonate (30mL) and EtOAc (40mL). The organics were separated and the aqueous extracted with another portion of EtOAc (40mL). The combined organics were washed with saturated aqueous sodium chloride, dried over MgSO 4 and concentrated in vacuo. The crude material was purified by flash 5 chromatography eluting with DCM then 10% MeOH / DCM and finally 6% ammonia solution, 7N in MeOH/EtOAc. The fractions containing product were combined and concentrated in vacuo to afford the title compound as a yellow solid, 67mg, 58.2%. 10 Step 3: Preparation of title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[4-(3-dimethylamino-propoxy)-phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-[4-(3-dimethylamino-propoxy) phenyl]-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide (67mg, 0.10mmol), K 2
CO
3 (71.4mg, 0.52mmol) and MeOH (2mL) were combined in a 15 microwave vial and heated at 1000C for 30 minutes. The mixture was concentrated in vacuo and the crude material was purified by preparative HPLC at pH 9 and then at pH 4 to afford the title compound as a pale orange solid, 0.8mg, 1.6%. LC/MS: RT = 1.98 Min (254nm), m/z = 495 [M+H]. Total run time 3.75 min (short 20 pos/neg),HP1100. 'H NMR (de DMSO): 6 1.87 (m, 2H), 2.16 (s, 6H), 2.37 (t, 2H), 4.04 (t, 2H), 5.41 (s, 2H), 7.04 (m, 2H), 7.27-7.41 (m, 5H), 7.62 (m, 2H), 7.80 (d, 1H), 8.10 (s, 1H), 8.40 (br s, 1 H), 8.43-8.50 (m, 3H), 9.92 (s, 1 H), 11.45 (d, 1 H) 25 Example 79: 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[1-(2-diethylamino ethyl)-1 H-Pyrazol-4-vl1-1 H-pyrrolof2.3-blpvridin-3-vIl-amide H3C N NH
N
H3C - N HN
NN
WO 2013/114113 PCT/GB2013/050212 118 The title compound was prepared according to the route outlined in Scheme 6. The title compound was prepared from 1 -benzyl-1 H-pyrazole-4-carboxylic acid [5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1 -(toluene-4-sulfonyl)-1 H pyrrolo[2,3-b]pyridin-3-yl]-amide, the product of Step 1 in Example 60. 5 Step 1: Preparation of [2-(4-Bromo-pyrazol-1-yl)-ethyl]-diethyl-amine CS2CO3 (1.66g, 5.1mmol) was added to a solution of 4-bromopyrazole (0.25g, 1.7mmol) in DMF (2mL) and the mixture stirred for 10 minutes. 2-Bromo-N,N diethylethylamine hydrobromide (0.577g, 2.21 mmol) was added and the reaction 10 heated at 700C 18 hours. The reaction was diluted with H 2 0 and extracted with DCM/IPA (4:1) (x2). The organics were combined, washed with saturated aqueous sodium chloride (x4), dried (MgSO4) and concentrated in vacuo to afford the title compound as a pale yellow oil, 275mg, 65.7%. 15 Step 2: Preparation of 1-benzyl-1H-pyrazole-4-carboxylic acid [5-[1-(2 diethylamino-ethyl)-1 H-pyrazol-4-yl]-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3 b]pyridin-3-yl]-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(4,4,5,5-tetramethyl 20 [1,3,2]dioxaborolan-2-yl)-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl] amide (90mg, 0.15mmol), [2-(4-Bromo-pyrazol-1 -yl)-ethyl]-diethyl-amine (74.2mg, 0.3mmol), K 2
CO
3 )62.5mg, 0.45mmol) THF (4mL) and H 2 0 (0.4mL) were combined in a microwave vial and degassed. Pd(dppf)Cl 2 (5.5mg, 0.01mmol) was added and the contents degassed again before heating at 1300C 25 for 1 hour under microwave irradiation. The mixture was degassed and a further portion of Pd(dppf)C1 2 (5.5mg, 0.01mmol) was added and degassed before heating at 1300C for 30 minutes. The reaction mixture was diluted with DCM and the organics separated. The aqueous was extracted with another portion of DCM and the combined organics were washed with saturated aqueous sodium 30 chloride, dried over MgSO 4 and concentrated in vacuo. The crude material was purified by automated column chromatography eluting with DCM to 15% MeOH/DCM (gradient) to afford the title compound, 24mg, 25.1%.
WO 2013/114113 PCT/GB2013/050212 119 Step 3: Preparation of title compound: 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[1-(2-diethylamino-ethyl)-1 H-pyrazol-4-yl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(4,4,5,5-tetramethyl 5 [1,3,2]dioxaborolan-2-yl)-1 -(toluene-4-sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl] amide (90mg, 0.15mmol), [2-(4-Bromo-pyrazol-1 -yl)-ethyl]-diethyl-amine (24mg, 0.038mmol), K 2
CO
3 (104.1mg, 0.75mmol) and MeOH (3mL) were combined in a microwave vial and heated at 800C for 30 minutes. The reaction mixture was concentrated in vacuo to one quarter volume and diluted with H 2 0. 10 After standing for 2hrs the solid was separated via filtration, washed with H 2 0 then Et 2 0 and dried in vacuo to afford the title compound as a grey powder, 7mg, 38.2%. LC/MS: RT = 0.92 Min (230nm), m/z = 483 [M+H]. Total run time 1.9 min (super short pos),HP1200. 15 'H NMR (de DMSO): 6 0.90-0.95 (t, 6H), 2.79-2.84 (t, 2H), 4.14-4.19 (t, 2H), 5.41 (s, 2H), 7.28-7.41 (m, 5H), 7. 72 (s, 1H), 7.85 (s, 1H), 8.09 (s, 1H), 8.16 (s, 1H), 8.27-8.30 (m, 1 H), 8.45-8.49 (m, 2H), 9.86 (br s, 1 H), 11.39 (br s, 1 H) 4 protons not seen 20 Example 80: 1-Benzvl-1H-pyrazole-4-carboxylic acid {5-[1-(2-pyrrolidin-1-yl ethyl)-1 H-pyrazol-4-vil-1 H-pyrrolo[2,3-blpvridin-3-vIl-amide N NN NH HN N
N)N
WO 2013/114113 PCT/GB2013/050212 120 The title compound was prepared according to the route outlined in Scheme 6, and using the methodology described for Example 79, substituting 1-(2-chloro ethyl)-pyrrolidine hydrochloride (376.1mg, 2.21mmol) for 2-bromo-N,N diethylethylamine hydrobromide in Step 1. The title compound was isolated as a 5 dark powder, 10mg, 13.8%. LC/MS: RT = 1.15 Min (230nm), m/z = 481 [M+H]. Total run time 1.9 min (super short pos),HP1200. 'H NMR (de DMSO): 6 1.63-1.69 (m, 4H), 2.83-2.88 (t, 2H), 4.21-4.26 (t, 2H), 5.41 (s, 2H), 7.28-7.41 (m, 5H), 7.72 (s, 1H), 7.84-7.86 (s, 1H), 8.09 (s, 1H), 8.18 10 (s, 1H) 8.28-8.31 (m, 1H), 8.45-8.49 (m, 2H), 9.87 (br s, 1H), 11.40 (br s, 1H) 4 protons not seen Example 81: 1-Pyridin-4-yImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-methoxv-1H-pyrrolof2.3-blpvridin-3-vil-amide N NH H3CO N H2N N~ N HN& 15 The title compound was prepared according to an analogous route to that outlined in Scheme 2. It was prepared from 4-fluoro-5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylamine, the product of Step 7, in Example 31. 20 Step 1: Preparation of 1-pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid4 bromomethyl pyridine hydrochloride (3.58g, 14.17mmol) was added to a suspension of ethyl 1H-pyrazole-4-carboxylate (1.89g, 14.17mmol) and cesium carbonate (10.43g, 32mmol) in acetone (50mL), under a nitrogen atmosphere, and the suspension stirred for 18 hours at RT. The reaction was diluted with H 2 0 25 and then extracted with EtOAc (x2). The combined extracts were washed with WO 2013/114113 PCT/GB2013/050212 121
H
2 0, saturated aqueous sodium chloride solution, dried (MgSO 4 ) and concentrated in vacuo. The residue was stirred in MeOH (50mL) and a solution of sodium hydroxide (0.896g, 22.4mmol) H 2 0 (15mL) was added. The reaction mixture was heated at reflux for 3 hours and then cooled to RT. The solvent was 5 removed in vacuo and the residue diluted with a little H 2 0. The pH of the mixture was adjusted to 4 by the careful addition of aqueous hydrochloric acid solution, 1.OM. After stirring for 10mins the solids were separated via filtration, washed well with H 2 0 and dried in vacuo to yield the desired title compound as a solid, 0.449g. The filtrate was extracted with EtOAc (x6) and combined extracts were 10 washed with saturated aqueous sodium chloride, dried over MgSO 4 and concentrated in vacuo to furnish a further crop of the title compound, 0.736g. This gave a total of 1.185g, 78%. Step 2: Preparation of 1-pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid (5 chloro-4-fluoro-1 H-pyrrolo[2,3-b]pyridin-3-yl)-amide 15 4-fluoro-5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-ylamine (97mg, 0.54mmol) was stirred in DMF (5mL). Et 3 N 109mg, 150uL, 1.08mmol) and 1-pyridin-4-ylmethyl 1H-pyrazole-4-carboxylic acid (119.7mg, 0.59mmol) were added followed by HATU (224.3mg, 0.54mmol). The reaction was stirred at RT for 18hrs and then diluted with H 2 0 (2OmL). The solution was extracted with EtOAc (2 x 50mL) and 20 10% MeOH in DCM (2 x 50mL). The combined organic extracts were dried over MgSO 4 and concentrated in vacuo. The residue was triturated with EtOAc to give the title compound as a pale brown solid 125mg, 63.7%. Step 3: Preparation of title compound: 1-pyridin-4-ylmethyl-1H-pyrazole-4 carboxylic acid [4-((R)-3-amino-piperidin-1 -yl)-5-methoxy-1 H-pyrrolo[2,3 25 b]pyridin-3-yl]-amide 1 -pyridin-4-ylmethyl-1 H-pyrazole-4-carboxylic acid (5-chloro-4-fluoro-1 H pyrrolo[2,3-b]pyridin-3-yl)-amide (125mg, 0.34mmol), (R)-piperidin-3-yl-carbamic acid tert-butyl ester (341.7mg, 1.71 mmol) and "BuOH (5mL) were combined in a microwave vial and heated under microwave irradiation at 1600C for 6 hours. 30 The solvent was removed in vacuo and the residue was taken up in DCM (5mL). TFA (3 mL) was added and the reaction mixture was stirred at RT for 18hrs. The reaction was concentrated in vacuo and taken up in DCM prior to loading onto a SCX-2 ion exchange column. The column was washed with DCM, MeOH and the compound of interest was eluted with ammonia solution 7 N in MeOH that WO 2013/114113 PCT/GB2013/050212 122 had been diluted to 0.5N using DCM. Fractions containing product were combined and concentrated in vacuo. The material was further purified by automated column chromatography eluting with DCM to 5% ammonia solution 7N in MeOH / 5% MeOH / DCM. The fractions containing pure product were 5 combined and concentrated in vacuo to afford the title compound as a pale orange solid 22mg, 14%. LC/MS: RT = 1.35 Min (270nm), m/z = 447 [M+H]. Total run time 3.75 min (short pos), HP1 100. 'H NMR (de DMSO): 61.18 (m, 1H), 1.44-1.76 (m, 5H), 2.85 (m, 2H), 3.03 (m, 10 2H), 3.21 (d, 1H), 3.86 (s, 3H), 5.50 (s, 2H), 7.16 (m, 2H), 7.71 (s, 1H), 8.06 (m, 2H), 8.55 (m, 2H), 8.63 (s, 1H), 9.76 (br s, 1H), 11.22 (br s, 1H) Example 82: 1-Pyridin-3-yImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-methoxv-1H-pyrrolof2.3-blpvridin-3-vil-amide N NH H3CO N H2N N~ N
H
2 N 15 The title compound was prepared according to an analogous route to that outlined in Scheme 2, and using the methodology described for Example 81, substituting 1 -pyridin-3-ylmethyl-1 H-pyrazole-4-carboxylic acid (119.7mg, 0.59mmol) for 1-pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid in Step 1. The 20 title compound was isolated as an off white solid, 48mg, 26.6%. LC/MS: RT = 1.50 Min (270nm), m/z = 447 [M+H]. Total run time 3.75 min (short pos), HP 1100. 1 H NMR (de DMSO): 6 1.2 (m, 1H), 1.41-1.75 (m, 5H), 2.85 (m, 2H), 3.03 (t, 2H), 3.21 (d, 1H), 3.86 (s, 3H), 5.47 (s, 2H), 7.40 (dd, 1H), 7.67-7.72 (m, 2H), 8.04 25 (m, 2H), 8.52-8.62 (m, 3H), 9.74 (br s, 1 H), 11.20 (br s, 1 H) WO 2013/114113 PCT/GB2013/050212 123 Example 83: 1-Pyridin-2-yImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-methoxv-1H-pyrrolof2.3-blpvridin-3-vil-amide N NH
H
3 C O 4HN N
H
2 N'N N 5 The title compound was prepared according to an analogous route to that outlined in Scheme 2, and using the methodology described for Example 81, substituting 1 -pyridin-2-ylmethyl-1 H-pyrazole-4-carboxylic acid (119.7mg, 0.59mmol) for 1-pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid in Step 1. The title compound was isolated as an off white solid, 56mg, 34%. 10 LC/MS: RT = 1.60 Min (270nm), m/z = 447 [M+H]. Total run time 3.75 min (short pos), HP1 100. 1 H NMR (de DMSO): 6 1.2 (m, 1H), 1.48-1.77 (m, 5H), 2.86 (m, 2H), 3.05 (m, 2H), 3.21 (d, 1H), 3.86 (s, 3H), 5.52 (s, 2H), 7.14 (d, 1H), 7.33 (dd, 1H), 7.74 (s, 1 H), 7.81 (t, 1 H), 8.02 (s, 1 H), 8.07 (s, 1 H), 8.56 (m, 2H), 9.78 (br s, 1 H), 11.21 15 (br s, 1H) WO 2013/114113 PCT/GB2013/050212 124 Example 84: 1-Pyridin-3-vImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-chloro-1H-pyrrolo[2,3-blpvridin-3-vil-amid N NH cr HN N
H
2 N N The title compound was prepared according to an analogous route to that 5 outlined in Scheme 2, using the methodology described for Example 24, substituting 1 -pyridin-3-ylmethyl-1 H-pyrazole-4-carboxylic acid (344.5mg, 1.7mmol) for 1-benzyl-1H-pyrazole-4-carboxylic acid in Step 6. After the usual work up as described in Step 7, the crude material was taken up in DCM and loaded onto a SCX-2 ion exchange column. The column was washed with DCM, 10 MeOH and the compound of interest was eluted with ammonia solution 7 N in MeOH that had been diluted to 0.5N using DCM. Fractions containing product were combined and concentrated in vacuo. The residue was further purified by automated column chromatography eluting with 2%Et 3 N in DCM to 20% MeOH /2%Et 3 N in DCM (gradient). Fractions containing pure material were combined 15 and concentrated in vacuo to afford the title compound as a pale yellow solid, 52mg, 21.4%. LC/MS: RT = 1.59 Min (270nm), m/z = 451 [M+H]. Total run time 3.75 min (short pos), HP 1100. 1 H NMR (de DMSO): 6 1.19 (m, 2H), 1.46 (m, 1H), 1.69 (m, 2H), 2.92 (m, 2H), 20 3.12 (m, 2H), 5.48 (s, 2H), 7.40 (dd, 1H), 7.67-(dt, 1H), 7.71 (s, 1H), 8.06 (s, 1H), 8.08 (s, 1H), 8.52-8.58 (m, 3H), 9.73 (br s, 1H), 11.69 (br s, 1H) 2 protons not seen WO 2013/114113 PCT/GB2013/050212 125 Example 85: 1-Pyridin-4-vImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-chloro-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH cr HN N
H
2 N N N& The title compound was prepared according to an analogous route to that 5 outlined in Scheme 2, using the methodology described for Example 24, substituting 1 -pyridin-3-ylmethyl-1 H-pyrazole-4-carboxylic acid (344.5mg, 1.7mmol) for 1-benzyl-1H-pyrazole-4-carboxylic acid in Step 6. After the usual work up as described in Step 7, the crude material was taken up in DCM and loaded onto a SCX-2 ion exchange column. The column was washed with DCM, 10 MeOH and the compound of interest was eluted with ammonia solution 7 N in MeOH that had been diluted to 0.5N using DCM. Fractions containing product were combined and concentrated in vacuo. The residue was further purified by automated column chromatography eluting with DCM to 12% MeOH / DCM (gradient). Fractions containing product were combined and concentrated in 15 vacuo. The residue was further purified by preparative HPLC at pH4. Fractions containing pure material were combined and concentrated in vacuo to afford a mixture of desired compound and 1-pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid [5-chloro-4-((R)-3-formylamino-piperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl] amide. This material was stirred in the minimum amount of MeOH and then 20 hydrochloric acid solution, 4M in 1,4-dioxane (2mL) was added. The reaction was stirred at RT for 18 hourss and the solvent was removed in vacuo. The residue was taken up in DCM, washed with 5% aqueous ammonia solution, dried (MgSO 4 ) and concentrated in vacuo. The residue was further purified by automated column chromatography eluting with 2%Et 3 N in DCM to 20% MeOH 25 /2%Et 3 N in DCM (gradient). Fractions containing pure material were combined WO 2013/114113 PCT/GB2013/050212 126 and concentrated in vacuo to afford the title compound as a pale yellow solid, 52mg, 13.2%. LC/MS: RT = 1.52 Min (270nm), m/z = 451 [M+H]. Total run time 3.75 min (short pos), HP 1100. 5 'H NMR (de DMSO): 6 1.19 (m, 2H), 1.48 (m, 1H), 1.69 (m, 2H), 2.25 (br s, 2H), 2.92 (m, 2H), 3.13 (m, 2H), 5.50 (s, 2H), 7.15 (m, 2H), 7.72 (s, 1H), 8.09 (m, 2H), 8.57 (m, 3H), 9.74 (br s, 1 H), 11.71 (br s, 1 H) Example 86: 1-Pyridin-2-vImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 10 amino-piperidin-1-vI)-5-chloro-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH cr' o 4HN N
H
2 N N N The title compound was prepared according to an analogous route to that outlined in Scheme 2, using the methodology described for Example 85, substituting 1 -pyridin-2-ylmethyl-1 H-pyrazole-4-carboxylic acid (344.5mg, 15 1.7mmol) for 1-benzyl-1H-pyrazole-4-carboxylic acid in Step 6. The title compound was isolated as a pale yellow solid, 30mg, 12.3%. LC/MS: RT = 1.69 Min (270nm), m/z = 451 [M+H]. Total run time 3.75 min (short pos), HP 1100. 1 H NMR (de DMSO): 6 1.20 (m, 2H), 1.50 (m, 1H), 1.72 (m, 2H), 2.08 (br s, 2H), 20 2.92 (m, 2H), 3.15 (m, 2H), 5.52 (s, 2H), 7.13 (d, 1H), 7.37 (dd, 1H), 7.75 (s, 1H), 7.81 (m, 1H), 8.04 (s, 1H), 8.09 (s, 1H), 8.56 (m, 2H), 9.79 (br s, 1H), 11.68 (br s, 1H) WO 2013/114113 PCT/GB2013/050212 127 Example 87: 1-Pyridin-4-vImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-methyl-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH
H
3 C 0 N HN N
H
2 N N NN The title compound was prepared according to an analogous route to that 5 outlined in Scheme 2. It was prepared from 4-fluoro-1 -triisopropylsilanyl-1 H-pyrrolo[2,3-b]pyridine, the product of Step 2, in Example 6. Step 1: Preparation of 4-Fluoro-5-methyl-1 H-pyrrolo[2,3-b]pyridine sec-Butyllithium solution, 1.4M in cyclohexane (8.76mL, 12.26mmol) was added 10 drop wise to a solution of 4-fluoro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine (2.05g, 7.01 mmol) in THF (75mL) at -780C. The reaction was stirred at -780C for 30 minutes and then methyl iodide (2.49g, 1.09mL, 17.52mmol) was added drop wise and the reaction was stirred at -780C for a further 45 minutes. The reaction was quenched by the addition of saturated aqueous ammonium chloride (50mL) 15 and the reaction allowed to attain RT. The mixture was extracted with EtOAc (x3) and the combined extracts washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The residue was taken up in THF (50mL) and tetrabutylammonium fluoride solution, 1.OM in THF (7.01mL, 7.01 mmol) was added drop wise at RT. The reaction mixture was stirred at RT 20 for 30 minutes and then partitioned between H 2 0 and EtOAc. The organic layer was separated and the aqueous was extracted with more EtOAc. The combined organic phases were washed with saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The residue was stirred in DCM/iso-hexane (1:1), filtered and washed with DCM/iso-hexane (1:1) prior to drying in vacuo. 25 This afforded the title compound as a white powder, 0.561g, 53.3%.
WO 2013/114113 PCT/GB2013/050212 128 Step 2: Preparation of 4-fluoro-5-methyl-3-nitro-1 H-pyrrolo[2,3-b]pyridine The title compound was prepared using the methodology described for Example 6, substituting 4-fluoro-5-methyl-1 H-pyrrolo[2,3-b]pyridine (600mg, 4mmol) for 5 Bromo-4-fluoro-1 H-pyrrolo[2,3-b]pyridine, in Step 5. The title compound was 5 isolated as a pale yellow powder, 609mg, 78.1%. Step 3: Preparation of 4-fluoro-5-methyl-1 H-pyrrolo[2,3-b]pyridin-3-ylamine The title compound was prepared using the methodology described for Example 6, substituting 4-fluoro-5-methyl-3-nitro-1 H-pyrrolo[2,3-b]pyridine (277mg, 1.42mmol) for 5-Bromo-4-fluoro-3-nitro-1 H-pyrrolo[2,3-b]pyridine, in 10 Step 6. The title compound was isolated as a brown powder, 230mg, 98.1%. Step 4: Preparation of 1-benzyl-1H-pyrazole-4-carboxylic acid (4-fluoro-5 methyl-1 H-pyrrolo[2,3-b]pyridin-3-yl)-amide 4-Fluoro-5-methyl-1 H-pyrrolo[2,3-b]pyridin-3-ylamine (230mg, 1.39mmol) was stirred in DMF (5mL) with DIPEA (0.462mL, 2.79mmol) and 1-pyridin-4-ylmethyl 15 1H-pyrazole-4-carboxylic acid (270mg, 1.33mmol). HATU (582mg, 153mmol) was added and the reaction was stirred at RT for 2 hours. The reaction mixture was diluted with H 2 0, and extracted with DCM/IPA (4:1) (x2). The combined extracts were washed with saturated aqueous sodium bicarbonate, saturated aqueous sodium chloride, dried (MgSO 4 ) and solvent removed in vacuo to afford 20 a black residue. This was triturated with MeOH/H 2 0 (1:1), filtered and washed with iso-hexane prior to drying in vacuo at 400C. This afforded the title compound as a brown powder, 198mg, 40.6%. Step 5: Preparation of title compound: 1-pyridin-4-ylmethyl-1H-pyrazole-4 carboxylic acid [4-((R)-3-amino-piperidin-1-yl)-5-methyl-1H-pyrrolo[2,3-b]pyridin 25 3-yl]-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid (4-fluoro-5-methyl-1 H-pyrrolo[2,3 b]pyridin-3-yl)-amide (198mg, 0.57mmol), p-toluenesulfonic acid monohydrate (430mg, 2.26mmol), (R)-piperidin-3-yl-carbamic acid tert-butyl ester (565.9mg, 2.83mmol) and NMP (6mL) were heated in a sealed tube at 1600C for 7 hours. 30 The mixture was purified by automated column chromatography eluting with DCM to 45% MeOH/DCM (gradient). The fractions containing product were combined and concentrated in vacuo. This still crude material was taken up in the minimum amount of DCM and Et 3 N (217.8mg, 0.3mL, 2.15mmol) was added. The mixture was stirred at RT and di-tert-butyl dicarbonate (150mg, WO 2013/114113 PCT/GB2013/050212 129 0.69mmol) was added followed by DMAP (5mg). This was stirred for 1 hour, diluted with DCM and washed with H 2 0, saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. This crude material was purified via automated column chromatography eluting with DCM to 10% MeOH/DCM 5 (gradient). The fractions containing the higher running mono boc product were combined and concentrated in vacuo. The residue was taken up in hydrochloric acid solution, 1.25M in MeOH (2mL) and heated under microwave irradiation at 800C for 30 minutes. The solvent was removed in vacuo and residue taken up in minimum volume of MeOH and applied to a SCX-2 ion exchange cartridge. This 10 was washed with MeOH and desired compound eluted with 4:1 DCM / 7N NH 3 in MeOH and concentrated in vacuo. Acetonitrile was added to the residue and after sonication for 10 minutes a fine precipitate formed. This was pelleted in a centrifuge and, after the liquors were decanted off, the solids were washed with Et 2 0 and filtered to give the title compound as a beige powder, 4.1mgs, 1.7%. 15 LC/MS: RT = 0.41 Min (230nm), m/z = 431 [M+H]. Total run time 1.9 min (super short pos),HP1200. 'H NMR (de DMSO): 6 1.11-1.22 (m, 1H), 1.43-1.54 (m, 1H) 1.64-1.77 (m, 2H), 2.36 (s, 3H), 2.78-2.85 (m, 1H), 2.85-2.93 (m, 1H), 3.00-3.05 (m, 2H), 3.17-3.24 (m, 1H), 5.51 (s, 2H), 7.13-7.16 (m, 2H), 7.68 (s, 1H), 7.93 (s, 1H), 8.07 (s, 1H), 20 8.54-8.57 (m, 2H), 8.59 (br s, 1 H), 9.78 (br s, 1 H), 11.28 (br s, 1 H) 2 protons not seen Example 88: 1-Pyridin-3-vImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-methyl-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH
H
3 C 0 N HN N
H
2 N N 25 25 WO 2013/114113 PCT/GB2013/050212 130 The title compound was prepared using the methodology described for Example 87, substituting 1-pyridin-3-ylmethyl-1H-pyrazole-4-carboxylic acid (406mg, 2mmol) for 1-pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid, in Step 4. It was isolated as a beige powder, 0.88mgs, 0.63%. 5 LC/MS: RT = 0.65 Min (230nm), m/z = 431 [M+H]. Total run time 1.9 min (super short pos),HP1200. 'H NMR (de DMSO): 6 1.11-1.23 (m, 1H), 1.40-1.52 (m, 1H) 1.63-1.77 (m, 2H), 2.36 (s, 3H), 2.77-2.85 (m, 1H), 2.85-2.94 (m, 1H), 2.99-3.06 (m, 2H), 3.16-3.25 (m, 1H), 5.47 (s, 2H), 7.38-7.44 (m, 1H), 7.65-7.70 (m, 2H), 7.93 (s, 1H), 8.03 (s, 10 1H), 8.51-8.62 (m, 3H), 9.76 (br s, 1H), 11.27 (br s, 1H) 2 protons not seen Example 89: 1-(4-Fluoro-benzvl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-methoxy-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH H3CO N
H
2 N N F 15 The title compound was prepared according to the route outlined in Scheme 7. It was made from [(R)-1-(3-amino-5-methoxy-1H-pyrrolo[2,3-b]pyridin-4-yl) piperidin-3-yl]-carbamic acid tert-butyl ester, the product of Step 5, in Example 32. Step 1: Preparation of [(R)-1-(3-{[1-(4-fluoro-benzyl)-1H-pyrazole-4-carbonyl] 20 amino}-5-methoxy-1 H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-3-yl]-carbamic acid tert-butyl ester To a solution of [(R)-1-(3-amino-5-methoxy-1H-pyrrolo[2,3-b]pyridin-4-yl) piperidin-3-yl]-carbamic acid tert-butyl ester (92mg, 0.25mmol), 1-(4-fluoro benzyl)-1H-pyrazole-4-carboxylic acid (61.6mg, 0.28mmol) and Et3N (69.6 L, 25 0.5mmol) in DMF (5ml) was added HATU (95.1mg, 0.25mmol) and the reaction WO 2013/114113 PCT/GB2013/050212 131 mixture was stirred at RT for 18 hours. The reaction mixture was concentrated in vacuo and the residue taken up in EtOAc (50 ml). It was washed with H 2 0, saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The crude material was purified by automated column chromatography eluting 5 with 30% EtOAc / iso-hexane to EtOAc (gradient). Fractions containing pure product were combined and concentrated in vacuo to afford the title compound as a brown solid, 82mg, 57.2%. Step 2: Preparation of title compound: 1-(4-fluoro-benzyl)-1H-pyrazole-4 carboxylic acid [4-((R)-3-amino-piperidin-1 -yl)-5-methoxy-1 H-pyrrolo[2,3 10 b]pyridin-3-yl]-amide To a solution of ((R)-1-{3-[(1-benzyl-1H-pyrazole-4-carbonyl)-amino]-5-methoxy 1 H-pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert-butyl ester (81mg, 0.14mmol) in DCM (5 mL) was added TFA (1mL) at RT. The reaction mixture 15 was stirred for a further 2 hours at RT and then concentrated in vacuo. The residue was taken up in DCM, washed with 5% aqueous ammonia solution, saturated aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The crude material was purified by automated column chromatography eluting with DCM to 20%MeOH (containing 5% 7N NH3 in MeOH) (gradient). Fractions 20 containing pure product were combined and concentrated in vacuo to afford the title compound as a white solid, 34mg, 51%. LC/MS: RT = 1.81 Min (270nm), m/z = 464 [M+H]. Total run time 3.75 min (short pos), HP1 100. 'H NMR (de DMSO): 61.18 (m, 1H), 1.45-1.71 (m, 5H), 2.85 (m, 2H), 3.03 (m, 25 2H), 3.21 (d, 1H), 3.86 (s, 3H), 5.40 (s, 2H), 7.21 (m, 2H), 7.34 (m, 2H), 7.72 (s, 1H), 8.01 (s, 1H), 8.06 (s, 1H), 8.55 (s, 1H), 9.73 (br s, 1H), 11.21 (br s, 1H) WO 2013/114113 PCT/GB2013/050212 132 Example 90: 1-(3-Methyl-benzvl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-methoxy-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH
H
3 C The title compound was prepared according to the route outlined in Scheme 7, 5 using the methodology described for Example 89, substituting 1-(3-methyl benzyl)-1H-pyrazole-4-carboxylic acid (79mg, 0.365mmol) for 1-(4-fluoro benzyl)-1 H-pyrazole-4-carboxylic acid, in Step 1. The title compound was isolated as a white solid, 59mg, 64.7%. LC/MS: RT = 1.86 Min (270nm), m/z = 460 [M+H]. Total run time 3.75 min (short 10 pos),HP1100. 1 H NMR (de DMSO): 61.19 (m, 1H), 1.44-1.75 (m, 5H), 2.29 (s, 3H), 2.85 (m, 2H), 3.03 (t, 2H), 3.21 (d, 1H), 3.86 (s, 3H), 5.36 (s, 2H), 7.07-7.14 (m, 3H), 7.26 (t, 1H), 7.73 (s, 1H), 8.00 (s, 1H), 8.06 (s, 1H), 8.55 (s, 1H), 9.74 (br s, 1H), 11.20 (br s, 1H) 15 Example 91: 1-(3-Fluoro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-methoxy-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH H3C O HN
H
2 N N N
F
WO 2013/114113 PCT/GB2013/050212 133 The title compound was prepared according to the route outlined in Scheme 7, using the methodology described for Example 89, substituting 1-(3-fluoro benzyl)-1H-pyrazole-4-carboxylic acid (80.4mg, 0.365mmol) for 1-(4-fluoro benzyl)-1 H-pyrazole-4-carboxylic acid, in Step 1. The title compound was 5 isolated as a white solid, 47mg, 59.5%. LC/MS: RT = 1.81 Min (270nm), m/z = 464 [M+H]. Total run time 3.75 min (short pos), HP1 100. 'H NMR (de DMSO): 6 1.21 (m, 1H), 1.46 (m, 1H), 1.66-2.13 (m, 4H), 2.86 (m, 2H), 3.03 (t, 2H), 3.21 (d, 1H), 3.86 (s, 3H), 5.44 (s, 2H), 7.07-7.19 (m, 3H), 7.42 10 (m, 1H), 7.70 (s, 1H), 8.04 (s, 1H), 8.06 (s, 1H), 8.60 (s, 1H), 9.73 (br s, 1H), 11.22 (br s, 1H) Example 92: 1-(2-Chloro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-methoxv-1H-pyrrolof2.3-blpvridin-3-vIl-amide N NH H3CO N
H
2 N N 15 The title compound was prepared according to the route outlined in Scheme 7, using the methodology described for Example 89, substituting 1-(2-chloro benzyl)-1H-pyrazole-4-carboxylic acid (86.5mg, 0.365mmol) for 1-(4-fluoro benzyl)-1 H-pyrazole-4-carboxylic acid, in Step 1. The title compound was 20 isolated as a white solid, 55mg, 53.6%. LC/MS: RT = 1.86 Min (270nm), m/z = 480 [M+H]. Total run time 3.75 min (short pos), HP1100. 1 H NMR (de DMSO): 6 1.17 (m, 1H), 1.44-1.72 (m, 5H), 2.84 (m, 2H), 3.04 (t, 2H), 3.20 (d, 1H), 3.86 (s, 3H), 5.52 (s, 2H), 7.15 (m, 1H), 7.38 (m, 2H), 7.52 (m, WO 2013/114113 PCT/GB2013/050212 134 1 H), 7.73 (s, 1 H), 8.04 (s, 1 H), 8.06 (s, 1 H), 8.50 (s, 1 H), 9.75 (br s, 1 H), 11.22 (br s, 1H) Example 93: 1-(2-Methyl-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 5 amino-piperidin-1-VI)-5-methoxy-1H-pyrrolo[2,3-blpVridin-3-vil-amide N NH H3CO kH N N
H
2 N'N CdH 3 The title compound was prepared according to the route outlined in Scheme 7, using the methodology described for Example 89, substituting 1-(2-methyl benzyl)-1H-pyrazole-4-carboxylic acid (79mg, 0.365mmol) for 1-(4-fluoro 10 benzyl)-1H-pyrazole-4-carboxylic acid, in Step 1. The title compound was isolated as a white solid, 52mg, 54.1%. LC/MS: RT = 1.86 Min (270nm), m/z = 460 [M+H]. Total run time 3.75 min (short pos), HP1100. 1 H NMR (de DMSO): 6 1.17 (m, 1H), 1.42-1.74 (m, 5H), 2.28 (s, 3H), 2.83 (m, 15 2H), 3.02 (t, 2H), 3.21 (d, 1H), 3.85 (s, 3H), 5.42 (s, 2H), 7.07 (d, 1H), 7.24 (m, 3H), 7.72 (s, 1 H), 8.01 (s, 1 H), 8.06 (s, 1 H), 8.41 (s, 1 H), 9.71 (br s, 1 H), 11.21 (br s, 1H) WO 2013/114113 PCT/GB2013/050212 135 Example 94: 1-(4-Fluoro-benzvl)-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-trifluoromethyl-1H-pVrrolo[2,3-blpVridin-3-vil-amide N NH F N F N
H
2 N N N F The title compound was prepared according to the route outlined in Scheme 8. 5 Step 1: Preparation of 4-chloro-1 -triisopropylsilanyl-1 H-pyrrolo[2,3-b]pyridine The title compound was prepared as described in Example 6, Step 1, substituting 4-chloro-1H-pyrrolo[2,3-b]pyridine (5g, 32.8mmol) for 4-bromo-11H pyrrolo[2,3-b]pyridine. It was isolated as a colourless oil, 8.27g, 81.7%. Step 2: Preparation of 4-chloro-5-iodo-1 H-pyrrolo[2,3-b]pyridine 10 sec-Butyllithium solution, 1.4M in cyclohexane (15.82mL, 22.15mmol) was added drop wise to a solution of 4-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3 b]pyridine (3.91g, 12.77mmol) in THF (50mL) at -780C. The reaction was stirred at -780C for 30 minutes and then a solution of iodine (8.03g, 31.64mmol) in THF (25mL) was added drop wise and the reaction was stirred at -78 OC for a further 15 45 minutes. The reaction was quenched by the addition of saturated aqueous ammonium chloride (50mL) and the reaction allowed to attain RT. The mixture was extracted with iso-hexane (2x75mL) and the combined extracts washed with saturated aqueous sodium sulfite (x2) and saturated aqueous sodium chloride. The solution was dried over anhydrous MgSO4 and concentrated to a colourless 20 oil. This was taken up in THF (25mL) and tetrabutylammonium fluoride solution, 1.OM in THF (12.7mL, 12.7mmol) was added drop wise at RT. The reaction mixture was stirred at RT for 30 minutes and then partitioned between H 2 0 and EtOAc. The organic layer was separated and the aqueous was extracted with more EtOAc. The combined organic phases were washed with saturated 25 aqueous sodium chloride, dried (MgSO 4 ) and concentrated in vacuo. The WO 2013/114113 PCT/GB2013/050212 136 residue was stirred in DCM, flitered and washed with DCM prior to drying in vacuo. This afforded the title compound as a white solid, 2.72g, 77.3%. Step 3: Preparation of 1-benzenesulfonyl-4-chloro-5-iodo-1H-pyrrolo[2,3 b]pyridine 5 Sodium hydride, 60% dispersion in mineral oil (0.508g, 12.7mmol) was added in portions to 4-chloro-5-iodo-1 H-pyrrolo[2,3-b]pyridine (2.72g, 10.74mmol) in DMF (20mL) at 0CC. The reaction was stirred for a further 15 minutes and then benzene sulphonyl chloride (1.9g, 1.37mL, 10.74mmol) was added and the reaction stirred at RT for 2 hours. The reaction mixture was diluted with H 2 0 and 10 after stirring for 15 minutes the precipitate was filtered off, washed with H 2 0 and with Et 2 0. This furnished the title compound as a white powder, 3.47g, 84.8%, after drying in vacuo. Step 4: Preparation of 1 -benzenesulfonyl-4-chloro-5-trifluoromethyl-1 H pyrrolo[2,3-b]pyridine 15 Copper (I) iodide (0.78g, 4.1mmol) was added to a solution of 1 benzenesulfonyl-4-chloro-5-iodo-1H-pyrrolo[2,3-b]pyridine (1.43g, 3.42mmol) in DMF (10mL). The mixture was degassed and methyl 2,2-difluoro-2 (fluorosulfonyl)acetate (2.3g, 11.96mmol) was added and mixture degassed again before heating at 100 C for 2.5 hours. The reaction was cooled to RT and 20 diluted with EtOAc (40mL). The precipitate was separated by filtering through a plug of celite. The filtrate was washed with H 2 0 (20mL), saturated aqueous sodium chloride (20mL),dried (MgSO 4 )and concentrated in vacuo. The crude material was purified by automated column chromatography eluting with iso hexane to 25% EtOAc/iso-hexane (gradient). Fractions containing pure product 25 were combined and concentrated in vacuo to afford the title compound as a white solid, 0.46g, 37.5%. Fractions containing pure product and small impurities were combined and concentrated in vacuo. The residue was triturated with Et 2 0 to afford the title compound as a white powder, 0.26g, 21.3%. This gave a yield of 0.72g, 58.8% overall. 30 Step 5: Preparation of 4-chloro-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridine 1 -benzenesulfonyl-4-chloro-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridine (1.5g, 4.16mmol) was stirred in THF (10mL) and LiOH monohydrate (520mgs, 12.47mmol) in H 2 0 (6mL) was added. The reaction mixture was stirred at RT for 64 hours and then the pH was adjusted to 7 by the addition of saturated WO 2013/114113 PCT/GB2013/050212 137 aqueous potassium hydrogen sulphate. This was extracted with EtOAc (2x30mL) and the combined organics washed with saturated aqueous sodium chloride, dried over MgSO 4 and concentrated in vacuo to afford the title compound as a pale yellow powder, 0.84g, 91.8%. 5 Step 6: Preparation of 4-chloro-3-nitro-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridine The title compound was prepared according to the methodology described for Example 6, Step 5, substituting 4-chloro-5-trifluoromethyl-1H-pyrrolo[2,3 b]pyridine (842mg, 3.82mmol) for 5-bromo-4-fluoro-1 H-pyrrolo[2,3-b]pyridine. It was isolated as a pale yellow powder, 0.78g, 76.9%. 10 Step 7: Preparation of [(R)-1 -(3-nitro-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridin-4 yl)-piperidin-3-yl]-carbamic acid tert-butyl ester The title compound was prepared according to the methodology described for Example 89, Step 1, substituting 4-chloro-3-nitro-5-trifluoromethyl-1 H 15 pyrrolo[2,3-b]pyridine (200mg, 0.75mmol) for 4-fluoro-5-methoxy-3-nitro-1H pyrrolo[2,3-b]pyridine. It was isolated as a yellow glass, 179mg, 55.4%. Step 8: Preparation of [(R)-1 -(3-amino-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridin 4-yl)-piperidin-3-yl]-carbamic acid tert-butyl ester 20 The title compound was prepared according to the methodology described for Example 31, Step 8, substituting [(R)-1-(3-nitro-5-trifluoromethyl-1H-pyrrolo[2,3 b]pyridin-4-yl)-piperidin-3-yl]-carbamic acid tert-butyl ester (179mg, 0.42mmol) for 2,2-dimethyl-propionic acid 4-((R)-3-tert-butoxycarbonylamino-piperidin-1-yl) 3-nitro-1 H-pyrrolo[2,3-b]pyridin-5-yl ester. It was isolated as a green gum, 25 149mgs, 88.9%. Step 9: Preparation of [(R)-1-(3-{[1-(4-Fluoro-benzyl)-1H-pyrazole-4-carbonyl] amino}-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-3-yl]-carbamic acid tert-butyl ester 30 1-(4-Fluoro-benzyl)-1 H-pyrazole-4-carboxylic acid (synthesis described in Example 17) was stirred as a suspension in DCM (2mL) and oxalyl chloride, 2.OM solution in DCM (0.17mL, 0.34mmol) was added drop wise at RT followed by a drop of DMF. The reaction was stirred for a further 15 minutes and the subsequent solution was concentrated in vacuo. The residue was taken up in WO 2013/114113 PCT/GB2013/050212 138 DCM (1mL) and added drop wise to a solution of [(R)-1-(3-amino-5 trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-3-yl]-carbamic acid tert butyl ester (62.3mg, 0.28mmol) in DCM (2mL) containing Et 3 N (90mg, 0.12mL, 0.85mmol). After stirring for a further 1 hour the reaction was diluted with DCM 5 and washed with H 2 0. The organics were separated, dried (MgSO 4 ) and concentrated in vacuo. The residue was taken up in MeOH (5mL) and after 50%w/v NaOH (1mL) was added, the mixture was stirred for 18 hours at RT. The solvent removed in vacuo and the residue taken up in DCM. It was washed with H 2 0, saturated aqueous sodium chloride, dried over MgSO 4 and 10 concentrated in vacuo. The crude material was purified via automated column chromatography eluting with 25% EtOAc/iso-hexane to EtOAc (gradient). The fractions containing product were combined and concentrated in vacuo to afford the title compound as a yellow glass, 52mg, 30.6%. Step 10: Preparation of title compound: 1-(4-Fluoro-benzyl)-1H-pyrazole-4 15 carboxylic acid [4-((R)-3-amino-piperidin-1-yl)-5-trifluoromethyl-1H-pyrrolo[2,3 b]pyridin-3-yl]-amide [(R)-1 -(3-{[1 -(4-Fluoro-benzyl)-1 H-pyrazole-4-carbonyl]-amino}-5-trifluoromethyl 1 H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-3-yl]-carbamic acid tert-butyl ester (50mg, 0.08mmol) was taken up in hydrochloric acid solution, 1.25M in MeOH (2mL) 20 and heated under microwave irradiation at 800C for 30 minutes. The solvent was removed in vacuo and residue taken up in minimum volume of MeOH and applied to a SCX-2 ion exchange cartridge. This was washed with MeOH and desired compound eluted with 4:1 DCM / 7N NH 3 in MeOH and concentrated in vacuo. The crude material was further purified via automated column 25 chromatography eluting with DCM to 15% MeOH (containing 5% 7N NH 3 in MeOH) /DCM (gradient). The fractions found to contain product were combined and concentrated in vacuo. The residue was triturated with deithyl ether to afford the title compound as a cream powder, 4.5mgs, 10.8%. LC/MS: RT = 0.93 Min (230nm), m/z = 502.2 [M+H]. Total run time 1.9 min 30 (super short pos),HP1200. 'H NMR (de DMSO): 60.82-0.93 (m, 1H), 1.38-1.50 (m, 1H), 1.54-1.65 (m, 2H), 2.70-2.81 (m, 2H), 2.80-3.00 (m, 2H), 3.1-3.09 (m, 1H), 5.42 (s, 2H), 7.16-7.24 (m, 2H), 7.28-7.36 (m, 2H), 7.70 ( s, 1H), 8.08 (s, 1H), 8.45-8.48 (m, 2H), 9.62 (br s, 1 H), 11.60-12.60 (br s, 1 H) 2 protons not seen WO 2013/114113 PCT/GB2013/050212 139 Example 95: 1-Benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino Piperidin-1-vI)-5-trifluoromethvl-1H-pyrrolof2.3-blpvridin-3-vIl-amide N NH ".0 F HN F N
H
2 N N 5 The title compound was prepared according to the methodology described for Example 94 in Steps 1 to 8. Step 9: Preparation of ((R)-1-{3-[(1-benzyl-1H-pyrazole-4-carbonyl)-amino]-5 trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert butyl ester 10 This was prepared using the methodology described for Example 31, Step 9, substituting [(R)-1 -(3-amino-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridin-4-yl) piperidin-3-yl]-carbamic acid tert-butyl ester (60mg, 0.15mmol) for 2,2-dimethyl propionic acid 3-amino-4-((R)-3-tert-butoxycarbonylamino-piperidin-1 -yl)-1 H pyrrolo[2,3-b]pyridin-5-yl ester and DIPEA (40mg, 50uL, 0.3mmol) for Et 3 N. The 15 title compound was isolated as a dark yellow glass, 63mg, 71.9%. Step 10: preparation of title compound: 1-benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 -yl)-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridin-3-yl] amide This was prepared using the methodology described for Example 94, Step 10, 20 substituting ((R)-1 -{3-[(1 -benzyl-1 H-pyrazole-4-carbonyl)-amino]-5 trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-4-yl}-piperidin-3-yl)-carbamic acid tert butyl ester (63mg, 0.11mmol) for [(R)-1-(3-{[1-(4-fluoro-benzyl)-1H-pyrazole-4 carbonyl]-amino}-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridin-4-yl)-piperidin-3-yl] carbamic acid tert-butyl ester. After the usual work up, the residue was taken up 25 in minimum volume of MeOH and applied to a SCX-2 ion exchange cartridge.
WO 2013/114113 PCT/GB2013/050212 140 This was washed with MeOH and the desired compound eluted with 4:1 DCM / 7N NHa 3 in MeOH and concentrated in vacuo. The material was further purified by trituration with Et 2 0 and then MeCN. This afforded the title compound as a beige powder, 4.3mg, 8.2%. 5 LC/MS: RT = 0.91 Min (230nm), m/z = 484.2 [M+H]. Total run time 1.9 min (super short pos),HP1200. 'H NMR (de DMSO): 60.90-1.00 (m, 1H), 1.40-1.51 (m, 1H), 1.54-1.68 (m, 2H), 2.80-3.00 (m, 4H), 3.07-3.13 (m, 1H), 5.42 (s, 2H), 7.20-7.40 (m, 5H), 7.70 (s, 1H), 8.10 ( s, 1H), 8.45-8.50 (m, 2H), 9.65 (br s, 1H), 11.00-13.00 (br s, 1H) 2 10 protons not seen Example 96: 1-Pyridin-3-vImethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3 amino-piperidin-1-vI)-5-trifluoromethyl-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH F."9 HN F N
H
2 N N N 15 The title compound was prepared according to the methodology described for Example 94, substituting 1-pyridin-3-ylmethyl-1H-pyrazole-4-carboxylic acid (57.5mg, 0.28mmol) for 1-(4-fluoro-benzyl)-1H-pyrazole-4-carboxylic acid, in Step 9. The title compound was isolated as a beige powder, 11.7mg, 28.2%. LC/MS: RT = 0.78 Min (230nm), m/z = 485 [M+H]. Total run time 1.9 min (super 20 short pos),HP1200. 1 H NMR (de DMSO): 60.83-0.93 (m, 1H), 1.38-1.51 (m, 1H), 1.54-1.64 (m, 2H), 2.71-2.82 (m, 2H), 2.84-3.00 (m, 2H), 3.02-3.10 (m, 1H), 5.48 (s, 2H), 7.38-7.43 (m, 1H), 7.63-7.72 (m, 2H), 8.10, (s, 1H), 8.45 (s, 1H), 8.50-8.55 (m, 3H), 9.65 (br s, 1 H), 11.60-12.60 (br s, 1 H) 2 protons not seen 25 WO 2013/114113 PCT/GB2013/050212 141 Example 97: 1-Pyridin-2-vImethyl-1H-pyrazole-4-carboxylic acid [4-(R)-3 amino-piperidin-1-vI)-5-trifluoromethyl-1H-pyrrolo[2,3-blpvridin-3-vil-amide N NH F N F N
H
2 N N N N The title compound was prepared according to the methodology described for 5 Example 94, substituting 1-pyridin-2-ylmethyl-1H-pyrazole-4-carboxylic acid (57.5mg, 0.28mmol) for 1-(4-fluoro-benzyl)-1H-pyrazole-4-carboxylic acid, in Step 9. The title compound was isolated as a beige powder, 15.1mg, 43.4%. LC/MS: RT = 0.82 Min (230nm), m/z = 485.2 [M+H]. Total run time 1.9 min (super short pos),HP1200. 10 1 H NMR (de DMSO): 60.88-0.99 (m, 1H), 1.42-1.54 (m, 1H), 1.57-1.69 (m, 2H), 2.73-2.84 (m, 2H), 2.84-3.00 (m, 2H), 3.04-3.11 (m, 1H), 5.53 (s, 2H), 7.10 (d, 1H), 7.31-7.37 (m, 1H), 7.72 ( s, 1H), 7.80 (m, 1H), 8.07, (s, 1H), 8.45-8.57 (m, 3H), 9.68 (br s, 1 H), 11.60-12.60 (br s, 1 H) 2 protons not seen 15 General Procedures All reagents obtained from commercial sources were used without further purification. Anhydrous solvents were obtained from commercial sources and used without further drying. Flash chromatography was performed with pre packed silica-gel cartridges (Isolute Flash Si II, 56 A, Biotage). Automated flash 20 chromatography was performed on a Teledyne Isco CombiFlash@ Rf purification system with pre-packed silica-gel cartridges (SilaSep T M Flash, 60 A, Silicycle). Ion exchange chromatography was performed using isolute SCX-2, SPE columns, Biotage. Thin layer chromatography was conducted with 5 x 10 cm plates coated with Silica 60 (Machery-Nagel). Microwave heating was performed WO 2013/114113 PCT/GB2013/050212 142 with a Biotage Initiator Eight m 2.0 instrument, a CEM explorer 24 or a CEM explorer 48. The compounds of the present invention were characterized by high performance liquid chromatography-mass spectroscopy (HPLC-MS) on either an 5 Agilent HP1200 Rapid Resolution Mass detector 6140 multimode source M/z range 150 to 1000 amu or an Agilent HP1100 Mass detector 1946D ESI source M/z range 150 to 1000 amu. The conditions and methods listed below are identical for both machines. 10 Column for 7.5min run: GeminiNX, 5pm, C18, 30 x 2.1mm (Phenomenex) or Zorbax Eclipse Plus, 3.5pm, C18, 30 x 2.1mm (Agilent). Temperature: 350C. Column for 3.75 min run: GeminiNX, 5pm, C18, 30 x 2.1mm (Phenomenex) or Zorbax Eclipse Plus, 3.5pm, C18, 30 x 2.1mm (Agilent). 15 Temperature: 35C. Column for 1.9 min run: Kinetex, 2.5 pm, C18, 50 x 2.1 mm (Phenomenex) or Accucore, 2.6pm, C18, 50 x 2.1mm. Temperature: 550C. Mobile Phase: A - H 2 0 + 10 mmol / ammonium formate + 0.08% (v/v) formic 20 acid at pH ca 3.5. B - 95% Acetonitrile + 5% A + 0.08% (v/v) formic acid. Injection Volume: 1 tL "Short" method gradient table, either positive (pos) or positive and negative (pos 25 / neg) ionisation Time (min) Solvent A (%) Solvent B (%) Flow (mL/min) 0 95 5 1 0.25 95 5 1 2.50 5 95 1 2.55 5 95 1.7 3.60 5 95 1.7 3.65 5 95 1 WO 2013/114113 PCT/GB2013/050212 143 3.70 95 5 1 3.75 95 5 1 "Super Short" method gradient table, either positive (pos) or positive and negative (pos / neg) ionisation Flow Time (min) Solvent A (%) Solvent B (%) (mL/min) 0 95 5 1.3 0.12 95 5 1.3 1.30 5 95 1.3 1.35 5 95 1.6 1.85 5 95 1.6 1.90 5 95 1.3 1.95 95 5 1.3 5 "Long" method gradient table, either positive (pos) or positive and negative (pos / neg) ionisation Time (min) Solvent A (%) Solvent B (%) Flow (mL/min) 0 95 5 1 0.25 95 5 1 5.50 5 95 1 7.25 5 95 1 7.50 95 5 1 10 Detection: UV detection at 230, 254 and 270 nm. The compounds of the present invention were also characterized by Nuclear Magnetic Resonance (NMR). Analysis was performed with a Bruker DPX400 spectrometer and proton NMR spectra were measured at 400 MHz. The spectral 15 reference was the known chemical shift of the solvent. Proton NMR data is reported as follows: chemical shift (6) in ppm, followed by the multiplicity, where WO 2013/114113 PCT/GB2013/050212 144 s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, dm = doublet of multiplets, ddd = doublet of double doublets, td = triplet of doublets, qd = quartet of doublets and br = broad, and finally the integration. 5 Some compounds of the invention were purified by preparative HPLC. These were performed on a H 2 0s FractionLynx MS autopurification system, with a Gemini-NX* 5 pm, C18, 100 mm x 21 mm i.d. Axia column from Phenomenex, running at a flow rate of 20 cm 3 min- with UV diode array detection (210 400nm), and mass-directed collection. Gradients used for each compound are 10 shown in Tables above. At PH 4: solvent A = 10 mM ammonium formate in HPLC grade H 2 0 + 0.08% v/v formic acid. Solvent B = 95% v/v HPLC grade acetonitrile + 5% v/v solvent A + 0.08% v/v formic acid. 15 At PH 9: solvent A = 10 mM ammonium formate in HPLC grade H 2 0 + 0.08% v/v ammonia solution. Solvent B = 95% v/v HPLC grade MeOH + 5% v/v solvent A + 0.08% v/v ammonia solution. The mass spectrometer was a H 2 0s Micromass ZQ2000 spectrometer, 20 operating in positive and negative ion electrospray ionisation modes, with a molecular weight scan range of 150 to 1000. IUPAC chemical names were generated using AutoNom Standard. Assay Protocols 25 CHK1 Enzyme Assay Assays for the CHK1 kinase activity were carried out by monitoring the phosphorylation of a synthetic peptide Chktide with the amino acid sequence, KKKVSRSGLYRSPSMPENLNRPR. The assay mixture containing the inhibitor and CHK1 enzyme was mixed together in a microtiter plate in a final volume of 30 50 tl and incubated for 40 minutes at 300C. The assay mixture contained 0.02mM unlabeled ATP, 0.5 .Ci 33 P-y-ATP, 15.M Chktide, 0.1mg/mL BSA, 50mM Hepes-NaOH pH 7.5 and 5nM CHK-1(1-289) 8HIS (Vernalis) enzyme. The reaction was stopped by adding 50jL_ of 50mM phosphoric acid. 90 L of the mixture was transferred to a pre-wetted 96-well WO 2013/114113 PCT/GB2013/050212 145 multi-screen MAPHNOB filtration plate (Millipore) and filtered on a vacuum manifold. The filter plate was washed with 3 successive additions of 1 00 l 50mM phosphoric acid and then with 50L MeOH. The filtration plate was dried for 10 min at 650C, scintillant added and phosphorylated peptide quantified in a 5 scintillation counter (Trilux, PerkinElmer). CHK-1 Enzyme Assay (TR-FRET) CHK activity was also assessed using LanthaScreen TR-FRET technology (Life Technologies) by monitoring the phosphorylation of a synthetic fluorescein 10 labelled peptide based on ezrin/radixin/moesin (ERM) (amino acid sequence GAGRLGRDKYKTLRQIRQ). The assay mixture containing the inhibitor and CHK-1 enzyme was mixed together in a microtiter plate in a final volume of 20 tl and incubated for 80 minutes at 300C. The assay mixture contained 50mM HEPES pH 7.5, 10 mM MgCl 2 , 1 mM EGTA, 15 0.01% Brij-35, 200pM ATP, 400nM fluorescein-labelled ERM (Life Technologies), and 1nM full length HIS-tagged CHK-1 (Life Technologies). The reaction was stopped by adding 20 L of TR-FRET dilution buffer (Life Technologies) containing 20mM EDTA and 1nM terbium-labelled anti-pERM antibody (Life Technologies). The quenched reaction was incubated for 30 20 minutes at room temperature with shaking to allow antibody to bind to phosphorylated ERM, and then fluorescence from the donor fluorophore (terbium) and acceptor fluorophore (fluorescein) was measured using a Synergy2 Multi-Mode Microplate Reader (BioTek) at 495nm and 520nm respectively. The TR-FRET ratio was calculated as 520nm/495nm. 25 CHK-1 Binding Assay (TR-FRET) Compounds were assessed for CHK-1 binding using LanthaScreen TR-FRET technology (Life Technology). Assay mixture containing inhibitor, 50mM HEPES pH 7.5, 10 mM MgCl 2 , 1 mM EGTA, 0.01% Brij-35, 2nM biotin-labelled anti-HIS 30 tag antibody (Life Technologies), 2nM Europium-labelled streptavidin (Life Technologies), 100nM AlexaFluor-labelled Tracer236 (Life Technologies), and either 1OnM or 30nM CHK-1(1-289)-8HIS (Vernalis) enzyme, was incubated in a microtitre plate for 120 minutes at 230C. A final volume of 15pL was used.
WO 2013/114113 PCT/GB2013/050212 146 Fluorescence from the donor fluorophore (europium) and acceptor fluorophore (Alexa Fluor) was measured using a Synergy2 Multi-Mode Microplate Reader (BioTek) at 620nm and 665nm respectively. The TR-FRET ratio was calculated as 665nm/620nm. 5 All the compounds exemplified in the patent were tested in one, two or all three of the above assays and were found to have an IC50 of less than 1 M. A majority of Examples 1-97 were found to have an IC50 of less than 0.1 M. 10 CHK1 Cellular Assay -Gemcitabine EC 50 Assay HT29 cells were purchased from ATCC (Manassus, VA, US) and cultured in Dulbecco's modified Eagles medium (DMEM) supplemented with 10% foetal calf serum (FCS) and penicillin / streptomycin at 370C, 5% C02 in a humidified incubator. 5x1 03 HT29 cells were seeded per well of a 96-well plate and allowed 15 to incubate overnight. Tripling dilutions of compound, prepared in DMEM / 10% FCS plus 15 nM gemcitabine, were added to the cells and incubated at 370C for 72 hours. Cells were then fixed with 10% trichloroacetic acid (TCA) stained with sulphorhodamine B (SRB) and the absorbance determined at 540 nm. Curves were analysed using XLFit 4 (Excel) with model 205 (fit = (A+((B 20 A)/(1+((C/x)AD))))).The EC 50 was determined as the concentration of compound that inhibited growth by 50% at a given concentration of gemcitabine. All the compounds exemplified in the patent were tested in the above assay in the presence of gemcitabine at 15nM, and were found to have an EC 50 of less than 1 M. A majority of Examples 1-97 were found to have an EC 50 of less than 25 0.1 M. 30

权利要求:
Claims (24)
[1] 1. A compound of formula I: N H N /' Z Z HN N N Y R1 5 (I) or a pharmaceutically acceptable salt thereof, wherein: each Z is independently (Alk)n-Rn-(Alk)n-X, 10 wherein each Alk is independently (C1 to C12) alkylene or (C2 to C12) alkenylene, each of which may be optionally substituted; each n is independently 0 or 1; each R is independently optionally substituted arylene or heteroarylene, or optionally substituted cycloalkylene or heterocyclic, -0-, -S-, -(C=0)-, -(C=S)-, 15 -SO 2 -, -C(=O)O-, -C(=0)NRA-, -C(=S)NRA-, -SO 2 NRA-, -NRAC(=O)-, -NRAS02 or -NRA- wherein RA is hydrogen, C1-C alkyl, -C1-C alkyl(cycloalkyl), C1-C alkyl(C 1 -C alkoxy) or C1-C alkoxy; each X is independently halogen, -H, -ORA, NRARA, optionally substituted aryl or heteroaryl, or optionally substituted cycloalkyl or heterocyclic, CN or 20 C(halogen)aHb, where a is 1, 2, or 3, and b is (3-a); Y is optionally substituted aryl or heteroaryl, or optionally substituted cycloalkyl or heterocyclic; and R 1 is H or C 1 -C alkyl. WO 2013/114113 PCT/GB2013/050212 148
[2] 2. A compound according to claim 1 wherein RA is hydrogen or C1-C alkyl.
[3] 3. A compound according to any preceding claim, wherein at least one Z is H, halogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted nitrogen-containing heterocycle, C1 to C alkyl or ORA 5
[4] 4. A compound according to claim 3, wherein one Z group is H, halogen, ORA or 1, to C6 alkyl, and the other Z group is optionally substituted aryl or optionally substituted nitrogen-containing heterocycle.
[5] 5. A compound according to claim 3 or claim 4, wherein the nitrogen containing heterocycle is substituted with NRA A 10
[6] 6. A compound according to claim 1 or 2, wherein at least one Z is (Alk)n optionally substituted arylene-(Alk)n-optionally substituted heterocycle.
[7] 7. A compound according to any preceding claim, wherein R 1 is H.
[8] 8. A compound according to any preceding claim, wherein C1 to C alkyl includes a cycloalkyl portion. 15
[9] 9. A compound according to any preceding claim, wherein Y is phenyl or heteroaryl optionally substituted with C1 to C alkyl, ORA, halogen or C1 to C alkoxy.
[10] 10. A compound according to claim 9, wherein Y is pyridyl, pyrrolyl, phenyl, or phenyl substituted with methyl, 0-methyl, bromine or chlorine. 20
[11] 11. A compound according to any preceding claim, which has the formula la: H N Z, N Yot or a pharmaceutically acceptable salt thereof, wherein: WO 2013/114113 PCT/GB2013/050212 149 Z 1 and Z 2 are independently (Alk)n-Rn-(Alk)n-X; and Alk, n, R, X, Y, RA and R 1 are as defined in claim 1.
[12] 12. A compound according to claim 11, wherein Z 1 is halogen, phenyl, ORA or C1 to C alkyl, and Z 2 is optionally substituted aryl or optionally substituted 5 heterocycle.
[13] 13. A compound according to claim 11, wherein Z 2 is halogen, CF 3 , cyclopropyl, phenyl, ORA or C1 to 06 alkyl, and Z 1 is optionally substituted aryl or optionally substituted heterocycle.
[14] 14. A compound according to any preceding claim, wherein the heterocycle 10 or nitrogen-containing heterocycle is an optionally substituted piperidine, piperazine or morpholine.
[15] 15. A compound according to any preceding claim, which is one of the compounds listed below, or a pharmaceutically acceptable salt thereof: 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl) 15 amide; 1 -Benzyl-1 H-pyrazole-4-carboxylic acid (1 H-pyrrolo[2,3-b]pyridin-3-yl)-amide; 1-Benzyl-1H-pyrazole-4-carboxylic acid (4-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl) amide; 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl) 20 amide; or 1 -Benzyl-1 H-pyrazole-4-carboxylic acid (5-piperidin-1 -yl-1 H-pyrrolo[2,3-b]pyridin 3-yl)-amide. N-{4-[(3R)-3-Aminopiperidin-1-yl]-5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl}-1-benzyl 1 H-pyrazole-4-carboxamide 25 1-Benzyl-1 H-pyrazole-4-carboxylic acid [4-((R)-3-amino-pyrrolidin-1 -yl)-5-bromo-1 H pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-4-((R)-3-methylamino-piperidin-1 30 yl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-bromo-4-((R)-3-ethylamino-piperidin-1 yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-amide 35 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-bromo-4-((R)-3-hydroxy-pyrrolidin-1 yl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-bromo-4-((R)-3-hydroxy-piperidin-1 yl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 40 WO 2013/114113 PCT/GB2013/050212 150 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-bromo-4-(3-dimethylamino-piperidin 1-yl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-bromo-4-[(R)-3-(cyclopentylmethyl 5 amino)-piperidin-1 -yl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-bromo-4-((R)-3-isobutylamino piperidin-1 -yl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 10 1 -Benzyl-1 H-pyrazole-4-carboxylic acid {5-bromo-4-[(R)-3-(2,2-dimethyl propylamino)-piperidin-1 -yl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-bromo-4-[(R)-3-(cyclopropylmethyl amino)-piperidin-1 -yl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 15 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 20 yl)-5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 25 1-(4-Methoxy-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Pyridin-2-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 30 1-Pyridin-3-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 35 yl)-5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide N-{4-[(3R)-3-aminopiperidin-1 -yl]-5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl}-1 benzyl-1 H-pyrazole-4-carboxamide 40 1-(4-Methyl-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 45 1-(4-Chloro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-(4-Methoxy-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 50 yl)-5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide WO 2013/114113 PCT/GB2013/050212 151 1-Benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-pyrrolidin-1-yl)-5-chloro 1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 5 N-{4-[(3R)-3-aminopiperidin-1 -yl]-5-cyclopropyl-1 H-pyrrolo[2,3-b]pyridin-3-yl}-1 benzyl-1 H-pyrazole-4-carboxamide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 -yl)-5 hydroxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 10 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 -yl)-5 methoxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1-yl)-5-methyl 15 1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4-piperidin-1-ylmethyl-phenyl)-1H pyrrolo[2,3-b]pyridin-3-yl]-amide 20 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4-{[(2-methoxy-ethyl)-methyl-amino] methyl}-phenyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4-pyrrolidin-1-ylmethyl-phenyl)-1H pyrrolo[2,3-b]pyridin-3-yl]-amide 25 1 -Benzyl-1 H-pyrazole-4-carboxylic acid {5-[4-(4-fluoro-piperidin-1 -ylmethyl) phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4-dimethylaminomethyl-phenyl)-1H pyrrolo[2,3-b]pyridin-3-yl]-amide 30 1 -Benzyl-1 H-pyrazole-4-carboxylic acid {5-[4-(3-fluoro-piperidin-1 -ylmethyl) phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4-methylaminomethyl-phenyl)-1H 35 pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(4-morpholin-4-ylmethyl-phenyl)-1H pyrrolo[2,3-b]pyridin-3-yl]-amide 40 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[4-(3,3-difluoro-pyrrolidin-1-ylmethyl) phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(3-dimethylaminomethyl-phenyl)-1H pyrrolo[2,3-b]pyridin-3-yl]-amide 45 1 -Benzyl-1 H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-piperidin-1 -ylmethyl) phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(3,3-difluoro-piperidin-1-ylmethyl) 50 phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide WO 2013/114113 PCT/GB2013/050212 152 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(3-azetidin-1 -ylmethyl-phenyl)-1 H pyrrolo[2,3-b]pyridin-3-yl]-amide 5 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(3,3-difluoro-azetidin-1-ylmethyl) phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(5-pyrrolidin-1-ylmethyl-thiophen-2 yl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 10 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(5-pyrrolidin-1-ylmethyl-thiophen-3 yl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[5-(3,3-difluoro-azetidin-1-ylmethyl) 15 thiophen-3-yl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [5-(3-pyrrolidin-1-ylmethyl-phenyl)-1H pyrrolo[2,3-b]pyridin-3-yl]-amide 20 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1-yl)-5-fluoro 1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1-yl)-5-phenyl 1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 25 1-Benzyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1-yl)-5-cyano 1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(2-morpholin-4-yl-ethoxy)-phenyl] 1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 30 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(3-dimethylamino-2,2-dimethyl propoxy)-phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid {5-[3-(3-morpholin-4-yl-propoxy)-phenyl] 35 1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(1-methyl-piperidin-3-ylmethoxy) phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 40 1 -Benzyl-1 H-pyrazole-4-carboxylic acid {5-[3-(oxetan-3-yloxy)-phenyl]-1 H pyrrolo[2,3-b]pyridin-3-yl}-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl] 1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 45 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [4-((3R,4R)-3-amino-4-cyclopropyl piperidin-1 -yl)-5-bromo-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(2-fluoro-4-pyrrolidin-1 -ylmethyl 50 phenyl)-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide WO 2013/114113 PCT/GB2013/050212 153 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(3-pyrrolidin-1 -yl-phenyl)-1 H pyrrolo[2,3-b]pyridin-3-yl]-amide 5 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [5-(1 -methyl-1 H-pyrazol-4-yl)-1 H pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridin 3-yl)-amide 10 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin 3-yl)-amide 1-(3-Methoxy-benzyl)-1H-pyrazole-4-carboxylic acid (5-bromo-1H-pyrrolo[2,3 15 b]pyridin-3-yl)-amide 1-(2-Fluoro-benzyl)-1 H-pyrazole-4-carboxylic acid (5-bromo-1 H-pyrrolo[2,3 b]pyridin-3-yl)-amide 20 1-(2-Cyano-benzyl)-1 H-pyrazole-4-carboxylic acid (5-bromo-1 H-pyrrolo[2,3 b]pyridin-3-yl)-amide 1-(1H-Pyrrol-2-ylmethyl)-1H-pyrazole-4-carboxylic acid (5-bromo-1 H-pyrrolo[2,3 b]pyridin-3-yl)-amide 25 1-(4-Fluoro-benzyl)-1 H-pyrazole-4-carboxylic acid (5-bromo-1 H-pyrrolo[2,3 b]pyridin-3-yl)-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl) amide 30 1-Benzyl-1H-pyrazole-4-carboxylic acid (5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl) amide 1-(4-Fluoro-benzyl)-1 H-pyrazole-4-carboxylic acid (5-chloro-1 H-pyrrolo[2,3 35 b]pyridin-3-yl)-amide 1-(3-Methoxy-benzyl)-1H-pyrazole-4-carboxylic acid (5-chloro-1H-pyrrolo[2,3 b]pyridin-3-yl)-amide 40 1 -Benzyl-1 H-pyrazole-4-carboxylic acid {5-[3-((S)-1 -methyl-pyrrolidin-2 ylmethoxy)-phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1 -Benzyl-1 H-pyrazole-4-carboxylic acid {5-[3-(1 -methyl-piperidin-3-yloxy) phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 45 1 -Benzyl-1 H-pyrazole-4-carboxylic acid {5-[4-(3-dimethylamino-propoxy) phenyl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 1-Benzyl-1H-pyrazole-4-carboxylic acid {5-[1-(2-diethylamino-ethyl)-1H-pyrazol 50 4-yl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide WO 2013/114113 PCT/GB2013/050212 154 1 -Benzyl-1 H-pyrazole-4-carboxylic acid {5-[1-(2-pyrrolidin-1 -yl-ethyl)-1 H-pyrazol 4-yl]-1 H-pyrrolo[2,3-b]pyridin-3-yl}-amide 5 1-Pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Pyridin-3-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 10 1-Pyridin-2-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Pyridin-3-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 15 yl)-5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 20 1-Pyridin-2-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Pyridin-4-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-methyl-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 25 1-Pyridin-3-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-methyl-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 30 1-(3-Methyl-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-(3-Fluoro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 35 yl)-5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-(2-Chloro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 40 1-(2-Methyl-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-(4-Fluoro-benzyl)-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 45 1 -Benzyl-1 H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 -yl)-5 trifluoromethyl-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 1-Pyridin-3-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 50 yl)-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide WO 2013/114113 PCT/GB2013/050212 155 1-Pyridin-2-ylmethyl-1H-pyrazole-4-carboxylic acid [4-((R)-3-amino-piperidin-1 yl)-5-trifluoromethyl-1 H-pyrrolo[2,3-b]pyridin-3-yl]-amide 5
[16] 16. A pharmaceutical composition comprising a compound according to any preceding claim and one or more pharmaceutically acceptable carriers and/or excipients.
[17] 17. A compound or composition according to any preceding claim, for use in therapy. 10
[18] 18. A compound or composition according to any preceding claim, for the treatment of conditions responsive to inhibition of protein kinase activity.
[19] 19. A method of treatment of a mammal suffering from a condition responsive to inhibition of protein kinase activity, comprising administering to the mammal an amount of a compound as claimed in any of claims 1 to 15 effective to inhibit 15 protein kinase activity in the mammal.
[20] 20. A compound, composition or method as claimed in claim 18 or 19, wherein the protein kinase is CHK1.
[21] 21. A compound or method as claimed in any of claims 18 to 20 wherein the condition responsive to inhibition of protein kinase or CHK1 activity is selected 20 from cancer and autoimmune disorders.
[22] 22. A compound or method as claimed in claim 21, wherein said autoimmune disorder is organ transplant rejection, lupus, multiple sclerosis, rheumatoid arthritis and osteoarthritis.
[23] 23. A compound or method according to any preceding claim, for the 25 treatment of cancer.
[24] 24. A compound or method according to claim 23, for the treatment of cancer by administration in combination with radiotherapy or chemotherapy.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2013213954B2|2016-02-25|1H-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

---

CN106999479B|2021-07-16|Heteroaryl compounds useful as inhibitors of SUMO activating enzyme

---

KR102181915B1|2020-11-23|N-pyrrolidinyl, n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

---

CN111601799A|2020-08-28|Fused imidazole derivatives as Il-17 modulators

---

BR112020019385A2|2021-03-30|SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE OF THE SAME

---

CA2712959C|2015-06-23|Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity

---

EP2534151B1|2018-11-14|8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds

---

EA019785B1|2014-06-30|Benzofuropyrimidinones as protein kinase inhibitors, pharmaceutical compositions containing them and use thereof

---

MX2014013751A|2015-08-07|Pyridazine and pyridine derivatives as nampt inhibitors.

---

MX2014013734A|2015-06-10|Nampt inhibitors.

---

JP2022500368A|2022-01-04|Polycyclic compounds and methods for targeted degradation of rapidly progressive fibrosarcoma polypeptides

---

TW201000475A|2010-01-01|Heterocyclic urea derivatives and methods of use thereof

---

WO2011010083A1|2011-01-27|Indolyl-pyridone derivatives

---

CA3075477A1|2019-02-14|Novel heterocyclic compounds as cdk8/19 inhibitors

同族专利:

---

公开号 | 公开日

---

CN106866658A|2017-06-20|

---

EP2809670B1|2017-05-17|

---

CN111484493A|2020-08-04|

---

US20210206762A1|2021-07-08|

---

HUE035332T2|2018-05-02|

---

US20180362526A1|2018-12-20|

---

ZA201405070B|2016-03-30|

---

US20150011533A1|2015-01-08|

---

EA026657B1|2017-05-31|

---

IL233595D0|2014-08-31|

---

CN106866658B|2021-04-27|

---

PT2809670T|2017-08-23|

---

EA201491376A1|2015-01-30|

---

IN2014DN06104A|2015-08-14|

---

CN104203948A|2014-12-10|

---

NZ627361A|2016-07-29|

---

IL233595A|2018-05-31|

---

PL2809670T3|2017-10-31|

---

AU2013213954B2|2016-02-25|

---

BR112014018795B1|2020-09-29|

---

ES2637340T3|2017-10-11|

---

JP2015505555A|2015-02-23|

---

MX2014009112A|2014-11-10|

---

MX352927B|2017-12-14|

---

WO2013114113A1|2013-08-08|

---

HK1200447A1|2015-08-07|

---

DK2809670T3|2017-08-28|

---

US10889582B2|2021-01-12|

---

CA2862940C|2021-09-14|

---

CN107011341A|2017-08-04|

---

GB201201566D0|2012-03-14|

---

EP2809670A1|2014-12-10|

---

US10000481B2|2018-06-19|

---

BR112014018795A2|2017-07-04|

---

JP6199316B2|2017-09-20|

---

CA2862940A1|2013-08-08|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US1012976A|1909-03-25|1911-12-26|Adolf Bordt|Adding-machine.|

---

WO2003028724A1|2001-10-04|2003-04-10|Smithkline Beecham Corporation|Chk1 kinase inhibitors|

---

US20050130954A1|2003-11-21|2005-06-16|Mitchell Ian S.|AKT protein kinase inhibitors|

---

ES2394759T3|2008-01-08|2013-02-05|Array Biopharma, Inc.|Pyrrolopyridines as kinase inhibitors|

---

AU2009207478B2|2008-01-22|2013-11-21|Vernalis Ltd|Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity|

---

AR071717A1|2008-05-13|2010-07-07|Array Biopharma Inc|PIRROLO [2,3-B] CHK1 AND CHK2 QUINASE INHIBITING PIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS TO PREPARE THEM AND USE OF THE SAME IN THE TREATMENT AND PREVENTION OF CANCER.|

---

AU2009258115B2|2008-06-11|2015-01-29|Genentech, Inc.|Diazacarbazoles and methods of use|

---

ES2433230T3|2009-08-06|2013-12-10|Merck Patent Gmbh|Novel urea bicyclic compounds|

---

WO2011146313A1|2010-05-19|2011-11-24|The University Of North Carolina At Chapel Hill|Pyrazolopyrimidine compounds for the treatment of cancer|

---

GB201201566D0|2012-01-30|2012-03-14|Vernalis R & D Ltd|New chemical compounds|GB201201566D0|2012-01-30|2012-03-14|Vernalis R & D Ltd|New chemical compounds|

---

RU2635359C2|2012-04-23|2017-11-13|Дженентек Инк.|Intermediate chemical compounds and methods for producing compounds|

---

RU2672725C2|2013-08-22|2018-11-19|Дженентек, Инк.|Method of preparing compound|

---

CN104829609B|2014-02-11|2016-08-03|北大方正集团有限公司|Substituted Pyridopyrimidine compound and its preparation method and application|

---

MA41559A|2015-09-08|2017-12-26|Taiho Pharmaceutical Co Ltd|CONDENSED PYRIMIDINE COMPOUND OR A SALT THEREOF|

---

US10032914B2|2015-10-20|2018-07-24|Taiwan Semiconductor Manufacturing Co., Ltd.|Semiconductor device and manufacturing method thereof|

---

RU2018133000A3|2016-02-23|2020-04-02|||

---

TW202043198A|2019-01-17|2020-12-01|美商Ｉｆｍ Ｄｕｅ有限公司|Compounds and compositions for treating conditions associated with sting activity|

---

WO2022015957A1|2020-07-15|2022-01-20|Ifm Due, Inc.|Compounds and compositions for treating conditions associated with sting activity|

---

WO2022015979A1|2020-07-15|2022-01-20|Ifm Due, Inc.|Compounds and compositions for treating conditions associated with sting activity|

---

WO2022015975A1|2020-07-15|2022-01-20|Ifm Due, Inc.|Compounds and compositions for treating conditions associated with sting activity|

法律状态:
2016-06-23| FGA| Letters patent sealed or granted (standard patent)|

优先权:

---

申请号 | 申请日 | 专利标题

---

GBGB1201566.5A|GB201201566D0|2012-01-30|2012-01-30|New chemical compounds|

---

GB1201566.5||2012-01-30||

---

PCT/GB2013/050212|WO2013114113A1|2012-01-30|2013-01-30|1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors|

---